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Hepatitis  B  virus  (HBV)  and  Hepatitis  C  virus  (HCV)  are  important  causes  of  liver 
inflammation  and  fibrosis.  More  than  500  million  people  are  persistently  infected 
worldwide  and  consequently  are  at  increased  risk  of developing  chronic  liver  disease, 
cirrhosis  and  hepatocellular carcinoma.  Both  viruses  share  some  similarities;  however, 
disease severity varies greatly from subject to subject and the variation in clinical course 
is a hallmark of viral  hepatitis.  The  failure of the  immune  system  to  prevent persistent 
infection and chronic  necroinflammatory  change  is central  to  understanding  the  disease 
caused by these human viruses.
The  Introduction  to  this  Thesis  reviews  our  current  understanding  of  the 
immunopathogenesis and natural history of both viruses in the context of the clinical and 
scientific challenge that chronic viral hepatitis represents.
The  body  of this  work  was  to  focus  on  immunological  events  which  might  shape  and 
possibly  dictate disease outcome  in  viral  hepatitis.  In  this thesis  I  set  out to  investigate 
areas of cellular immunity which may contribute to pathology or protection in HBV and 
HCV.  I have focused on the impact of cross-reactive T cells activated by HCV peptides 
and  report  that  this  may  constitute  a  common  occurrence  in  human  viral  infections.  I 
explore  the  role  of the  NK  cell  receptor,  NKG2D,  in  the  modulation  of  CD8+T  cell 
response  in  type  B  and  C  chronic  viral  hepatitis  and  report  the  impact  of  this  novel 
receptor in human liver disease for the first time.
2This  Thesis  concentrates  on  areas  of T  cell  immunology  which  I  feel  will  add  to  our 
understanding  of viral  hepatitis.  It  is  this  better definition  of the  basic  immunology  of 
these two important human  viruses  which  will  form  the bedrock  in  the development of 
more efficient preventive and therapeutic strategies in the future.
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15CHAPTER 1 
GENERAL INTRODUCTION1.1.1  HEPATITIS B VIRUS (HBV)
Hepatitis B  virus  (HBV)  is  a non-cytopathic,  hepatotropic  DNA  virus that causes  acute 
and  chronic  necroinflammatory  liver  diseases  (Seeger  and  Mason,  2000).  Acute 
infections may be clinically silent or cause an acute liver inflammation that may produce 
serious  illness,  and  in  0.5%  of subjects  can  lead  to  fatal  fulminant  hepatitis.  The  vast 
majority  of adults  acutely  infected  with  HBV  control  virus  replication,  develop  a  long 
lasting immunity and recover from the disease. In contrast, neonatal infections are rarely 
resolved  and most of these children become chronically  infected  (Stevens et al.,  1975). 
Chronic infections can also occur in about 5% of infected adults. As in the acute infection 
such chronically infected individuals can be asymptomatic or experience varying grades 
of chronic  liver  injury  that  may  lead  to  the  development  of hepatocellular  carcinoma 
(HCC) (Beasley,  1988). It has been calculated that the risk of developing liver cancer in 
HBV  infected  subjects  is  over  100-fold  that  of  age-matched  non  HBV  infected 
individuals  (Beasley  et al.,  1981).  Worldwide  deaths from  liver cancer caused by  HBV 
infection are thought to exceed one million per year (Pisani et al.,  1999) (Figure 1.1).
17HBV
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Figure 1.1. Geographic distribution of HBV infection.
1.1.2  Biology of HBV
HBV  is  a  member  of a  family  of  viruses  referred  to  as  Hepadnaviridae  (Figure  1.2). 
Viruses closely related to HBV  have been found in woodchucks (Summers et al.,  1978) 
and ground squirrel  (Testut et al.,  1996). These viruses have about 70%  homology with 
HBV  but do not infect humans or other primates.  More distantly  related viruses,  with a 
similar genetic organisation are found  in  ducks, geese and  primates.  Due to the  limited 
host range of HBV  (namely humans and great apes) and the  lack of in vitro systems to
18infect  normal  human  hepatocytes,  these  related  viruses  are  currently  used  as  a  model 
system to characterise the mechanisms of hepadnavirus replication and to explore various 
disease profiles.
Hepatocytes  are the only confirmed  site of replication for HBV.  Bile ductule, epithelial 
cells or subsets of cells in the pancreas, kidney or lymphoid cells may also be targets of 
infection, but the evidence of replication in these extrahepatic sites is controversial and at 
the  moment  these  sites  are  not  considered  in  discussion  of  viral  replication  and 
pathogenesis. The replication of hepadnaviruses is characterised by the synthesis of a ~3- 
Kb  partially  double  stranded,  relaxed  circular  DNA  (rcDNA)  genome  by  reverse 
transcription  of an  RNA  intermediate,  the pregenome  (Summers and  Mason,  1982).  At 
the  initiation  of  infection  the  viral  rcDNA  genome  is  converted  into  cccDNA.  The 
cccDNA  serves  as  the  template  for  the  transcription  of  viral  mRNAs.  One  of  these 
mRNAs,  called  the  pre-genome,  is  used  to  synthesise  the  core  protein  (nucleocapsid 
subunit)  and  the  viral  reverse  transcriptase.  The  reverse  transcriptase  binds  to  its  own 
mRNA templates and is packaged into nucleocapsids where viral DNA synthesis occurs.
Mature  nucleocapsids  containing  rcDNA  are  then  enveloped  in  the  endoplasmic 
reticulum  and  exported  from  the  cell  via  the  Golgi  (Ganem  et  al.,  1994;  Seeger  and 
Mason, 2000).
The  genome  of  HBV  contains  four  open  reading  frames  that  encode  the  viral 
nucleocapsid,  polymerase,  envelope  and  X  proteins.  Core  and  polymerase  genes  are
19essential  for  viral  DNA  replication.  The  envelope  open  reading  frame  encodes  for 
polypeptides (S, M  and L), all of which  are essential for envelopment of nucleocapsids. 
The  function  of  hepatitis  X  protein  is  unknown,  but  the  protein  is  required  for  the 
establishment  of  infection  in  vivo  (Chen  et  al.,  1993)  but  is  dispensable  for  viral 
replication in transfected cells (Blum et al.,  1992).
The  nucleocapsid  open  reading  frame  contains  two  start  codons  that  define  two 
overlapping proteins. The  shorter of these proteins (hepatitis B core antigen, HBcAg)  is 
the  viral  capsid  protein  that  assembles  in  the  cytoplasm  of the  hepatocytes  to  form  the 
icosahedral  subviral particles  that  package  the  viral  reverse  polymerase  and  the  pre­
genome  (Crowther  et  al.,  1994).  The  longer  protein  (pre  core)  is  translocated  into  the 
endoplasmic reticulum where it undergoes truncation of its carboxy and amino terminal 
residues  and  is  secreted  into  the  blood  as  HBeAg  (Ou  et  al.,  1986;  Roossinck  et al.,
1986).
The presence of HBeAg in the serum of HBV infected patients is a serological marker of 
viral  replication,  but  since  HBeAg  is  dispensable  for  in  vivo  infection  (Chang  et  al.,
1987), its exact function is unknown. Experiments in mice suggest that HBeAg can cause 
depletion of Thl  helper cells (Milich,  1997; Milich et al.,  1990) thereby suppressing the 
anti-viral immune response. A similar tolorogenic effect may also be present in neonatal 
infection,  although  this  possibility  has  not  been  proven  in  the  natural  host  of 
hepadnaviruses.
20All  the  hepadnaviruses  express  the  three  envelope  components  S,  M  and  L.  All  three 
proteins contain the smallest (226 amino acids long) S domain referred to as hepatitis B 
surface antigen (HBsAg). The two larger proteins contain S plus an amino acid extension 
containing  the  pre-S2  antigen  (M  protein,  226  +51  AA  long)  or  pre  S2  and  pre  SI 
antigens  (L  protein,  226  +  51  +  163  AA  long)  (Heermann  et  al.,  1984;  Stibbe  and 
Gerlich,  1983a;  Stibbe  and  Gerlich,  1983b).  All  three  envelope  proteins  are  found  as 
components of the 42  nm-diameter infectious  viral  particle  (Dane  particle)  (Figure  1.2) 
(Neurath et al.,  1985). L and M constitute roughly 30% of the envelope protein content of 
the  virus  particle  (Heermann  et  al.,  1987).  S  by  itself  and  together  with  the  larger 
envelope  proteins  also  forms  filamentous  and  spherical  “surface  antigen”  particles  that 
are  secreted  from  infected  cells  in  at  least  100-fold  excess  over  complete  virions. 
Lacking viral nucleic acid, these particles are not infectious, but can reach concentrations 
of several micrograms per millilitre of blood of HBV  infected patients (Kim and Tilles, 
1973). The reasons for maintaining high levels of HBsAg production are still uncertain, 
but  may  be  implicated  in  tolerisation  of  the  immune  response  and  may  help  absorb 
neutralising antibodies during the progression of infection.  Complexes made up of these 
particles with their cognate antibodies are probably responsible for the immune complex 
syndromes that can occur during HBV infection.
As already mentioned, the function of X protein is poorly defined, but it has been shown 
to be essential for virus replication in vivo (Chen et al.,  1993). Antibodies against X have 
been  found  in  sera  of  HBV  infected  individuals,  demonstrating  its  expression  during 
natural  infection.  In  vitro  experiments  from  cell  culture,  have  demonstrated  that  X  can
21activate the transcription of host genes  (Balsano et al.,  1991;  Hu  et al.,  1990; Twu  and 
Schloemer,  1987),  however  since  X  does  not  seem  to  be  a  DNA-binding  protein,  its 
effects on transcription are thought to be indirect. Apart from the transactivation activity, 
X has been proposed to stimulate signal transduction or binding to protein targets such as 
p53  (Feitelson  et  al.,  1993;  Takada  et  al.,  1995;  Wang  et  al.,  1994)  or  proteasome 
subunits  (Sirma  et al.,  1998).  Therefore,  it  is  clear  that  X-defective  virus  is  unable  to 
initiate infection in vivo but the physiological role of X in the life cycle of HBV remains 
unresolved.
One  other  important  point  in  the  replication  of  HBV  is  that  the  use  of  reverse 
transcriptase (Summers and Mason,  1982) results in a high rate of DNA mutations, due to 
the lack of proofreading function of this enzyme. The presence of these  viral  mutations 
can lead to the selection of viruses able to escape recognition by the different arms of the 
adaptive immune response (Bertoletti et al.,  1996).
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Figure 1.2. The main components of the Dane particle.
1.1.3  Host-virus relationship: parameters influencing different outcomes.
The  variability  in  the  outcome  of  infection  with  viruses  may  depend  on  the  balance 
between  viral  parameters that determine the ability of the virus to propagate and persist 
on  one  hand,  versus  the  facets  of the  immune  system  that  determine  its  efficiency  in 
controlling virus replication (Zinkernagel,  1996).
Viral parameters include the initial infectious dose, the kinetics of viral replication and its 
ability  to  spread.  These  viral  features  are  balanced  by  the  variables  of  the  immune
23system:  kinetics,  specificity  and duration  of the humoral  and  cellular mediated  immune 
response  and  other  non  antigen  specific  effector  mechanisms  such  as  activation  of the 
adaptive immune response and cytokine production.
How these variables influence outcome are usually difficult to study in humans, but such 
work has been addressed in greater detail in the animal models of hepadnavirus infection. 
Epidemiological  data  have  shown  that  the  age  of  infection  is  a  critical  parameter  that 
influences  the  outcome  of HBV,  with  infection  of neonates  being  associated  with  the 
development of persistent infection (Stevens et al.,  1975). Experimental work performed 
in  ducks  and  woodchucks  confirm  this  epidemiological  data.  Persistent  infection  with 
woodchuck hepatitis virus (WHV) followed the transmission of virus to neonatal animals 
whilst infection of older animals is usually transient (Cote et al., 2000).  Identical results 
were reported in ducks infected with DHBV, where persistent infection results following 
experimental inoculation of newly hatched animals (Jilbert et al.,  1998).
The  effect  of the  dose  of  virus  in  the  outcome  of  infection  is  also  supported  by  the 
experiments  in  ducks  and  woodchucks.  Higher  doses  of  virus  generally  induced  high 
rates of chronicity (Cote et al., 2000; Jilbert et al.,  1998). However, the data here are less 
consistent. Infection with a single viral particle is sufficient to initiate persistent infection 
in  ducks  (Jilbert  et  al.,  1996)  and  low  doses  of  WHV  have  been  shown  to  induce  a 
persistent infection in woodchucks (Cote et al., 2000). It is possible that kinetics of viral 
replication,  not  tested  in  these  studies,  can  influence  the  outcome  of  infection. 
Mathematical  models of the relationship between  kinetics of virus replication  and  CTL
24expansion  have  indeed  suggested that slower replicating  viruses could  induce  a  weaker 
CTL response (Bocharov et al., 2004). Therefore, it is possible that the replication speed 
of HBV, in addition to age at exposure and quantity of initial inoculum, can all influence 
the pathogenesis of HBV  infection.  Accordingly with this possibility,  HBV  strains with 
enhanced viral  replication have been demonstrated to be responsible for an epidemic of 
fulminant hepatitis (Baumert and  Liang,  1996),  reinforcing the  possibility  that  speed of 
viral  replication  may  influence the  pathogenesis of HBV  infection.  A  further important 
point  of the  work  performed  in  animals  infected  with  hepadnaviruses  is  the  fact  that 
persistent  infection  is  not  the  evolution  of  a  classical  acute  hepatitis.  Chronicity  in 
woodchucks  developed  in  animals  that,  after  infection,  mounted  a  diminished  immune 
response  with  reduced  cytokine  production  and  had  a  mild  form  of  acute  hepatitis 
(Nakamura et al., 2001). This suggests that the initial vigour of the immune response is a 
key factor in determining the outcome of infection.
251.1.4  Immune parameters correlating with HBV control
There are clear differences in the adaptive immunity of patients with chronic and resolved 
HBV infection. HBV-specific CD4 and CD8 T cell responses with a T helper (Th) type  1  
profile  of cytokine  production  are  detectable  and  quantitatively  stronger  in  peripheral 
blood  mononuclear cells  of subjects  with  a  favourable  outcome.  Patients  with  chronic 
infections  are  characterised  by  weaker  or  undetectable  virus-specific  T  cell  responses 
(Ferrari et al.,  1990; Jung et al.,  1991; Maini et al.,  1999; Penna et al.,  1996; Penna et al., 
1997;  Rehermann  et al.,  1995;  Webster et al.,  2004).  Whether the  association  between 
different outcomes of HBV  infection and the  vigour and breadth of the HBV-specific T 
cell response has a causative effect has been difficult to demonstrate.
CD8+  T  cell  deletion  experiments  performed  in  HBV  infected  chimpanzees  have 
provided  strong  support for the concept  that CD8+ T cells  are the  main  cellular subset 
responsible for viral clearance (Thimme et al., 2003). Direct analysis of the frequency of 
CD8+ T cells in patients who clear HBV infection have shown that HBV-specific CD8+ 
T  cells  can  reach  ~2%  of circulating  CD8+  T  cells  during  the  acute  phase  of disease 
(Maini et al.,  1999; Webster et al., 2000). Furthermore, the quantity of circulating HBV- 
specific CD8+ T cells is even higher years after recovery in subjects with acute hepatitis 
(0.2-0.5% of circulating CD8+ T cells) than in subjects with chronic infection (HBeAg+ 
patients), in whom such cells are barely detectable (Maini et al., 2000). These results are 
consistent  with  previous  studies  showing  a  very  weak  CTL  response  in  patients  with 
chronic  HBV  infection,  usually  only  detectable  during  spontaneous  (Rehermann  et al.,
261996c) or therapy  induced  clearance of HBeAg (Boni  et al.,  2001).  In addition,  studies 
conducted  in  patients  during  the  incubation  phase  of  acute  HBV  infection,  have 
demonstrated  the  expansion  of  virus-specific  IFN-y+  CD8+  and  CD4+  T  cells.  Virus 
clearance was preceded by the expansion of both helper and cytotoxic T cells and present 
only in subjects who controlled the infection (Webster et al., 2000). This underlines the 
necessity  of a coordinated  helper and cytotoxic T  cell  response  in  host defence against 
HBV infection (Figure  1.3).
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Figure 1.3. The host defence mechanisms against virally infected cells. The coordinated immune 
response  involves  type  I  IFNs  recruiting  the  innate  immune  responses for viral  containment and 
finally the adaptive immune reponses providing persistent control of infection.
27The importance of CD4 helper T cells in promoting CTL survival and effector function is 
supported  in  HBV  infection  by  the  fact  that  CD4  responses  are  only  consistently 
detectable  in  acute  infection  (Ferrari  et  al.,  1990)  and  in  chronic  patients  undergoing 
HBeAg  seroconversion  (Tsai et al.,  1992).  In  acutely  infected  HBV  patients who have 
the  ability  to  mount  a  protective  multispecific  CTL  response,  the  HBV-specific  T  cell 
response is both strong and Thl-like (Penna et al.,  1997). Furthermore the responses are 
also directed to a number of different epitopes within the structural proteins investigated 
(Ferrari  et  al.,  1991).  This  multispecificity  of  the  CD4  response  may  also  be  highly 
relevant  to  viral  control.  Consistent  with  this  interpretation,  heterozygosity  of class  II 
alleles has been shown to be associated with more favourable HBV control (Thursz et al.,
1997).
The recent analysis of one HBV-HCV acutely co-infected patient who developed chronic 
HBV  infection  has  provided  further  evidence  of  the  significance  of  the  coordinated 
activation  of  CD4  and  CD8+  T  cells.  Longitudinal  analysis  of  HBV-specific  T  cell 
responses, from the time of infection to chronicity, shows the presence of a multi-specific 
CD8+ T cell response in the absence of a CD4+ T cell response (Urbani et al., 2005b).  It 
is likely that the absence of CD4 help prevented the maturation of a functionally efficient 
CD8+ T cell response.
Despite  the  cellular  immune  response  being  a  major  contributor  to  HBV  clearance, 
humoral responses also play a role in controlling HBV.  HBV clearance is associated with 
the production of anti-HBs antibodies (Alberti et al.,  1978)  and sera with high levels of
28anti-viral antibodies (specific for the viral envelope) can control HBV infection (Grady et 
al,  1978).
It is also  important to stress that effective viral control does not necessarily  imply  viral 
eradication.  It  is  now  accepted  that  patients  who  recover  completely  following  acute 
hepatitis do not eradicate HBV infection. Several studies have shown that HBV is present 
(Cacciola et al.,  1999;  Chazouilleres et al.,  1994; Michalak et al.,  1994) and retains the 
ability to replicate in the liver of patients who have cleared serum HBsAg (Mason et al.,
1998).  Such persistence of low level HBV replication may in fact be critical to maintain 
an efficient HBV-specific T cell response that has been shown to persist for several years 
after acute HBV infection (Penna et al.,  1996; Rehermann et al.,  1996c).
Thus,  it  seems  clear that  subjects  who  are  able  to  control  HBV  replication  are  able  to 
express  a  co-ordinated  T  cell-immune  response  characterised  by  the  expansion  of  a 
functionally active multispecific CTL response (Chisari and Ferrari,  1995). However, we 
still do not have a clear understanding as to why chronic patients are unable to mount a 
comparable  HBV-specific  T  cell  immune  response.  In  addition  to  the  factors  already 
discussed;  from patient age to  mode of transmission  (vertical  infection)  (Stevens  et al., 
1975),  genetic  factors  of the  host  (Thursz  et al.,  1997)  and  viral  parameters  (dose  and 
kinetics);  the  role  of  viral  proteins  produced  by  HBV  (Milich  et  al.,  1990)  and  their 
ability to alter the magnitude of the T cell response should not be overlooked.
29The production of HBeAg, the secreted non-particulate form of nucleoprotein, has been 
demonstrated  to  mediate  immunoregulatory  function  (Milich  et al.,  1998).  In  a  murine 
model  system,  HBeAg  can  cross  the  placenta  and  establish  an  antigen-specific  T  cell 
tolerance  (Milich  et al.,  1990).  Furthermore,  HBeAg  is  able  to  delete  HBeAg-specific 
Thl  cells and skews the HBV-specific T cell response towards Th2 (Milich,  1997; Milich 
et al.,  1998). Thus, high production of HBeAg could be responsible for the inhibition of 
an efficient anti-viral immune response, thereby contributing to viral persistence.
1.1.5  Non-cytopathic or cytopathic control of HBV
Several  studies have  shown  HBV  infected  hepatocytes  are  more  likely  to be  controlled by 
intracellular inactivation mediated by cytokines than by direct killing (Guidotti et al.,  1999). 
This  mechanism  has  been  studied  extensively  in  HBV  transgenic  mice  where  HBV 
replication  is completely  abolished  in the hepatocytes by cytokine-dependent pathways that 
do not require cell death (Guidotti and Chisari,  1996; McClary et al., 2000). IFN-y and TNF- 
a  are  able  to  selectively  degrade  replicating  genomes  of HBV;  thereby  clearing  the  virus 
without  the  need  to  kill  infected  cells  (Guidotti  and  Chisari,  1996).  This  non-cytopathic 
mechanism  of viral  clearance  is  not  peculiar to  HBV.  Control  of murine  cytomegalovirus 
(CMV) infection (Tay and Welsh,  1997) and Lysteria monocytogenes (Kagi and Hengartner, 
1996)  in the liver seems to be primarily  mediated by IFN-y production rather than perforin 
dependent (direct killing) pathways.  Lymphochoriomeningitis virus (LCMV) is also cleared 
from hepatocytes by  non-cytopathic mechanisms that are not operative  in non-parenchymal
30cells  or  splenocytes  (Guidotti  et  al.,  1999).  Therefore,  clearance  of viruses  from  infected 
hepatocytes does not require massive lysis of infected cells, perhaps constituting a strategy to 
preserve  the  functional  integrity  of  a  vital  organ  from  massive  immune-mediated 
cytodestruction.  The fact  that clearance  of HBV  infection  from  the  liver occurs  before  the 
peak  of  acute  liver  damage  in  chimpanzees  (Guidotti  et  al.,  1999)  and  also  in  humans 
(Webster  et  al.,  2000)  seems  to  demonstrate  that  non-cytopathic  anti-viral  pathways 
mediated by cytokines contribute substantially to viral control in the natural HBV infection.
However, because hepatocytes are capable of activating intracellular events leading to viral 
control after cytokine stimulation, this does not imply that  1) they are resistant to direct CTL 
mediated lysis, or 2) that cellular necrosis or apoptosis is not important in resolution of acute 
hepatitis B. Lysis of hepatocytes by Fas has been clearly demonstrated (Kondo et al.,  1997) 
and  an  incremental  change  in  the  level  of  transaminases  is  always  present  during  HBV 
clearance  in  patients  with  acute  hepatitis  (Webster et al.,  2000).  Furthermore,  a  degree  of 
apoptosis  and  regeneration  of  hepatocytes  occurs  in  acute  and  chronic  liver  damage  in 
woodchuck hepatitis virus infection (Guo et al., 2000), showing that hepatocyte lysis is also 
occurring during virus control in infected hepatocytes.
311.1.6  Pathogenesis of liver damage during HBV infection
Since HBV is a non-cytopathic virus, it has been assumed that the extent of liver damage 
is proportional to the recognition of infected hepatocytes by CTL (Figure  1.4).  However, 
the  demonstration  that  HBV  can  be  almost  cleared  by  non-cytopathic  mechanisms 
mediated by cytokines has challenged this model (Bertoletti and Maini, 2000).
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Figure 1.4. Role of virus-specific CTL, protection or pathology?
The  ability  to  identify  antigen-specific  T  cells  directly  ex  vivo  using  HLA-class  I 
tetramers  (Altman  et  al.,  1996)  has  provided  the  opportunity  to  investigate  the 
relationship between  HBV-specific T cells and  liver damage  in  humans.  Direct ex vivo
32quantification  of HBV-specific  CD8+ T  cells,  combined  with  the  demonstration  of the 
peculiar capacity of hepatocytes to clear viral infections by non-cytopathic mechanisms, 
have led to a new interpretation of the pathogenesis of liver damage during chronic viral 
infections (Bertoletti  and Maini,  2000).  Using HLA-class I tetramers it has been  shown 
that chronic HBV infected patients lacking evidence of liver damage but controlling HBV 
replication possess functionally active HBV-specific CD8+ T cells both in the circulation 
and in the liver. By contrast, patients with a high  level of HBV replication and evidence 
of  liver  inflammation  show  a  different  pattern  of  virus-specific  CD8+  T  cells.  The 
frequency  of  intrahepatic  CD8+  T  cells  specific  for  core  18-27,  representing  the 
immunodominant core epitope, were much lower in these patients due to their dilution in 
a  large  infiltrate  of  apparently  non-antigen  specific  T  cells.  Interestingly,  the  actual 
number of intrahepatic  HBV-specific CD8+ T cells  was  similar to that  seen  in  patients 
without  liver  disease,  taking  into  account  the  difference  in  the  size  of the  total  CD8 
infiltrate.  These  results  in  chronic  HBV  infection  show  that  comparable  numbers  of 
intrahepatic  virus-specific  CD8+  T  cells  could  be  associated  with  either  protection  or 
pathology (Maini et al., 2000) (Figure  1.5).
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Figure 1.5. Virus-specific CTL controlling viral  replication independent of liver damage
These  data  demonstrate  that  the  quantity  of virus-specific  cells  does  not appear to  be  the 
variable  directly  determining  the  extent  of  virus-induced  liver  pathology.  Indeed,  the 
presence  of  liver-infiltrating  HBV-specific  CD8+  T  cells  in  the  absence  of  liver 
inflammation  suggests  that control  of viral  replication  and the  occurrence  of liver damage 
may be independent events.  Hepatic pathology could in part be the consequence of the large 
infiltrate  of antigen  non-specific  mononuclear  cells,  since  this  is  the  one  variable,  which 
correlates with  the  extent of liver inflammation.  The  importance of non-antigen  specific T 
cell  recruitment in the pathogenesis of liver damage has been shown  in a transgenic  mouse 
model of fulminant hepatitis (Ando et al.,  1993) and in the concanavalin A-induced model of 
hepatitis (Kusters et al.,  1996; Tiegs et al.,  1992)(Figure  1.6).
34Figure 1.6. The recruitment of a large volume of non-virus specific CTL with resulting liver damage, 
where virus specific CTL fail to control the virus.
The  recruitment  of  non-antigen  specific  CD8+  T  cells  seems  to  be  mediated  by  IFN-y 
(Moskophidis  and  Kioussis,  1998).  This  cytokine  should  therefore  be  seen  not  only  as  an 
anti-viral cytokine able to clear infection without causing liver damage, but also as a typical 
inflammatory  cytokine,  causing  activation  of  macrophages  (Young  and  Hardy,  1995), 
increased susceptibility to TNF-mediated hepatic damage (Morita et al.,  1995) and initiating 
the recruitment of T  cells (Cook et al.,  1995;  Shields et al.,  1999; Taub et al.,  1993),  NK 
cells (Salazar-Mather et al.,  1998) or NKT cells (Kaneko et al., 2000) through the release of 
chemotactic cytokines.
A  functional  efficient  CTL  response  recruited  to  “the  right  place  at  the  right  time”  in  an 
infected  liver may  be  able to  control  HBV  replication  without causing  massive  or chronichepatocyte destruction. Virus-specific CTL can persist in the liver, controlling and inhibiting 
viral  replication  in  the  hepatocytes  without  causing  biochemical  or  histologically  evident 
liver disease. A circulating reservoir of virus-specific CD8+ T cells able to clonally expand, 
migrate  to  the  liver,  produce  the  correct  anti-viral  cytokines  and  mature  to  effector  from 
memory cell phenotype will be necessary to maintain viral control and to respond quickly to 
alterations in the rate of viral replication.  In line with this interpretation patients controlling 
HBV  infection  present  a  strong  and  multispecific  CD8+  T  cell  response  that  persists  for 
several decades after acute hepatitis (Rehermann et al.,  1996c).
In contrast, chronic HBV patients present a defective CD8+ T cell response. The presence of 
a  CTL  response  unable  to  control  HBV  could  then  cause  the  chronic  recruitment  of 
inflammatory cells that will sustain the necro-inflammatory activity promoting the long term 
complications of HBV infection, namely fibrosis, cirrhosis and hepatocellular carcinoma.
361.1.7  Natural History of Hepatitis B
Primary HBV infection in the naive host is usually asymptomatic. Symptomatic infection 
can  occur,  and  is  usually  associated  with  a  self  limited  course.  Whereas  vertical 
transmission of HBV from mother to neonate almost always results in chronic hepatitis, 
infection  during  adulthood  usually  results in resolution  of the acute  illness and  lifelong 
immunity to reinfection (Wright and Lau,  1993). Despite this,  1- 5% of HBV infection in 
healthy  adults  does  not  resolve  spontaneously  but  develops  into  persistent  infection. 
Persistent infection can be subclinical, with normal liver enzymes and unremarkable liver 
histology  and  patients  with  this  profile  of  chronic  HBV  infection  are  termed 
asymptomatic carriers.  Despite this,  some  asymptomatic carriers of HBV  with  minimal 
liver injury have been reported to have significant levels of intrahepatic viral replication 
(de Franchis et al.,  1993). Patients with persistent infection with abnormal liver enzymes 
and liver histology are referred to as having chronic hepatitis B  infection. Chronic HBV 
carriers, defined as persons positive for HBsAg for more than 6 months, are at increased 
risk  of  developing  cirrhosis,  hepatic  decompensation  and  hepatocellular  carcinoma 
(HCC)(Beasley,  1988; Lok and McMahon, 2001; McQuillan et al.,  1989). There is a 4-10 
week  incubation  period  before  HBsAg  becomes  detectable  in  the  peripheral  blood  at 
which  time  viraemia  is  usually  well  established.  This  is  followed  by  the  detection  of 
antibodies to the  HBV  core  antigen  (anti-HBc  antibodies)  and the presence  of the  IgM 
isotype reflects early/recent infection (Hoofnagle, 1981). The emergence of HBeAg in the 
blood  has  been  shown  in  animal  studies  to  coincide  with  hepatocyte  infection  rates  of 
between  75  and  100%  (Kajino  et al.,  1994).  All  of these  factors  contribute  to the  high
37levels  of  infectivity  in  acute  HBV  infection,  with  both  vertical  and  horizontal 
transmission being documented  (Koff et al.,  1977). The development of abnormal  liver 
function  tests,  with  elevated  aminotransferases  coincides  with  the  establishment  of the 
cell-mediated immune response as previously discussed in the pathogenesis section. The 
loss  of  HBeAg,  HBsAg  and  the  emergence  of  anti-HBe  &  anti-HBs-antibodies  is 
associated  with  undetectable or low  levels of HBV DNA.  This low  level HBV DNA is 
reported in some patients to persist for life (Prince et al., 2001), but is considered to be of 
low infectivity in the absence of detectable HBsAg.
1.1.8  Clinical picture of persistent infection
Persistent  HBV  infection  is  reflected  clinically  by  detectable  HBsAg  in  the  blood  and 
continued viral replication. The level of HBV DNA is usually dependent on the presence 
of  HBeAg  with  high  titres  of HBV  DNA  being  associated  with  HBeAg  positivity.  In 
patients  with  circulating  HBeAg,  the  levels  of virus  can  be  as  high  as  or  exceed  109 
virions per ml, and such patients remain highly infectious (Weinberger et al., 2000). The 
development of anti-HBe antibodies is associated with a significant drop in the levels of 
viraemia.  However, even with chronic HBV infection, there is continued loss of HBeAg 
from the blood and this is reported to occur at  a rate of 5-10%  per year (Ribeiro et al., 
2002).  With loss of HBeAg and the development of anti-HBe antibodies there is often a 
transient  hepatic  flare  reflecting  immune  mediated  destruction  of infected  hepatocytes. 
Seroconversion is usually accompanied by up to a 5 log drop in the HBV DNA titre. This
38picture reflects the dynamic nature of HBV infection with a continued immune challenge 
modulating the course of the disease.  Even  with  HBeAg  seroconversion,  it is accepted 
that  there  is  continued  HBV  replication  in  up  to  85%  of  patients  with  anti-HBe 
antibodies, typically at lower levels (less than  105  molecules per ml) (Tedder et al., 2002).
HBeAg-negative  subjects  usually  have  low  levels  of  viral  DNA,  normal 
aminotransferases and tend to have a good prognosis (de Franchis et al.,  1993). However, 
this  picture  is  often  different  in  Southern  Europe  and  Asia,  where  up  to  20%  of such 
carriers  have  high  levels  of  HBV  DNA  and  significantly  elevated  aminotransferases 
(Sung et al., 2002). The majority of this group of patients are believed to have mutations 
in the pre core region  of the  virus  and  so do not express  HBeAg  (Carman  et al,  1990; 
Brunetto et al.,  1991).
1.1.9  Hepatitis B and Therapy
An  understanding of viral  clearance  or eradication  of HBV  (undetectable  viral  DNA  as 
measured by  stringent PCR techniques) remains a challenge for scientists and clinicians 
alike. The loss of HBsAg marking the end of chronic HBV carrier status, as an end-point 
is unfortunately rare.  1-2% of patients per annum are reported to achieve loss of HBsAg 
with  current  treatment  modalities,  or  spontaneously.  This  stresses  the  difference  in 
disease outcome and goals of treatment in type B and C viral hepatitis.
39Despite the argument for broadening the population of patients where treatment may be 
indicated, HBeAg positive patients with active disease remain the core population where 
indications for therapy are unequivocal. This specific population have an increased risk of 
progression  to chronic hepatitis  and cirrhosis  (Liaw  et al.,  1988)  and  they  also have  an 
increased  risk  of  hepatocellular  carcinoma  above  that  of  other  carriers  (Yang  et  al., 
2002).  At the other end of the clinical spectrum, asymptomatic HBeAg-negative chronic 
carriers with viral  loads below  105  genomes/ml and normal liver enzyme values, tend to 
have  a  relatively  stable  course  with  low  rates  of  progression,  either  clinical  or 
pathological  (de  Franchis  et  al.,  1993).  At  present  this  group  of  patients  is  largely 
excluded from therapy. However, there is a growing argument even for treatment of these 
patients, because of the possible risk of the development of hepatocellular carcinoma, as 
this risk  may be  higher in certain ethnic groups  (Yang et al.,  2002;  Yuan  et al.,  2005). 
HBeAg-negative patients with substantial viraemia and elevated liver enzymes should be 
offered  anti-viral  therapy,  though  the  most effective  treatment  strategy  remains  unclear 
(Hadziyannis et al., 2003; Lok and McMahon, 2001).
Nor  is  it  clear,  which  markers  best  measure  a  response  to  therapy  in  this  patient 
population.  Reduction  in  viral  load  is  routinely  analysed  and  a  downward  trend 
interpreted as a response, but there are few studies detailing the clinical interpretation of 
results.  On  the  contrary,  HBeAg  seroconversion  in  HBeAg  positive  individuals  and 
reduction  in  viral  load  are  all  features  which  are  known  to  be  associated  with 
improvement in liver histology and survival (Niederau et al.,  1996).
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by the development of resistance to nucleoside analogues. Interferon alfa first licensed for 
the treatment of chronic HBV in  1992, and administered subcutaneously three times per 
week resulted in HBeAg loss, development of anti-HBe antibodies and a decline in serum 
alanine aminotransferase levels, in about 30% of patients who tolerated the drug. Such a 
response  to  interferon  is  also  considered  to  be  durable  long  after  discontinuation  of 
therapy (Wong et al.,  1993). The side effects of interferon alpha have frequently deterred 
patients  from  embarking  on  a  course  of interferon  as  a  first choice  in  the  treatment of 
HBV.  Fevers,  myalgia,  thrombocytopaenia and depression  are all  well  documented  and 
are often intolerable to many patients.  Moreover, interferon’s immunomodulatory effect, 
namely  an  augmented  immune  responsiveness,  is  suggested  by  the  flares  of  liver 
enzymes,  which  can  be  induced  by  its  administration.  However,  such  flares  may 
precipitate  overt  liver  failure  in  patients  with  advanced  liver  disease  and  so  interferon 
remains contra-indicated in this patient group.
Lamivudine,  a  nucleoside  analogue  reverse  transcriptase  inhibitor,  with  the  ability  to 
directly block replication of the HBV genome was initially used in the treatment of HIV 
and was approved for the treatment of HBV in  1998. The initial use of lamivudine in the 
treatment of HIV and HIV/HBV co-infection revealed substantial reductions in the level 
of HBV  DNA  and  these  findings  were  replicated  in  patients  with  chronic  HBV  mono­
infection  (Dienstag  et  al.,  1999;  Puoti  et  al.,  2002).  Treatment  with  lamivudine  is 
associated  with  a  3  to  4  log  reduction  in  circulating  levels  of HBV  DNA  in  the  early 
stages of therapy. There is an associated rapid loss of HBeAg and seroconversion to anti-
41HBe positive  status  in  upto 20%  of patients  at 48  weeks therapy;  a reduction  in  serum 
aminotransferases usually ensues.  Lamivudine is generally  well tolerated with few side- 
effects;  furthermore  it  does  not  possess  the  overt  immunomodulatory  properties  of 
interferon  and  so  can  be  used  in  patients  with  advanced  liver  disease  and  even  in 
decompensated  cirrhosis  (Villeneuve  et  al.,  2000).  As  a  result,  lamivudine  is  now  the 
most widely used first line agent in the treatment of HBV infection.
However, there is evidence that lamivudine requires an  adequate host immune response 
to be effective and the link between HBeAg clearance and high pre-treatment values for 
alanine  aminotransferases  has  been  demonstrated  (Chien  et  al.,  1999).  Pre-treatment 
values  of  aminotransferases  greater  than  five  times  the  upper  limit  of  normal  were 
associated  with  a  HBeAg  seroconversion  rate  of  65%  compared  with  only  5% 
seroconversion rate for those with pre-treatment aminotransferases of less than twice the 
upper limit of normal,  a rate  similar to that for spontaneous  loss of HBeAg.  The exact 
interplay between lamivudine and the immune response is still being investigated, though 
it is hypothesized that by reducing the viral load lamivudine enables the immune response 
to deal more effectively with the remaining infected hepatocytes in the host. This ability 
of lamivudine to bolster or reverse the CTL hyporesponsiveness has also been reported 
(Boni et al., 2001).
The limitation of lamivudine is the high rate of viral resistance. There is an ongoing need 
for newer and more effective agents (Leung et al., 2001; Liaw, 2000). Drug resistance in 
lamivudine monotherapy  is mediated largely by point mutations in the YMDD motif of
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lamivudine therapy  15-20% of patients have resistant variants in the circulation and this 
rises  to  40%  at  2  years  and  up  to  67%  after  4  years  (Liaw,  2000).  Despite  the 
development of resistance, 40-50% of patients have undergone HBeAg seroconversion by 
the end of 4 years of therapy. How best to tackle lamivudine resistance is still a subject 
for debate.  Discontinuation of antiviral  therapy  can be  associated  with exacerbations of 
liver injury (Honkoop et al., 2000) and this pattern of liver injury has also been observed 
on the withdrawal of other antiviral agents (Marcellin et al., 2003).
Adefovir  dipivoxil,  approved  by  the  FDA  for  the  treatment  of  HBV  in  2002,  is  a 
monophosphate  nucleotide  analogue  that  requires  intracellular  conversion  by  cellular 
kinases to its virologically active diphosphate metabolite.  Adefovir diphosphate inhibits 
viral  DNA  polymerase  enzymes  of  various  hepatitis  and  herpes  viruses  as  well  as 
retroviruses  including  HIV.  Incorporation  of the  drug  into  viral  DNA  results  in  DNA 
chain termination and eventual impairment of viral replication (Marcellin et al., 2003). At 
lower doses than previously used in HIV, Adefovir (lOmg per day) can lead to a 3-4 log 
reduction  in  HBV  DNA  in  HBeAg  positive  patients  and  there  is  associated  histologic 
improvement  in  the  liver  (Marcellin  et al.,  2003).  Efficacy  in  the  treatment of HBeAg 
negative  patients  with  elevated  liver  enzymes  and  HBV  DNA  is  well  documented 
(Hadziyannis et al., 2003). Furthermore, it has shown potency in inhibiting the replication 
of lamivudine  resistant  HBV  mutants,  both  in-vitro  and  in-vivo,  making  it  the  drug  of 
choice in cases of lamivudine resistance (Perrillo et al., 2000; Ying et al., 2000).
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the long acting formulation of interferon, peginterferon alfa-2a have been available since 
2005.  Entecavir  is  extremely  potent  and  highly  selective  for HBV  polymerase  with  no 
activity  against  HIV  (Lai  et  al.,  2002).  Again  it  is  reported  to  be  active  against 
lamivudine resistant HBV. Tenofovir, presently licensed for the treatment of HIV, has not 
yet  been  approved  by  the  FDA  for  the  treatment  of  HBV  infection.  This  adenine 
nucleotide analogue is active against the HBV polymerase and has reported reductions of 
4 logs in the circulating levels of HBV DNA with activity also extended to patients with 
lamivudine resistance (Nelson et al., 2003; Ristig et al., 2002).
Despite  the  growing  number of antivirals  at  our disposal  and  more  importantly  a  very 
effective  vaccine,  HBV  continues  to  evade  current  management  strategies.  This  is 
primarily as a consequence of drug resistance. The best strategy to overcome this obstacle 
is  still  unclear.  With  an  increasing  number  of antiviral  agents,  some  of which  I  have 
discussed,  only randomized controlled clinical trials will  address what the best agent or 
combination  of agents  will  be  to  treat  chronic  HBV  in  the  future.  However,  the  sub- 
optimal  therapies  currently  at  our  disposal,  challenges  our  understanding  of HBV  at  a 
molecular  level.  Clearer  understanding  of the  immunopathology  of HBV  is  a  requisite 
for improved  finite treatment of HBV.  Better definition of the host’s immune response 
and  the  pathogenesis  of  HBV  will  also  provide  much  needed  insight  into  how  the 
immune system can be manipulated to tackle this virus. This thesis will examine the role 
of the NK cell  activating receptor NKG2D  in  the immunopathogeneis of chronic HBV
44infection.  The definition  of this novel  receptor and  its place  in  governing  CD8+ T 
response in chronic viral hepatitis will be investigated in humans for the first time.1.2.1  HEPATITIS C VIRUS
Hepatitis  C  virus  (HCV)  is  a non-cytopathic,  hepatotropic  RNA  virus.  HCV  can  cause 
both acute and chronic hepatitis, but is believed to cause chronic infection in 60-80% of 
infected  adults  (Figure  1.7)  and  as  many  as  200  million  people  are  estimated  to  be 
persistently infected worldwide. Chronic HCV infection is a major cause of liver damage 
leading to liver fibrosis, cirrhosis and hepatocellular carcimoma. Host immune responses 
are critical in determining the outcome of infection, with efficient helper and cytotoxic T 
cell responses resulting in viral control, while failure to mount such responses results in 
the insidious disease that is chronic HCV infection.
Several factors have impeded progress in the study of hepatitis C, all of which relate to 
the  limitations  of studying  the  virus  in  man,  its  natural  host.  Furthermore,  the  lack  of 
reliable  and  efficient  cell  culture  systems  has  compounded  this  problem.  Despite  this, 
experimental  data  is  providing  greater  insight  into  the  mechanisms  of  type  C  viral 
hepatitis. Studies in the chimpanzee, the only animal that can be infected with HCV have 
provided a clearer understanding of the in vivo immunological response in HCV infection 
(Rehermann and Nascimbeni, 2005).
This  Introduction  will  provide  an  overview  of  our  current  understanding  of  HCV 
immunopathogenesis  in  the  context  of  the  increasing  clinical  challenge  that  HCV 
represents. This essential background information will provide a platform for the work of
46this  thesis  which  examines  specific  areas  of  T  cell  im m unology  in  chronic  HCV 
infection.
Figure 1.7. The natural history of HCV infection.
1.2.2  A brief history of HCV
The  identification  of HCV  in  1989 (Choo et al.,  1989)  ended  a  protracted  search  for the 
major  cause  of  hepatitis  arising  from  blood  transfusions.  Since  the  developm ent  of 
diagnostics  for the  hepatitis  A  virus  (H A V )  and  HBV  in  the  1970s,  it  was  apparent that 
there  was  a  blood  borne,  so  called  non-A,  non-B  hepatitis  (N A N BH )  virus  which  had
47remained elusive  (Feinstone et al.,  1975). The difficulty in detection,  identification  and 
verification  of  this  NANBH  agent,  as  what  is  now  known  as  type  C  viral  hepatitis, 
reflects  the  difficulty  in  reliably  isolating  this  virus.  Although  readily  transmissible  to 
chimpanzees, progress in  studies of the  virus was limited by the failure of conventional 
immunological methods to identify specific viral antibodies and antigens (Bradley,  1985). 
Subsequent to the designation  of this  NANBH  agent as  HCV,  the  same group reported 
the development of a recombinant protein based assay for HCV antibody detection (Kuo 
et al.,  1989) and in  1990 a PCR assay was developed that could specifically detect HCV 
RNA genomes in liver and serum (Weiner et al.,  1990).
1.2.3  Epidemiology
Prevalence  rates  vary  considerably  with  geographical  location  throughout  the  130 
countries  worldwide  reported  to  be  affected  (Figure  1.8).  The  prevalence  of  HCV 
seropositivity  in  healthy  blood  donors  in  the  U.K  is  of  the  order  of  0.01-0.02%. 
Prevalence rates in Equatorial Africa are recorded at up to 6.5% and up to 28% in Egypt, 
where parenteral antischistosomal therapy is thought to have contributed to the high rates 
of  antibodies  against  HCV  (Frank  et  al.,  2000).  In  the  United  States,  1.8%  of  the 
population is positive for HCV antibodies with 74% of this group being positive for HCV 
RNA,  equating  to  2.7  million  chronically  infected  persons.  Illegal  drug  use,  more 
specifically  injection  drug  use,  and  high  risk  sexual  behaviour  are  factors  strongly 
associated with HCV infection (Alter et al.,  1999).
48Prior  to  the  introduction  of  screening,  a  significant  proportion  of  infected  subjects 
acquired HCV through  the transfusion of contaminated blood or blood products  (Alter, 
1994;  Schiff,  1994; Tong et al.,  1995). The screening of donor blood products for anti- 
HCV  antibodies  has  reduced  the  risk  of infection  to  less  than  1   in  103,000  transfused 
units  (Schreiber  et  al.,  1996).  This  is  still  nearly  five  times  the  estimated  risk  of 
transfusion  related  infection  with  HIV-1  infection  (1  in  493,000)  but  about  half  the 
equivalent risk for transfusion related infection with HBV (1  in 63,000) (Schreiber et al., 
1996).  The  more recent  introduction  of screening  pooled  samples by  polymerase  chain 
reaction  (PCR)  will  ensure  that  the  risk  associated  with  blood  transfusion  will  now  be 
even lower than previously estimated (Beld et al., 2000).
In  some cases of HCV  infection,  no apparent risk factors can be identified (Alter et al., 
1992). This is an important point as it clearly may suggest an underestimation of absolute 
numbers  of infected  individuals  if all  risk factors have  not been  identified.  Alter et al. 
reported  a  number  of  associations  identified  as  increasing  the  risk  of  HCV  infection 
namely poverty, high risk sexual behaviour, less than  12 years education and having been 
divorced or separated (Alter et al.,  1999). Skin piercing procedures, tattooing, traditional 
practices (using non-sterilized knives) have also been shown to transmit the virus (Hayes 
and  Harkness,  2001).  Sexual  transmission  is  considered  to  be  an  inefficient  means  of 
transmission, and  whether this is a consequence of low levels of the virus in the genital 
fluids  or tissues  or due  to the  lack  of appropriate receptors  in  the  genital  tract remains 
unclear. What is clear is that sexual transmission of HCV is less efficient than is the case 
for HIV-1  (Wyld et al.,  1997).  However, sexual transmission is reported to be facilitated
49by  co-infection  with  HIV-1  but  the  precise  mechanism  of  this  is  poorly  understood. 
Vertical  transmission  is  also  increased  significantly  in  the  presence  of  maternal  co- 
infection  with  HIV  (Thomas et al.,  1998).  By contrast,  vertical  transmission of HCV  in 
the mono-infected mother is rare and this represents one of the major differences between 
type C and type B viral hepatitis.
HCV  virions  have  also  been  detected  in  saliva of infected  persons,  but this and  casual 
household  contacts  such  as  shared  razors  and  toothbrushes  all  appear to  be  inefficient 
modes of transmission of HCV (Couzigou et al.,  1993).
Figure 1.8. Geographic distribution of HCV infection.
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501.2.4  Biology of HCV
HCV  is  a  single  stranded  RNA  virus,  which  belongs  to  the  Flaviviridae  family;  with 
hepatitis  G  virus,  yellow  fever  virus  and  dengue  virus  being  the  most  closely  related 
human viruses (Robertson et al.,  1998).
The HCV genome is a single stranded positive sense RNA with 9,500 nucleotides and is 
comprised  of  a  single  long  open  reading  frame  (ORF)  flanked  by  two  untranslated 
regions (UTRs).  HCV encodes a polyprotein of approximately 3,000 amino acids which 
is  cleaved  into  10  polypeptides,  including  three  structural  (core,  El  and  E2)  and  non- 
structural proteins.  The envelope  protein  2  (E2) contains the two hypervariable regions 
(HVR  1   and  HVR  2)  which  show  marked  sequence  variability  owing  to  a high  rate  of 
mutation, the result of selective pressure by virus-specific antibodies. E2 also contains the 
CD81  binding site. CD81  is located on hepatocytes and B lymphocytes and is considered 
the cellular receptor or co-receptor for the  virus  (Pileri  et al.,  1998).  The  nonstructural 
proteins (NS) encode the virus-specific protease, helicase and polymerase and because of 
the  central  role  of these  proteins  in  the  virus  life  cycle,  they  are  targets  for  antiviral 
therapies (Kolykhalov et al., 2000). Likewise, the highly conserved untranslated regions 
at both ends of the viral RNA are also potential targets for antiviral therapies as they play 
a critical role in polyprotein translation and viral replication (Tang et al.,  1999).
51There  are  six  known  genotypes  (Gl-6)  and  more  than  50  subtypes  of HCV.  Different 
HCV genotypes have distinct geographical distribution in their prevalence.  Genotype  la 
is  the  most  common  in  the  U.S.A  and  Northern  Europe,  while  genotype  lb  has  a 
worldwide  distribution.  Genotype  2  represents  10-30%  of  all  HCV  types  but  is 
particularly common in Italy and Japan. More recently genotype 3a, with its origins in the 
Indian  subcontinent  and  Southeast  Asia,  has  spread  widely  and  rapidly  through  the 
intravenous drug  using community.  Genotypes 4,  5  and 6  are rare in  the  West,  but  are 
commonly  found in  Africa and the Middle East (G4),  South Africa (G5)  and Southeast 
Asia in the case of genotype 6. HCV genotype is the principal determinant of response to 
anti-viral  therapy  and  also  dictates  treatment  strategy  in  terms  of duration  of  therapy 
(Tang et al.,  1999).
1.2.5  HCV pathogenesis 
Early events
HCV  infection  results  in  strong  activation  of innate  immunity  and  has  been  shown  to 
significantly  induce  Type  1   interferons  (IFN),  IFN-a/p.  These  cytokines  possess  both 
antiviral  functions  and  immunomodulatory  effects  (Biron,  2001).  Despite  the resulting 
vigorous  innate  immune  response,  chronic  HCV  infection  appears  to  develop  in  the 
majority of individuals  and thus underlines the  inability  of the innate immune response 
alone to control virus (Bigger et al., 2001; Su et al., 2002).
52HCV infection in the chimpanzee model has demonstrated changes in the IFN-a response 
genes  within  2  days  of  HCV  inoculation  and  these  changes  parallel  virus  replication 
kinetics  (Bigger  et  al.,  2001).  HCV  replicates  immediately  in  man  and  viraemia  is 
detectable  within  1-2  weeks after exposure  (Thimme  et al.,  2001)  and  within  3  days in 
chimpanzees (Bassett et al., 2001). The ability of HCV to act as a type 1   IFN-a inducer is 
supported  by  the  enhanced expression  of IFN-a/p  genes  in  patients  with  chronic  HCV 
(Patzwahl et al., 2001). Studies to date have reported the antiviral effects of IFN may be 
limited to the early stages of HCV infection and this is supported by the efficacy of IFN- 
a   monotherapy  in  the  treatment  of patients  with  acute  HCV  infection  (Jaeckel  et al., 
2001). The role of type  1   IFNs appears to be the restriction of excessive viral replication 
in  the  early  phase  of  infection  and  not  HCV  clearance.  The  study  of  viral  kinetics 
supports this interpretation where the initial rapid and early peak of viraemia is followed 
by a 4-6 week period where the levels of HCV RNA remain stable or augment minimally 
(up to  106 RNA copies/ml in chimpanzees and  107in humans)(Bassett et al., 2001; Bigger 
et al.,  2001;  Major et al.,  1999).  This  period  of infection  is  remarkable  for the  lack  of 
HCV-specific T and B cell induction and the absence of liver inflammation. NK and NK- 
T cells are cellular components of the innate immune system that produce IFN-y and kill 
infected cells (Biron and Brossay, 2001). IFN-y production has antiviral effects but also 
mediates the recruitment of inflammatory cells to the liver (Kaneko et al.,  2000; Liu et 
al.,  2000;  Trobonjaca  et  al.,  2001).  However,  the  ability  of HCV  to  evade  the  innate 
immune  response  cannot  be  overlooked.  Recent  experimental  data  suggest  that  the 
NS3/4A  complex  cleaves  the  viral  polyprotein  but  also  cellular proteins  and  interferes
53with the signal cascade of RIG-1  and CARDIF which play a role in interferon expression 
and signalling (Li et al., 2005; Meylan et al., 2005).
The overt lack of liver inflammation in the first 4-6 weeks of infection suggests that the 
contribution of NK and NK-T cells is minimal in this period (Bassett et al., 2001; Bigger 
et al., 2001; Major et al.,  1999). The HCV protein E2 has been shown to directly inhibit 
global  NK  cell  function  (Crotta  et  al.,  2002;  Tseng  and  Klimpel,  2002)  which  could 
explain the absence of liver inflammation in the presence of HCV replication and IFN-a 
mediated NK  cell  recruitment to the  liver.  Bigger et al.  also reported  no change  in the 
expression levels of Interferon regulatory factor-1   (IRF-1), a transcription factor essential 
for  NK  cell  activity  in  vivo  (Duncan  et  al.,  1996),  in  the  livers  of  acutely  infected 
chimpanzees (Bigger et al., 2001).
The  first  signs  of  liver  inflammation,  namely  elevated  aminotransferases,  heralds  the 
involvement of the adaptive immune response with the detection of HCV-specific T cells 
in the circulation and liver (Thimme et al., 2002; Thimme et al., 2001).
HCV kinetics & the cellular immune response
Differences  in  the  timing  and  detection  of the  cellular  immune  response  in  HCV  may 
contribute to the difference of disease profile in  HBV and HCV  infection.  Despite this, 
patients  who  spontaneously  recover  from  HBV  and  HCV  infection  demonstrate  the 
ability to mount an efficient T and B cell response (Figure  1.9). On the contrary, patients
54who  develop  chronic  infection  are  found  to  have  weak  or  narrowly  focused  T  cell 
responses that are delayed and  som etim es transient (Rehermann and  Nascimbeni, 2005).
HBV-HCV
Share several features of adaptive immune response
Resolved infection  Persisten infection
Presence of an integrated activation  T   •   , ™   j ^   11 &   Impaired T and B  cell response
of both cellular and humoral arms  r  ..  ,  ,  r . . .   t unctional  delects
ol adaptive immunity.
1
Ability to mount an efficient T and B cell response 
is the main mechanism responsible for HBV and HCV control.
Figure 1.9. The control of HBV  &  HCV  infections is dependent on the same facets of the host’s 
immune response
Type  C  viral  hepatitis  differs  from  HBV  in  that  high  HCV  titres  are  usually  detected  in 
the  blood  within  1-2 weeks o f infection.  Despite this,  there  is a  major delay  between  the 
appearance  of high  viral  titres  and  the  detection  of HCV-specific T  cells  in  the  blood  of 
infected  patients.  As  mentioned,  it  can  take  from  5-9  weeks  for  such  responses  to  be 
detected  in  humans,  as  demonstrated  by  the  analysis  of  T  cell  responses  in  a  subject 
exposed  to  HCV  through  needlestick  injury  (Thimme  et  al.,  2001).  Sequential  liver 
biopsies  from  experimentally  infected  chimpanzees  showed  that  virus-specific  C D4  and 
CD8  T  cells  accumulate  in  the  liver  8-14  weeks  after  infection,  coinciding  with  viral
55clearance and  liver disease (Cooper et al.,  1999;  Thimme et al.,  2002).  Furthermore,  it 
has now been established that such virus-specific CD4 and CD8 T cell responses persist 
after viral  clearance  (Ferrari  et al.,  1994)  and  can  be  detected  up to  two decades  after 
recovery,  while  HCV-specific  antibodies  are  lost  in  some  individuals  (Takaki  et  al., 
2000).
A  prospective  study  in  intravenous  drug  users  has  provided  evidence  for  protective 
immunity  in  some  individuals.  Previous  HCV  infection  was  associated  with  a  reduced 
risk of developing a new viraemia or persistent infection on re-exposure to HCV (Mehta 
et al.,  2002).  Studies  in chimpanzees  support  this  clinical  observation  and  animals  that 
had previously recovered from HCV infection were found to have a milder course of liver 
disease  and  achieved  viral  clearance  within  a  shorter  timeframe  when  re-challenged. 
Viral clearance correlates with strong peripheral T cell responses and intrahepatic IFN-y 
production  (Bassett  et al.,  2001;  Weiner  et al.,  2001).  CD4  and  CD8  T  cell  depletion 
studies  have  demonstrated  the  need  for  CD4  help  in  the  maintenance  of  protective 
immunity while CD8 T cells have been shown to be the principal effectors of protective 
immunity (Grakoui et al., 2003; Shoukry et al., 2003). Furthermore, these studies suggest 
CD4 help  appears  to enable the  CD8+ T cells  to  keep pace  with  the evolution  of viral 
escape mutations.
561.2.6  T cell failure in HCV infection
HCV-infected  patients  who  develop  chronic  infection  are  characterized  by  weak, 
narrowly focused or absent virus-specific CD4 and CD8 T cell responses in the acute and 
chronic  phase  of HCV  infection  (Neumann-Haefelin  et  al.,  2005).  The  lack  of HCV- 
specific  T  cell  response  is  a  consequence  of  either  primary  T  cell  failure  or  T  cell 
exhaustion/deletion.  The  analysis  of  the  early  phase  of  HCV  infection  in  healthcare 
workers  after  accidental  needlestick  injury  reported  that  2/4  patients  who  developed 
persistent infection had no demonstrable HCV-specific CD4 T cell  response throughout 
the course of infection, indicative of primary T cell failure. The CD4 T cell response in 
the other two patients was transient or episodic (Thimme et al., 2001) and the loss of the 
CD4  T  cell  responses  coincided  with  re-emergence  of  viremia,  suggesting  T  cell 
exhaustion.
The mechanisms of primary T cell failure remain unclear. There are reports of dendritic 
cell  (DC)  dysfunction  in  chronic  hepatitis  C,  where  both  DC  and  macrophages  exhibit 
impaired  antigen  presentation,  but  this  remains  controversial.  However,  reduced  11-12 
production is reported in chronic HCV and this correlates with weak HCV-specific T cell 
responses  (Anthony  et al.,  2004).  Deletion  of virus-specific  T  cells  in  the  presence  of 
continuous high viral loads in LCMV infected mice (Moskophidis et al.,  1993) may help 
to explain  T cell  exhaustion  resulting  in  chronic  HCV  infection.  In  the  LCMV  model, 
high  viral  loads driving the  activation  and  expansion of antigen-specific  CD8  cells  can 
lead to functional inactivation resulting in irreversible anergy and/or deletion.
571.2.7  Viral escape mutations
The  appearance  of  the  adaptive  immune  response  is  associated  with  the  selection  of 
quasispecies and escape mutants (Erickson et al., 2001). Viral escape mutations result in 
inefficient  antigen  recognition  by  impairing  antigen  binding  to  the  MHC  molecules 
and/or T cell receptors.  The high rate of HCV replication together with its quasispecies 
nature and lack of proof reading capacity of the RNA polymerase contributes to the rapid 
diversification of the viral population. The same studies report that progressive evolution 
of viral diversity in hypervariable region  1   of E2 results in chronically evolving hepatitis. 
T cell escape is reported to be an early event (Erickson et al., 2001) and it is noteworthy 
that escape  mutations  detected  in  chronically  infected  patients did  not diversify  further 
during several years of follow-up (Chang et al.,  1997). The selection of escape variants in 
the presence of weak as opposed to robust HCV-specific T cell response (Cooper et al., 
1999; Erickson et al., 2001) suggests that it is the weak T cell responses which make viral 
escape possible.
1.2.8  T cell dysfunction
T  cell  dysfunction  is  a  reported  phenomenon  in  the  early  stages  of acute  HCV  in  all 
patients,  irrespective  of  outcome.  However,  in  those  with  a  self  limited  course  of 
infection, recovery of CD8+ T cell function was associated with a decline in viremia and 
resolution  of  disease  (Thimme  et  al.,  2001)  while  CD8+  T  cell  function  remained
58suppressed in those who progressed to chronic infection (Urbani et al., 2002). Urbani et 
al  also  reported  functional  differences  in  virus-specific  CD8+  T  cells  between  acute 
hepatitis B  and C, thus supporting a role for virus-specific CD8 cells in  successful viral 
clearance. HCV-specific CD8 cells in the acute phase of infection express lower levels of 
perforin  and display reduced  functional capacity  in terms of proliferation,  lytic  activity 
and  IFN-y  production  in  contrast  to  the  functional  efficiency  reported  in  HBV.  This 
suggests the  functional  defect  is  present  irrespective  of the  final  outcome  of HCV,  but 
may only be a transient effect.
Studies in mice have indicated that high viral loads may lead to T cell unresponsiveness, 
referring to the  inability  of CD8+ T cells  to produce  IFN-y upon  antigenic  stimulation 
(Neumann-Haefelin  et al.,  2005).  Data  is  limited  on  the  effect  of viral  load  on  T  cell 
function during the natural course of infection. However,  studies have demonstrated the 
enhancement of the proliferative responses of HCV-specific CD4+ T cells in chronically 
HCV  infected patients during combination  antiviral therapy  (Barnes et al., 2002),  again 
suggesting that high viral loads may inhibit virus-specific T cell responses.
T cell dysfunction is not limited to the circulatory compartment, nor is it restricted to the 
CD8 T cell population (Ulsenheimer et al., 2003). Furthermore, it has been reported that 
the effects of HCV on T cell maturation are not limited to HCV-specific CD8+ T cells. 
CMV-specific T cells  were  shown to express  a less mature phenotype  in chronic HCV 
infection (Lucas et al., 2004), but no functional impairment in vitro was reported in these
59patients.  Regulatory T cells described in the blood and livers of individuals with chronic 
HCV may also contribute to the suppression of HCV-specific T cell function.
Viral  proteins  have  also  been  shown  to  directly  modulate  immune  responses  to  HCV. 
HCV core protein expressed in hepatocytes and lymphocytes interacts with TNF receptor 
1   (TNFR1)  and  Fas,  modulating  the  apoptosis of these cells  (Neumann-Haefelin  et al., 
2005). Extracellular core protein interacts with the complement receptor gClqR on naive 
T cells, dendritic cells and macrophages and so impairing T cell activation, proliferation 
and  IFN-y production  (Kittlesen  et al.,  2000).  Circulating  HCV  core  protein  has  been 
shown to inhibit IFN-y secretion by CD8+ T cells. The addition of exogenous IL-2 to in 
vitro T cell culture has been demonstrated to reverse the inhibitory effects of HCV core 
on T cell function (Accapezzato et al., 2004).
1.2.9  Humoral immune responses
HCV-specific  antibodies do not reflect specific stages of disease as is the case in  HBV. 
The appearance of HCV-specific antibodies is variable in infected patients; no antibodies 
appear early after infection and may be delayed for up to 2-3 months or not appear at all. 
HCV-specific  antibodies are not maintained for life and can disappear  10-20 years after 
recovery from infection (Rehermann and Nascimbeni, 2005).  Antibodies specific for the 
HCV  envelope  glycoproteins  (El  and  E2)  have  been  shown  to  neutralize  in  vivo 
infectivity of HCV in chimpanzees and modulate HCV RNA levels in vaccinated and re­
60challenged  chimpanzees  (Foms  et al.,  2000).  The  development  of tissue  culture  based 
assays has allowed the identification of antibodies that block HCV entry into hepatocytes.
The  use  of replicon  systems,  although  incapable  of supporting  virus  production,  have 
advanced our understanding of the HCV viral life cycle. This work has recently led to the 
isolation of JFH-1  which  is capable of viral particle production in permissive cells,  and 
thus expediting studies of HCV replication (Bukh and Purcell, 2006). Pseudoparticles are 
retroviral nucleocapsids surrounded by lipid envelope into which HCV glycoproteins can 
be embedded, enabling studies of possible antibody neutralisation.
Antibodies that neutralize HCV pseudotypes in vitro have been found to be strain specific 
and  present  at  very  low  levels  in  vivo  during  the  first  six  months  of  HCV  infection. 
Patients  who  recover  within  the  first  months  of HCV  infection  test  negative  with  this 
assay (Bartosch et al., 2003; Logvinoff et al., 2004).  Logvinoff et al also reported that it 
may  take  up  to  6-12  months  until  antibodies  with  increased  neutralization  titres  and 
crossreactivity with El  and/or E2 of different HCV quasi species appear. While recovered 
patients  test  negative,  the  highest  antibody  titres  are  found  in  patients  with  established 
chronic HCV infection, which is indicative of the emergence of escape mutants (Farci et 
al., 2000).
611.2.10  Clinical Course of HCV infection
Acute HCV infection, as described, is characterized by detectable viraemia in the serum 
of almost all patients within  1-2  weeks of exposure.  However, the acute phase of HCV 
infection is usually asymptomatic and is rarely diagnosed at this time. As a consequence, 
there  is  a  lack  of  experimental  data  investigating  the  host  cellular  immune  response 
during this critical phase of the infection. Clinical symptoms such as jaundice, which are 
attributed to T-cell mediated liver injury,  are rare  in HCV but when present appear 6-8 
weeks after exposure to the virus.  There are also reports of severe acute hepatitis  and a 
fulminant hepatitis related to HCV, but again, this is extremely rare (Farci et al., 1996). 
HCV is reported to establish chronic hepatitis in 60-80% of infected adults (Seeff, 2002). 
Chronic  HCV  infection  is  associated  with  a  prolonged  symptom-free  period  with  the 
interval between primary infection and the development of cirrhosis lasting between 20 
and 30 years.  Once persistent  infection  is established,  which is associated  with hepatic 
necroinflammation and a varying degree of fibrosis, spontaneous clearance of viraemia is 
rare (Seeff et al., 2000) and the major long-term complications of chronic hepatitis C are 
cirrhosis,  end-stage  liver  disease  and  hepatocellular  carcinoma.  Death  due  to  chronic 
HCV  infection  is  most  frequently  observed  in  persons  with  cirrhosis,  and  cirrhosis  is 
estimated to develop in 20% of infected individuals.
Despite  the  many  studies  reporting  natural  history  of  HCV,  chronicity  and  the 
development  of  cirrhosis,  there  are  a  number  of conflicting  reports  regarding  disease 
progression.  Studies  reporting  the  outcome  of  patients  infected  with  HCV  through
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of cirrhosis is as low as 2%, twenty years after exposure (Kenny-Walsh,  1999; Wiese et 
al., 2000). How best to interpret this discrepancy is unclear.
One  explanation  relates  to  the  study  population,  the  patients  included  in  these  studies 
shared  a  common  number of characteristics  reported  to  be  associated  with  a  favorable 
outcome to HCV  (or slow rate of progression of disease); these include female  sex  and 
young age at infection;  and  therefore may underestimate the true percentage of patients 
developing clinical sequelae. It is also argued that the homogenous nature of these study 
populations  is  unrepresentative  of HCV  infection  in  the  general  population  where  the 
development  of HCV  related  chronic  liver disease  is  known  to  be  highly  variable  and 
unpredictable.
In  contrast  male  sex,  older  age  at  infection  and  co-infection  with  HIV-1  or  HBV  are 
associated with a predicted accelerated clinical progression (Poynard et al.,  1997; Zarski 
et al.,  1998). Alcohol intake is also reported to have a pronounced effect on the course of 
disease.
The development of hepatocellular carcinoma (HCC)  in HCV  is  also  reported to differ 
from  that  in  HBV.  It  is  reported  that  HCC  can  develop  in  the  absence  of cirrhosis  in 
patients with chronic hepatitis B, but this is extremely rare  in patients  with  hepatitis C. 
On the contrary, established HCV related cirrhosis is associated with a 1-4% risk per year
63of  developing  HCC,  (Tsukuma  et  al.,  1993)  necessitating  increased  supervision  of 
cirrhotic patients and cancer screening programmes.
The changing landscape of HCV infected individuals; where injection drug use is now the 
major risk factor for HCV  infection  has brought  new challenges to the management of 
hepatitis C virus.  Co-infection  with HIV-1  (and other viruses)  will  add to the burden of 
already sub-optimal treatment strategies. The gravity of this situation has been reported in 
a European cohort,  where 75%  of HIV-1  positive patients with a history of intravenous 
drug use were reported to be co-infected with HCV (Soto et al.,  1997).
This fell to 33% in HIV-1  patients in the absence of injection drug use, highlighting the 
possible increased sexual transmission of HCV in the presence of HIV-1. With or without 
injection  drug  use,  HIV  co-infection  is  associated  with  an  accelerated  course  of HCV, 
with a reported risk of cirrhosis of 25% after 15 years in this cohort, compared with 6.5% 
in  HCV  mono-infected  persons  (Sanchez-Quijano  et  al.,  1995).  A  similar  pattern  of 
accelerated disease is also reported for individuals with HBV/HCV  co-infection  (Zarski 
et al.,  1998).
1.2.11  Hepatitis C and Therapy
Treatment of hepatitis C was initially based on the administration of interferon alfa, with 
its  ability  to  alter  host-virus  interactions  in  a  way  that  is  not  fully  understood.  The
64antiviral effect of interferon is mediated through the host response (Pawlotsky, 2000) and 
it  appears  to  be  most  effective  in  the  setting  of early  HCV  infection.  Interferon  is  a 
natural cellular protein capable of 1)  induction of cytokine secretion, 2) induction of an 
antiviral state in their target cells, 3) recruitment of immune cells and 4) induction of cell 
differentiation (Baron et al.,  1991; Lengyel,  1982).
However, it has been the addition of ribavirin, a synthetic guanosine analogue, which has 
potentiated  the  antiviral  effects  of  interferon  alfa  (Pawlotsky,  2000)  and  dramatically 
changed response rates in HCV. Ribavirin selectively inhibits viral RNA polymerases in 
vitro and in the past was used primarily for the treatment of severe respiratory  syncitial 
virus infection  in  infants.  When given alone, ribavirin has not proven to be effective in 
the  treatment  of  chronic  HCV  (Di  Bisceglie  et  al.,  1995).  The  mechanisms  of  how 
ribavirin potentiates the immunomodulatory effects of interferon are not well defined. It 
has  been  reported  that  ribavirin  could  alter  the  Th-l/Th-2  balance  by  causing  a  shift 
towards Th-1 responses (Hultgren et al.,  1998), alternatively it may relate to the ability of 
ribavirin  to  suppress  HCV-specific  IL-10  production  (Cramp  et  al.,  2000).  With  the 
combination of ribavirin and interferon, given for 24 weeks (genotype 2 & 3) or 48 weeks 
(genotype  1   & 4), 40% of all patients achieve a sustained virologic response (SVR) and 
the associated potential longterm benefits (Poynard et al.,  1998).
The  addition  of  the  polyethyleneglycol  (PEG)  molecule  to  interferon  produced  a 
biologically  active  molecule  with  a  longer  half-life  and  improved  pharmacokinetics 
compared with the natural molecule. This led to the introduction of the more convenient
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interferon, when given alone for 48 weeks, was reported to double the SVR rate seen with 
standard interferon in the treatment of chronic hepatitis C (Lindsay et al., 2001; Zeuzem 
et  al.,  2000).  Despite  this,  relapse  rates  remained  high  with  pegylated  interferon 
monotherapy and most patients with genotype  1   HCV failed to achieve SVR. The natural 
progression from here, to optimize treatment strategies was to give pegylated interferon 
in  combination  with  ribavirin  (previously  shown  to  decrease  the  risk  of relapse  when 
given in combination with standard interferon).
This combination of antiviral therapy has increased the SVR rate compared with that of 
previous  combination  therapy  over  the  same  timeframe  (Manns  et  al.,  2001).  The 
improved response rates of upto 80%  in genotypes 2 &  3  and 50% in genotypes  1   & 4 
coupled  with  the  more  convenient  once  weekly  dosing  with  pegylated  interferon  in 
combination  with  daily  ribavirin  has  led  to  the  introduction  of  this  regimen  as  the 
standard for the treatment of hepatitis C virus.
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MATERIALS AND METHODS2.1  GENERAL MATERIALS AND METHODS
The  Materials  and  Methods  employed  in  this  thesis  vary  in  the  two  different  studies 
undertaken. Materials and methods specific for each project are discussed in more detail 
in the respective chapters.
2.2  Ethics
Ethics approval was sought and granted by the local Ethics committee at the Royal Free 
Hospital,  London for  all  patients  recruited from the  Viral  Hepatitis  Clinic  at  the Royal 
Free. Collaborative work with the Department of Obstetrics and Gynaecology, UCL was 
approved  by  the  local  Ethics  committee  at  University  College  London  Hospitals. 
Additionally,  patients  recruited  for  inclusion  in  the  cross-reactivity  study  by  our 
collaborators  in  Parma,  Italy  had  approval  for this  study  by  formal  submission  to  their 
local  Ethics  committee.  Patients  were  invited  to  partake  in  the  study  and  if agreeable, 
informed written consent was obtained before inclusion. The study protocol conformed to 
the ethical guidelines of the  1975 Declaration of Helsinki.
682.3  Viral testing at the Royal Free Hospital
Specific clinical viral testing was performed using the following:
Viral  serology for hepatitis B  virus was performed with the HBsAg-Ultra (Biomedieux, 
France).  The  remaining  serological  markers  (HBeAg,  anti-HBe  etc.)  were  tested  with 
Vitros  ECI  Analysers  (Clinical  Diagnostics,  UK).  HBV  DNA  was  measured  using  the 
Roche Cobas Taqman HBV  assay  (Genotypes A-G). The dynamic range of HBV DNA 
measurement is  12 IU/ml-100 xlO6   IU/ml. Viral loads by quantitative PCR at The Royal 
Free were given  in both  IU  and copies/ml,  with the  value for IU being  multiplied by  a 
factor of 5.82 to obtain the level in copies/ml.
HCV antibodies were tested with Vitros ECI ELISA (Ortho-Clinical Diagnostics, USA). 
Anti-HCV positive subjects but HCV RNA negative were then tested with a Chiron HCV 
RIBA (Chiron, USA) to confirm anti-HCV positive status.
At present HCV RNA is tested with the automated Abbott system.
Initially this was Abbott LCX HCV PCR (Abbott, USA) with a lower limit of detection 
of 50 IU/ml. Currently Abbott Real Time, HCV PCR with a lower limit of detection of 23 
IU/ml.  Prior to March 2004, HCV RNA was tested with Bayer branched DNA or Bayer 
TMA assay (Bayer, Germany) with a lower limit of detection of 650 IU/ml.  HCV RNA 
positive samples were routinely tested for genotype. This was determined using a Bayer 
AutoLiPA (Bayer, Germany).
692.4  Clinical Definitions
1. Negative Controls
Individuals  without  viral  or  biochemical  evidence  of viral  hepatitis.  Specifically  these 
individuals had no history of exposure to or indeed risk factors for viral hepatitis. None of 
the negative controls were laboratory or hospital workers.
2. Exposed non-infected individuals
Individuals exposed  to  virus  but  with  no clinical/diagnostic  parameters  of infection.  In 
this  study  all  of  these  subjects  were  the  sexual  partners  (SP)  of  chronically  infected 
patients.
3. True naives
Cord  blood  was  obtained  from  infants  born  to  HCV  negative  mothers  and  the 
immunological profile in this instance was considered as a truly naive T cell population 
against which all other responses were measured.
4. Chronic HCV
Chronic  HCV  infection  is  characterised  by  elevated  liver  function  tests  (LFTs)  and 
defined as the detection of HCV RNA by PCR (detection limit as described above) on at 
least two consecutive occasions six months apart.
705. Spontaneously resolved HCV infection
Spontaneously resolved HCV infection  is defined  as the  absence of detectable levels of 
HCV RNA by PCR (using the assay described above), in the presence of HCV antibodies 
on at least two occasions six months apart.
6. Chronic HBV
HBsAg is the hallmark of hepatitis B virus infection and its persistence in the blood for 
more  than  six  months  implies  chronic  infection.  Tests  for  HBV  DNA  in  the  serum 
(described above) are used to assess the level of HBV replication.
7. Normal liver tissue
Liver  tissue  acquired  at  the  time  of  hepatic  resection  for  liver  metastases.  Liver 
specimens acquired were negative for chronic viral hepatitis and were from subjects with 
no known history of chronic liver disease. Liver tissue was acquired from the tumour free 
margins at the time of metastasis resection.
8. Orthotopic Liver Transplantation (OLT)
Liver retrieved  at  the  time  of OLT  for chronic  viral  hepatitis.  Explant  tissue  acquired 
from patients undergoing transplantation for end-stage chronic viral hepatitis. Liver tissue 
was cut and removed from the explant under the supervision of the histopathologists.
712.5  Peripheral blood samples
Peripheral blood samples were obtained from patients and negative controls recruited for 
the study. This included the acquisition of blood from patients with chronic viral hepatitis 
(HBV  and  HCV  infection),  and  in  some  instances  the  sexual  partners  of  patients 
attending  the  viral  hepatitis  clinic  at  the  Royal  Free.  Blood  was  usually  drawn  in  the 
clinic  and  between  40-50ml  of blood  was collected  for the purpose  of the  study  at the 
time of venepuncture. In patients recruited for the NKG2D study, blood was taken at the 
time of liver biopsy, usually performed on the ward and described below. Blood samples 
were  collected  in  heparinised  vacutainers  and  then  taken  to the  laboratory  (Institute  of 
Hepatology,  Chenies  Mews)  where  the  isolation  of peripheral  blood  mononuclear cells 
(PBMC) was performed.
PBMC  were  isolated  by  density  gradient centrifugation.  The  whole  blood  was  layered 
onto  lymphoprep  (Oslo,  Norway)  taken  from  a  4°C  fridge  and  allowed  to  reach  room 
temperature.  The  blood  to  lymphoprep  ratio  was  2:1.  This  was  then  centrifuged  at 
2100rpm for 20 minutes  with no brake. The PBMC fraction was removed with a sterile 
Pasteur pipette  and  washed  once  at  1800rpm  for  10  minutes.  One  further  slower wash 
was  then  performed  (llOOrpm)  for  9  minutes.  PBMC  were  then  resuspended  and 
counted. The majority of experiments were set up directly ex vivo using the fresh PBMC. 
Where this was not possible, PBMC were resuspended in freeze medium, transferred to 
cold  freezing  vials  (Nunc,  U.S.A)  and  immediately  transferred  to the  -80°C  freezer for
72analysis at a later time. PBMC were frozen in aliquots of 10-15xl06cells/vial. Short term 
storage was at -80°C and long term storage was in liquid nitrogen.
To  defrost  frozen  PBMC,  vials  of  cells  were  rapidly  thawed  in  a  water  bath  and 
immediately washed in RPMI before resuspension and use.
2.6  HCV peptides and Matrix design
The experimental work in chapter 3 centres on the use of a large panel of synthetic HCV 
peptides covering the HCV  polyprotein.  601  15-mer peptides based on  the  sequence of 
HCV-1  [genotype  la  covering  all  structural  (core,  El,  E2)  and  non-structural  proteins 
(NS3,  NS4,  NS5)]  and  overlapping  by  10  residues  were  grouped  in  pools  of  12  in  a 
matrix  array,  such  that  each  peptide  was  present  in  two  pools  only.  106  peptide  pools 
were used in total, and the matrix for pools A1-A24 (peptides  1-144) are shown in Table 
2 . 1.
A positive response in two peptide pools containing the same peptide could then be used 
to  identify  the  single  putative  response,  which  was  then  confirmed  by  repeating  the 
experiment with the individual peptide.
The full list of all peptides used is given in Appendix  1.
73Al A2 A3 A4 A5 A6 A7 A8 A9 A10 All A12
A13 1 2 3 4 5 6 7 8 9 10 11 12
A14 13 14 15 16 17 18 19 20 21 22 23 24
A15 25 26 27 28 29 30 31 32 33 34 35 36
A16 37 38 39 40 41 42 43 44 45 46 47 48
A17 49 50 51 52 53 54 55 56 57 58 59 60
A18 61 62 63 64 65 66 67 68 69 70 71 72
A19 73 74 75 76 77 78 79 80 81 82 83 84
A20 85 86 87 88 89 90 91 92 93 94 95 96
A21 97 98 99 100 101 102 103 104 105 106 107 108
A22 109 110 111 112 113 114 115 116 117 118 119 120
A23 121 122 123 124 125 126 127 128 129 130 131 132
A24 133 134 135 136 137 138 139 140 141 142 143 144
Table 2.1, The HCV matrix, peptides  1-144
742.7  Intrahepatic T cells
The experimental work in Chapter 4 is based primarily on the acquisition of human liver 
tissue and the harvesting of intrahepatic lymphocytes.  Patients being investigated in the 
viral  hepatitis clinic  at the  Royal  Free  were invited to  partake  in the  study.  In  the  first 
instance, written informed consent was obtained and only where sufficient core material 
was attained  at the  time of biopsy  was  liver tissue  used  as part of the  study.  Generally 
speaking, only  liver tissue in excess of the  1.5cm in  length was used for the purpose of 
the study. Tissue was fixed in  10% zinc formalin for routine histological examination and 
surplus liver tissue was taken directly from the hospital ward to the laboratory for ex vivo 
analysis.
Further  specimens  were  obtained  at  the  time  of orthotopic  liver transplantation  and  at 
resection  of liver metastases.  OLT for end-stage  chronic  viral  hepatitis  (HBV  &  HCV) 
provided  the  opportunity  to  acquire  greater volumes  of liver tissue  and  so  run  parallel 
experiments  to  compare  and  optimize  methodology.  It  also  enabled  us  to 
comprehensively  study  the  effects  of  various  cytokines  on  the  same  population  of 
intrahepatic  lymphocytes  (IHL).  The  importance  of this  can  not  be  overstated  as,  the 
acquisition and study of human tissue is becoming increasingly challenging.
Diseased tissue was washed extensively in Hanks balanced salt solution (HBSS) and then 
manually disrupted in RPMI  1640 (Autogen Biotech) plus 10% fetal calf serum.
Resection of liver metastases provided us with the opportunity to acquire “normal” liver
75tissue. This tissue, from patients with no known liver disease, was resected away from the 
tumour margins, washed and disrupted in the same manner as the virally infected livers. 
Harvesting of IHL from fresh liver tissue is described in Chapter 4 and patient peripheral 
blood lymphocytes (PBL) were prepared in parallel by standard density gradient 
centrifugation as described previously.
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ANALYSIS OF T CELL RESPONSE AND THE 
INFLUENCE OF CROSS-REACTIVITY IN 
HEPATITIS C VIRUS
773.1.1  INTRODUCTION
CD8+  T  cells  recognize  processed  peptides  presented  in  the  antigen  binding  sites  of 
MHC class 1   proteins.  Presented  peptides are  usually  8  or 9 amino acids in  length  with 
distinct motifs that require two or three residues of the peptide to fit into the MHC groove 
(Falk  et al.,  1991).  The T cell  Receptor (TCR)  binds  to the  peptide-MHC  complex  by 
means of only  a few contacts  with  the peptide  side-chains that project out of the MHC 
groove (Bjorkman,  1997).
These  features  are  the  basis  of  the  specificity  of T  cell  recognition,  but  T  cells  also 
present an intrinsic degeneracy in their recognition of peptides. It has been calculated that 
a given TCR has the ability to recognize a million different peptide-MHC combinations 
(Mason,  1998).  For  this  reason,  single  T  cells  can  recognize  different  peptides  that 
present variable degrees of amino acid (AA) homology (Anderson et al.,  1992; Kuwano 
et al.,  1991)  and this degeneracy  of T cell  recognition  represents the  structural basis of 
the phenomenon of cross-reactivity (Welsh and Selin, 2002).
The  analysis  of  T  cell  clones  that  had  unexpected  crossreactivity,  such  as  vesicular 
stomatitis virus (VSV)- and influenza virus-specific CTLs, and were found to cross-react 
with uninfected allogenic targets (Braciale et al.,  1981a; Braciale et al.,  1981b;  Sheil et 
al.,  1987),  was explained by T cell degeneracy. Similarly, EBV infection in humans has 
shown  high  degrees  of  allospecific  CTL  activity  being  generated  during  infection 
(Burrows et al.,  1997; Tomkinson et al.,  1989; Yang and Welsh,  1986). This was initially
78attributed  to,  non-specific,  polyclonal  bystander  activation,  a  term  referring  to  the 
activation of T cells in which the TCRs are not being triggered by the antigens that are 
driving the immune response, but through a cytokine dependent process.  However, it is 
now considered to be secondary to T cell clones that are crossreactive with virus-infected 
syngenic targets and uninfected targets that express allogenic MHC antigens (Burrows et 
al., 1999; Nahill and Welsh,  1993; Selin et al.,  1994).
Importantly,  CD8+  T  cell  cross-reactivity  between  HCV  and  influenza  A  virus 
determinants have recently been demonstrated (Urbani et al.,  2005a; Wedemeyer et al.,
2001).
3.1.2  The phenomenon of T cell cross-reactivity presents two important implications 
in the study of viral immunopathogenesis:
The  presence  of  potentially  cross-reactive  T  cells  can  alter  the  clinical  and 
immunopathological profile of viral infection. Cross-reactivity could also account for the 
reported presence of virus- reactive T cells in subjects who lack all serological markers of 
viral infections.  Historically these results were interpreted as indicative of previous viral 
exposure.
We  have  analyzed  this  immunological  phenomenon  during  HCV  infection.  Before 
reporting the experimental data, we will provide a short overview of the impact of cross­
reactivity during viral infection.
793.1.3  Heterologous immunity during viral infection
The clinical  and pathological profiles of viral infections are variable.  Differences in the 
infection dose, viral strain and genetic make-up of the host have been invoked to explain 
the variability of outcomes and pathological manifestations.  A further possibility  is that 
the  variability  in  the  pathology  caused  by  viral  infections  strictly  reflects  different 
profiles  of T  cell  immunodominance  and  different  kinetics  of  T  cell  responses.  This 
phenomenon has been demonstrated in mice and  it is caused by the presence of a large 
repertoire  of memory T cells from earlier infections that can  cross-react  with  a  second 
infecting viral  pathogen,  leading to a massive recruitment of pre-existing  memory cells 
into a primary immune response (Brehm et al., 2002; Chen et al., 2001; Welsh and Selin,
2002).
3.1.4  Viral infections in the mouse model
Chen  et al reported  a  potent role  for memory  CD8+ T cells  in  heterologous  immunity 
using  a  respiratory  model  system  for  viral  infection  (Chen  et  al.,  2001).  Mice  were 
intranasally  infected  with  two  unrelated  viruses, LCMV  and  vaccinia  virus  (VV).  The 
mice  were  first  immunised  with  LCMV,  an  RNA  virus,  and  then  challenged  with  the 
unrelated  VV  (a  DNA  virus).  This  study  demonstrated  that  a  heterologous  virus  can 
induce  the  activation  of  cytotoxic  function  and  IFN-y  production  of  memory  T  cells 
specific to a previously encountered virus.  They also report the selective expansion and
80modulation of the original T cell repertoire as well as the organ-dependent redistribution 
of  these  antigen-specific  heterologous  memory  T  cells.  Intracellular  staining  of 
lymphocytes  isolated  from  VV-infected  LCMV  immune  mice  provided  evidence  that 
LCMV-specific  memory  CD8+  T  cells  were  activated  in  vivo  to  produce  IFN-y.  This 
resulted  in  a  reduction  in  the  viral  load  and  altered  immunopathology,  as  anti-IFN-y 
could enhance VV  titres in the LCMV  immune mice and blocked the infiltration of the 
lung with LCMV-specific memory T cells upon VV challenge. The absence of activated 
memory  T  cells  resulted  in  severe  lung  pathology  (acute  inflammatory  responses  and 
fulminant  pulmonary  oedema)  which  undoubtedly  contributed  to  the  high  mortality 
associated with VV infection in control mice.
However, it is noteworthy that the accumulation of LCMV-specific CD8+ T cells in the 
lung could also produce architectural changes, which again could be ablated by treatment 
with anti- IFN-y. The development of bronchiolitis obliterans in some of the VV-infected 
LCMV-immune mice was also attributed to this phenomenon. This study also reports the 
selective  expansion  and  accumulation  of  certain  epitope-specific  populations  of  the 
LCMV-specific  memory  CD8+  T  cells  on  exposure  to  VV.  Chen  et  al  attribute  this 
activation  and  selective expansion  in  the  lung to cross-reactive T  cell  responses.  Three 
VV  peptides  are  reported  to  share  homology  with  LCMV  NP205  and  are  capable  of 
stimulating  LCMV-specific  CD8+  T  cells  to  produce  IFN-y.  The  complexity  of  the 
memory CD8+ T cell response is also highlighted by this study,  where exposure to VV 
was  associated  with  a  differential  accumulation  of  LCMV-specific  CD8+  T  cells  to 
different  anatomical  sites.  The  selective  expansion  of  specific  epitopes  in  each  site
81resulted  in  the  development  of  different  repertoires.  It  has  been  proposed  that  the 
functional type of each LCMV epitope-specific memory T cell population may influence 
where they traffic during the resting memory state and during acute VV challenge.
3.1.5  Viral infections in humans
Many  viruses in humans,  such as Epstein-Barr virus, varicella-zoster and even the  1918 
influenza  virus  strain  have  been  reported  to  cause  much  more  severe  infections  in 
teenagers  and  young  adults  compared  with  the  disease  profile  in  young  children 
(Simonsen  et al.,  1998;  Welsh and  Selin,  2002).  Such  variations may be  attributable to 
immunopathology  occurring  as  a  consequence  of  the  reactivation  of  memory  T  cells 
which may be more prominent in  an immunologically mature individual.  Infection with 
Dengue virus is of importance in considering this phenomenon. The gravity of infection 
with different Dengue serotypes in a dengue virus immune individual can lead to severe 
immunopathological  responses.  These  responses  are  considered  the  consequence  of 
potent  reactivation  of  cross-reactive  T  cells  in  the  absence  of  protective  antibody 
responses (Welsh and Selin, 2002).
Urbani  et al.  in  a  recent  study  demonstrated  the potential  significance  of heterologous 
immunity in the pathogenesis of hepatitis C virus infection (Urbani et al., 2005a).  HCV 
typically has an asymptomatic onset but persistent infection is reported to develop in the
82majority of infected persons (60 to 80%) despite the presence of a CD8+ T cell response 
(Lechner et al., 2000b; Thimme et al., 2001).
Clinical symptoms (usually mild) may be present in up to one third of adults with acute 
HCV infection. Despite this, a severe acute hepatitis can develop but is rarely fulminant. 
The mechanisms responsible for such variability in the course and outcome of infection 
are poorly understood. Urbani et al. reported an association between a peculiar hierarchy 
of immunodominance of HCV-specific CD8+ T cell responses, cross-reactivity between 
HCV  and  influenza-specific  CD8  cells  and  a  severe clinical  course  of hepatitis  C.  The 
results  of this  study  suggest  a  role  for CD8+  T  cell  cross-reactivity  in  influencing  the 
severity  of the  HCV  associated  liver  pathology.  Furthermore,  it  illustrates  a  model  of 
disease  induction  that  can  be  applied  to  different  viral  infections  in  which 
immunopathology are sustained by the anti-viral immune response (Urbani et al., 2005a).
In  the  Urbani  study,  the  global  HCV-specific  T  cell  response  was  analysed  in  eight 
patients with  acute HCV with  variable outcomes. Two of the eight patients developed a 
severe clinical  course of acute  HCV  with extremely elevated  aminotransferases, rapidly 
rising bilirubin levels and prolonged prothrombin time. The remaining six patients had a 
mild  course  of  liver  disease  in  keeping  with  the  usual  course  of HCV  infection.  The 
comprehensive  analysis of the  HCV-specific T cell  repertoire revealed T cell  responses 
narrowly focused on a few peptide pools in the 2 patients with severe hepatitis,  while a 
multispecific  T  cell  response  was  detected  in  the  remaining  patients.  Analysis  with 
intracellular cytokine staining revealed only a single sequence containing the previously
83identified HLA-A2 restricted NS3  1073-1081  CD8 epitope (Wedemeyer et al., 2001) to 
be present in the two patients with  severe hepatitis. Ex vivo tetramer staining confirmed 
the ELISPOT data, with a robust but narrowly focused CD8+ T cell response against the 
NS3  1073-1081  epitope described.  The vigour of this response was unprecedented; with 
NS3  1073-1081  tetramer + CD8+ T cells reaching values of 36% and  12% of total CD8+ 
T cells from the respective patients. These frequencies exceed those previously reported 
in acute HCV infection (Thimme et al., 2001; Urbani et al., 2002) and those detected in 
the patients with a mild course of infection also included in this study.
The peculiar vigour of this response and the resulting different clinical course is thought 
to be related to differences in the T cell repertoire in each individual patient. This theory 
is  supported  by  the  high  degree  of sequence  homology between  HCV  NS3  1073-1081 
and  the  influenza  A  neuraminidase  epitope  NA  231-239.  The  demonstration  of cross­
reactivity between these two HCV and influenza sequences in humans and in HLA-A2+ 
positive mice (Wedemeyer et al.,  2001) adds to the argument for a private repertoire of 
memory  T  cells  with  the  ability  to  cross-react  with  heterologous  viruses,  in  this  case 
HCV.  Despite the rapid  and robust expansion  of the  NS3  1073-1081  specific CD8+ T 
cells,  the  virus  was  not  controlled  and  liver  pathology  was  severe.  Thus,  a  robust but 
isolated  response  is  inadequate  for  viral  control.  This  has  implications  in  terms  of 
antiviral  vaccine  development  where  a  CD8+  T  cell  response  focused  on  a  single 
immunodominant  epitope  with  poor  antiviral  activity  may  in  fact  have  severe 
pathological consequences.
843.1.6  The influence of T cell cross-reactivity on HCV-peptide specific T cell response
Based  on  these  observations  we  set  out  to  determine  whether  cross-reactive  T  cells 
activated  by  HCV-peptides  is  a  common  finding  in  the  human  T  cell  response.  We 
investigated whether such HCV-specific T cell responses previously considered a sign of 
prior HCV exposure could be accounted for by cross-reactivity. In order to address these 
questions  we  comprehensively  analysed  the  global  HCV-specific  response  in  a 
heterogenous group of subjects using the most advanced techniques at our disposal.
Newer  immunological  tools  have  improved  in  vitro  analyses  of  the  prevalence  and 
function  of  antigen-specific  CD4+  and  CD8+  T  cell  responses  in  persistent  viral 
infections.  The  most  significant  of these  advances  have  been  the  capability  to  directly 
visualise epitope-specific cells (MHC-class I and class II tetrameric complexes)(Altman 
et  al.,  1996;  Novak  et  al.,  1999)  and  the  ability  to  measure  the  secretion  of  T  cell 
cytokines  [intracellular cytokine  staining,  ELISPOT  (Miyahira  et al.,  1995;  Schauer  et 
al.,  1996)].
Furthermore,  the  understanding  that the  in  vivo T  cell  stimulatory  complex,  formed by 
MHC molecules and processed viral peptide, can be mimicked in vitro by the addition of 
synthetic  peptides  (Germain,  1994)  to  PBMC  has  evolved  into  their  direct  use  in  the 
analysis of specific T cell responses.  Measurement of T cell reactivity using large pools 
of synthetic peptides spanning different pathogenic antigens is becoming the standard for 
the  study  of pathogen-specific  T cell  repertoire  in  humans.  This  method  is  particularly
85useful in the analysis of T cell responses against viruses that do not easily infect antigen 
presenting  cells,  such  as  hepatitis  C  virus  (HCV)(Cerny  et al.,  1995;  Cox  et al.,  2005; 
Lauer et al., 2004; Lauer et al., 2002; Urbani et al., 2005a).
Different patterns of HCV-specific T cell response are demonstrable in recovered versus 
chronically  infected  HCV  patients.  Historically  this  differential  response  was  analysed 
using limited arrays of HCV proteins and peptides (Cerny et al.,  1995; Diepolder et al., 
1995; Koziel et al.,  1995; Missale et al.,  1996; Rehermann et al.,  1996b).  More recently 
the  use  of  comprehensive  panels  of  synthetic  peptides  spanning  the  entire  HCV 
polyprotein have confirmed and detailed further the broader and stronger HCV-specific T 
cell  response profile present in resolved  HCV  infection  (Cox  et al.,  2005;  Lauer et al., 
2004).  The contrast between this response  and the profound quantitative  and functional 
defects  of  HCV-specific  T  cells  observed  in  chronically  infected  subjects  has  been 
emphasised by this technique.
However,  the  use  of  such  broad  panels  of  peptides  could  increase  the  possibility  of 
detection of HCV-peptide reactive T cells which have not been initially primed by HCV 
virions,  but  are  cross-reactive  T  cells  triggered  by  unrelated  antigens.  Indeed,  T  cells 
present  an  intrinsic  degeneracy  in  their  recognition  of  peptides.  Single  T  cells  can 
recognize different peptides that present variable degrees of AA homology (Anderson et 
al.,  1992; Kuwano et al.,  1991) and this degeneracy of T cell recognition represents the 
structural basis of the phenomenon of cross-reactivity (Welsh and Selin, 2002). CD8+ T 
cell cross-reactivity between HCV and influenza A virus determinants have recently been
86demonstrated (Wedemeyer et al., 2001) and could have a potential impact on the profile 
of disease associated with HCV infection (Urbani et al., 2005b).
Cross-reactivity could also account for the reported presence of HCV-peptide reactive T 
cells in subjects who lack all serological markers of HCV infection (Koziel et al.,  1997; 
Scognamiglio  et al.,  1999).  These  results  were  interpreted  in  the  past  as  indicative  of 
previous HCV exposure since patients acutely infected with HCV can maintain long term 
HCV-specific cellular immunity still detectable after loss of humoral responses (Takaki et 
al.,  2000).  However,  T  cell  cross-reactivity  among  homologous  peptides  covering 
sequences  of  different  pathogens  cannot  be  excluded.  This  phenomenon  has  obvious 
implications in  data analysis but it can  also  influence the outcome of HCV infection  if 
HCV infects an individual with pre-existing memory responses which can be rapidly and 
efficiently  recalled  by  homologous  HCV  sequences.  In  this  context,  the  protective 
efficacy  of  HCV-peptide  reactive  T  cells  found  in  HCV-exposed  but  ostensibly  non 
infected subjects may be more difficult to predict if these cells merely represent T cells 
specific  for  unrelated  pathogens  cross-reacting  with  HCV  peptides  but  not  primed  by 
HCV.
In this Chapter,  we  set out to  analyze  whether cross-reactive T cells  activated by  HCV 
peptides  is  a  common  occurrence  in  humans.  The  magnitude,  function  and  cross­
reactivity of HCV peptide reactive T cells were  studied in non-HCV infected newborns 
and  adults.  Comparisons  were  made  with  responses  present  in  both  resolved  HCV 
infection  and  in  chronically  infected  patients.  We  demonstrate  that  non-HCV  infected 
adults possess HCV-peptide reactive T cells,  which can react with peptide sequences of
87common pathogens. The impact of cross-reactive T cells in the interpretation of the data 
found  in  HCV-infected  subjects  and  their  potential  ability  to  alter  the 
immunopathological profile of viral infection is discussed.
883.2  MATERIALS AND METHODS
3.2.1  Subjects
Thirty-two subjects  were  included  in  the  study.  Blood  was  obtained  from  ten  healthy 
volunteers,  comprising  the  negative  control  group  (N.C,  subjects  1-10),  all  were  anti- 
HCV  negative  and  without  any  HCV  risk  factors.  A  further  six  subjects,  the  sexual 
partners  (S.P,  subjects  11-16)  of  six  chronically  infected  HCV  patients  were  studied. 
Patients with resolved (subjects  17-22) and chronic (subjects 23-32) HCV infection were 
recruited from the viral hepatitis clinics at the Royal Free Hospital, London and Divisione 
Malattie  Infettive,  Parma.  All  patients  with  chronic  HCV  had  raised  serum  alanine 
aminotransferase (ALT), detectable anti-HCV and HCV RNA for a period of more than 
six months.  Patients with resolved HCV were anti-HCV positive (ELISA and RIBA) on 
two  occasions  over  a  six  month  period but  HCV  RNA  was  undetectable  by  PCR.  The 
age,  sex, disease profiles,  serological  status, risk factors and ALT levels for all subjects 
are  outlined  in  Table  3.1.  Cord  blood  from  anti-HCV  negative  mothers  (n=5)  was 
provided through our collaboration with the Department of Obstetrics and Gynaecology, 
UCL.  The  study  was  approved  by  the  local  Ethics  Committee  at  the  Royal  Free  and 
University College Hospitals.
89Subject no. Diagnosis HCV RNA Anti-HCV Risk Factors ALT Age Sex
1 N.C. negative negative none normal 33 M
2 N.C. negative negative none normal 30 M
3 N.C. negative negative none normal 43 F
4 N.C. negative negative none normal 34 M
5 N.C. negative negative none normal 29 F
6 N.C. negative negative none normal 24 M
7 N.C. negative negative none normal 27 F
8 N.C. negative negative none normal 28 F
9 N.C. negative negative none normal 35 F
10 N.C. negative negative none normal 41 M
11 S.P. negative negative + normal 36 F
12 S.P. negative negative + normal 42 F
13 S.P. negative negative + normal 47 F
14 S.P. negative negative + normal 39 M
15 S.P. negative negative + normal 45 F
16 S.P. negative negative + normal 36 F
17 Resolved negative positive + normal 42 M
18 Resolved negative positive + normal 46 F
19 Resolved negative positive + normal 38 M
20 Resolved negative positive + normal 57 M
21 Resolved negative positive + normal 48 F
2.2 Resolved negative positive + normal 41 M
23 Chronic positive positive + elevated 54 M
24 Chronic positive positive + elevated 37 F
25 Chronic positive positive + elevated 40 F
26 Chronic positive positive + elevated 46 M
27 Chronic positive positive + elevated 42 M
28 Chronic positive positive + elevated 24 M
29 Chronic positive positive + elevated 32 M
30 Chronic positive positive + elevated 43 M
31 Chronic positive positive + elevated 36 F
32 Chronic positive positive + elevated 51 M
Table 3.1: Characteristics of the study groups.
N.C. = negative control, S.P. = sexual partner, + denotes presence of known risk factors. N.C. had 
no  exposure  to  or  risk  factors  for  HCV.  None  of  the  individuals  recruited  were  laboratory  or 
hospital workers.
903.2.2  Synthetic peptides and antibodies
Synthetic  peptides  representing  a  panel  of  601  15-mer  peptides  overlapping  by  10 
residues  and  spanning  the  entire  sequence  of  HCV-1  were  purchased  from  Chiron 
Mimotopes  (Victoria,  Australia).  Peptides  homologous  to  HCV  reactive  peptides 
covering  selected  sequences  of human  herpes  virus  (HHV1)  and  vaccinia  virus  (VV) 
were purchased from Primm It (Milano, Italy). Anti-CD8 (conjugated with Quantum Red 
or fluorescein isothiocyanate - FITC) and anti IFN-y FITC were purchased from SIGMA 
Aldrich (Saint Louis, MI). Anti-perforin (FITC) was purchased from BD Pharmingen.
3.2.3  Isolation of peripheral blood mononuclear cells (PBMC) and in vitro expansion 
of HBV and HCV-specific cytotoxic T cells
PBMC  were  isolated  from  fresh  heparinized  blood  or  cord  blood  by  Ficoll-Hypaque 
density gradient centrifugation and suspended in RPMI  1640 supplemented with 25 mM 
Hepes,  2  mM  L-glutamine,  50  pcg/m\  gentamycin  and  8%  human  serum  (complete 
medium)  and  used  immediately  in ELISPOT assays or expanded  in  vitro.  For in  vitro 
expansion,  PBMC  were  dispensed  in  96-well  plates  at  a  concentration  1.5  x  106/ml  in 
complete medium and stimulated with peptides at 1   fiM final concentration. Recombinant 
IL-2  was  added  on  day  4  of  culture  (50  IU/ml)  and  the  immunological  assays  were 
performed on day 8-10.
913.2.4  IFN-y intracellular staining
Freshly  separated  PBMC  or  cells  obtained  after  in  vitro  expansion  were  incubated  in 
medium alone (control) or with viral peptides (1  piM) for lh; Brefeldin A (10 ^g/ml) was 
added for an additional 4 h of incubation. After washing the cells were stained with anti- 
CD8  or anti-CD4 quantum red monoclonal  antibody for 20 min  at 4°C,  and then  fixed 
and permeabilized as described.  Cells were stained with anti-IFNy -FITC for  15  min at 
room  temperature,  washed  again,  and  analyzed  on  a Becton  Dickinson  flow  cytometer 
(FACScalibur) using the CELLQuest software.
3.2.5  ELISPOT assay
601  15-mer  peptides  based  on  the  sequence  of  HCV-1  [genotype  la  covering  all 
structural  (core,  El, E2) and non-structural proteins (NS3, NS4, NS5)]  and overlapping 
by  10 residues were grouped in pools of  12  in a matrix array (Lauer et al., 2004),  such 
that each peptide was present in two pools only.
HCV-specific  T  cell  responses  ex  -vivo  were  analysed  after  overnight  stimulation  with 
individual  peptide  mixtures.  Each  plate  contained  1   PHA  stimulated  well  as  a positive 
control  to  confirm  the  validity  of  the  assay.  Briefly,  96  well  plates  (Multiscreen-IP- 
Millipore  S.A.S.,  Malshelm,  France)  were coated  overnight at 4°C  as recommended by 
the manufacturer with 5 pg/ml capture mouse anti-human IFN-y mAb (1  DIK, Mabtech,
92Sweden). Plates were then washed 7 times with PBS/0.05% Tween 20, and blocked with 
RPMI/10% FCS for 2 hours at 37°C.  2 x  105  PBMC were seeded per well, and peptides 
were added at a concentration of 10 pg/ml. After overnight incubation at 37 Celsius, 5% 
C02,  the  plates  were  washed  with  PBS/0.05%  Tween  20,  and  then  50  pL  of  1   pg/ml 
biotinylated  secondary  mouse  anti-human  IFN-y  mAb  (7B6-1,  Mabtech,  Sweden)  was 
added. After 3 hours of incubation at room temperature, plates were washed 4 times and 
100  pi  goat  alkaline  phosphatase  anti-biotin  Ab  (Vector Laboratories  Inc.  Burlingame, 
CA, USA) was added to wells, and the plates were incubated for a further 2 hours at room 
temperature.  Plates  were  then  washed  4  times,  and  75  pi  of  alkaline  phosphatase 
conjugate substrate (5-bromo-4-chloro-3-indolyl phosphate, Biorad Laboratories-Ercules, 
CA,  USA)  was  added.  After 4  to  7  minutes,  the colorimetric  reaction  was  stopped  by 
washing  with  distilled  water.  Plates  were  air-dried  and  spots  were  counted  using  an 
automated ELISPOT reader  (AID ELISPOT Reader  System,  Autoimmune  Diagnostika 
Gmbh,  Strassberg,  Germany).  The  number  of  specific  IFN-y  secreting  PBMC  was 
calculated by subtracting the number of spots obtained in the non- stimulated control well 
from  the  stimulated  sample.  A  positive  control  (PBMC  stimulated  with  PHA)  was 
included with each plate to validate the sensitivity of the assay.
3.2.6  Multiple Cytokine secretion assays
The production of multiple cytokines (IFN-y, TNF-a, IL-2, IL-4, IL-5,  and IL-6) in the 
supernatant of the HCV-peptide reactive T cell lines was tested using a BD ™ Cytometric
93Bead Array (BD bioscience).  100( lx 1 of supernatants of peptide stimulated or unstimulated 
HCV-peptide  reactive T cell  lines  generated  as  described  above  was  collected  after  18 
hours of peptide stimulation. Production of cytokines was tested simultaneously with the 
assay according to the manufacturers’ instructions.
3.2.7  Statistical Analysis
The Mann-Whitney  U  test  was  used  where appropriate to determine the  significance of 
differences between groups; a p-value of <0.05 was taken as significant.
943.3  RESULTS
3.3.1  Direct  ex  vivo  quantitation  of  ELISPOT  response  in  cord  blood  of  HCV 
negative infants
To  exclude  the  interference  by  the  repertoire  of memory  T cells  specific  for unrelated 
pathogens present  in  adults,  overlapping  peptides  covering the  entire  HCV  polyprotein 
were  initially  tested  on  lymphocytes  derived  from  cord  blood  of infants  born  to  anti- 
HCV-  negative  mothers.  The  601  peptides  covering  the  entire  HCV  genome  were 
grouped in a matrix array into pools of 12 and used to directly stimulate IFN-y production 
from T cells in a direct ex vivo ELISPOT assay.  Figure 3.1  shows the results of all five 
tests. PH  A stimulated wells of cord blood detected at least 100 SFC/ well. In contrast, the 
HCV  peptide  stimulated  wells  were  predominantly  negative.  However,  a  number  of 
individual mixtures did elicit a response higher than background, but this never exceeded 
12 SFC/well in all the subjects analyzed.
We  assume  that  cord  blood  represents  the  closest  example  of  a  truly  naive  T  cell 
repertoire, thus we based our calculation of what constitutes a positive result in adults on 
these results. The mean of the maximum responses obtained in each of the five different 
cord blood  specimens was calculated to be  10.2  SFC/well.  HCV-peptide reactive T cell 
responses  in  adults  were  considered positive  if the number of spots per well  minus the 
background  was  at  least  3  times  the  mean  value  of maximum  responses  found  in  cord 
blood (3x10= 30 SPF/well,  150 SPF/106  PBMC).
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Figure 3.1:  IFN-y  production  by  direct  ex vivo  ELISPOT  analysis  on  cord  blood.  PBMC  from 
cord blood from  the  5  different  indicated  newborns  were  stimulated overnight with  106 pools of 
overlapping  15-mer  peptides  covering  the  whole  HCV  sequence  and  with  PHA.  SFC  =  spot 
forming cells.
3.3.2  Direct ex vivo quantitation  of ELISPOT response in  HCV infected  and non­
infected subjects
The pools of HCV peptides covering HCV  proteins were then tested directly ex vivo in 
six patients with resolved HCV infection (anti-HCV positive, HCV-RNA negative on two 
different occasions 6 months after infection), ten patients with chronic HCV infection and 
sixteen  subjects with no serological markers of HCV infection.  Ten anti-HCV negative 
subjects had no classical risk factors for HCV infection (N.C.  1-10, Table 3.1) and were 
considered the control group.  A further six subjects were anti-HCV negative but all had
96reported exposure to HCV, (i.e. were sexual partners of HCV-RNA positive patients with 
chronic hepatitis, (S.P. 11-16, Table 3.1)).  The results of the direct ex vivo ELISPOT of 
two representative subjects from each group are shown in Figure 3.2A.
HCV-peptide reactive T cells were easily detectable ex vivo in resolved patients, (Figure 
3.2,  Sub. 17)  in  keeping  with  several  previous  studies.  The  overall  responses  to  all 
different peptide pools presented a median total magnitude of 850 (Range 710-2421) SFC 
/20xl06   cells.  Some  pools  were  able  to  elicit  a  response  reaching  a  magnitude  of 277 
SFC/well  and further analysis  with  individual  peptides revealed the presence of at least 
three T cell epitopes recognized in each of the patients with resolved HCV infection.
The  overall  quantity  of IFN-y  producing T cells  detected  in  PBMC  from  patients  with 
chronic  HCV  infection  and  HCV-negative  subjects  was  lower  than  that  observed  in 
resolved  patients;  median  total  magnitude  of  response  to  all  peptide  pools  was  104 
(Range  24-292)  SFC/20xl06  cells  in  chronic,  411  (Range  208-502)  in  N.C.  and  479.5 
(Range 328-548) in S.P.; but HCV-peptide reactive T cells could be detected in all tested 
subjects  irrespective  of  their  HCV  infection  status  or  risk  factors.  In  keeping  with 
previous  studies,  the  T cell  responses  present  in  negative  controls,  sexual  partners  and 
chronically infected individuals lack the multispecificity found in patients with resolved 
HCV  infection.  The  magnitudes  of the  individual  responses  were  variable but  in  some 
cases (see Figure  3.2,  Subject 2,  where response to pool  14 was  106 SFC/2xl05) HCV- 
peptide pools were able to elicit a magnitude almost identical to those found in resolved 
HCV  infection.  Interestingly,  the  direct  ex  vivo  frequency  of HCV-peptide  reactive  T
97cells found in patients with chronic HCV was lower than those present in HCV negative 
patients  (Figure  3.2A,  3.2B).  The  difference  in  total  SFC  between  these  two  groups 
(Figure 3.2B) was found to be statistically significant (p<0.0001).
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Figure  3.2:  IFN-y  production  by  direct  ex  vivo  ELISPOT  analysis  on  adults.  PBMC  were 
stimulated overnight with  106 pools  of overlapping  15-mer peptides  covering the  whole  HCV 
sequence.  A)  Results  of 2  representative  subjects from  each  group  of HCV  infected  and  non­
infected patients are shown. The line corresponds to a value of 30 SFC/ 2xl05 PBMC. Responses 
superior to this  value  were  considered  positive.  B)  Quantity  of SFC  stimulated  by  all  peptide 
pools covering the  whole  HCV  polyprotein.  Each dot represents an individual patient for each 
group. C) Number of positive peptide pools in each subject. Dots represent individual patients.
98To confirm that the IFN-gamma production found by direct ex vivo ELISPOT analysis in 
HCV  negative  patients  was  sustained  by  CD4+  or  CD8+ T  cells  we  generated  HCV- 
peptide  reactive  T  cell  lines.  CD4+  or  CD8+ T  cells  able  to  react  to  individual  HCV 
peptides  can  be  demonstrated  in  HCV-negative  subjects  and  sexual  partners  of  HCV 
infected patients (Figure 3.3). Their profile of cytokine production was Thl/Tcl, with the 
ability  to  produce  IFN-y  and  TNF-a  but  not  IL-4,  IL-5  or  IL-2  after  peptide  specific 
stimulation. (Figure 3.3, B). These results show that HCV-peptide reactive T cells can be 
detected  in  the  circulation  of  HCV-negative  subjects  at  frequencies  and  magnitudes 
comparable to those  in  sexual  partners of HCV-positive  subjects and  higher than those 
observed in chronically infected patients.
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Figure 3.3:  Characterization  of  HCV-peptide  reactive  T  cells  present  in  HCV-negative  control 
subjects. A) Dot plot analysis of IFN-y producing T cells specific for HCV-NS3  i436- 5oand  HCV- 
NS5B  2811-25 peptides.  PBMC were stimulated with individual peptides and after  10 days, were re­
stimulated  with  the  stimulatory  peptide.  Frequency  of  IFN-y  producing  cells  was  tested  with 
Intracellular  cytokine  staining.  B)  Multiple  cytokine  analysis  of  supernatants  of  the  peptide 
stimulated  cells.  Supernatants  of  T  cell  lines  demonstrating  presence  of  IFN-y  +  cells  were 
analyzed for the indicated cytokines. Supernatants were collected after overnight stimulation with 
HCV peptide.  Pep = peptide.
993.3.3  HCV-peptide reactive T cells after in vitro expansion
The low quantity of HCV-peptide reactive T cells observed in chronically HCV infected 
patients  is  attributable  to  their  low  frequency  in  the  blood  and  to  the  impaired  IFN-y 
production  of these T cells  (He  et al.,  1999;  Lauer et al.,  2004;  Lechner et al.,  2000a; 
Urbani  et  al.,  2002).  In  vitro  expansion  of  peptide  stimulated  PBMC  is  a  strategy 
previously used (Lauer et al., 2002; Penna et al.,  1991; Rehermann et al.,  1996a; Webster 
et  al.,  2004)  to  detect  peptide-specific  T  cells  present  at  low  frequencies  in  the 
circulation. Thus, to further evaluate the HCV-peptide reactive T cell repertoire present in 
HCV  infected  (resolved  and  chronic)  and  in  HCV  negative  subjects,  T  cell  responses 
against  HCV  peptide  pools  were  analyzed  after  in  vitro  expansion.  PBMC  of  HCV 
infected  patients  and  HCV  negative  subjects  (N.C.  and  S.P.)  were  stimulated  with  the 
different peptide mixtures and after  10 days of in vitro expansion, the presence of HCV- 
peptide reactive T cells was tested.
In vitro expansion increased the number of peptide pools able to elicit a T cell response in 
all  groups.  The  subsequent  identification  of  the  individual  peptides  able  to  elicit  a 
response  shows  that  HCV  negative  (N.C.)  subjects  have  T  cells  able  to  recognize  a 
median of 4.5  (Range 3-6)  HCV peptides (Figure 3.4).  In contrast, broad HCV peptide- 
reactive T cell responses were detected in the blood of all six patients with resolved HCV 
infection, with a median of 21.5 (Range  15-25). In six patients with chronic infection, the 
HCV-specific  repertoire  was  broader than  that  of HCV  negative  subjects.  The  median 
number  of  individual  peptides  recognized  by  chronic  HCV  patients  analyzed  was  7
100(Range 3-15)  and comparison  between  this group  and the  negative  controls (N.C) was 
found  to  be  statistically  significant  (p=0.0055).  This  demonstrates  a  significant 
enhancement of the HCV-peptide specific T cell  repertoire in the circulation of patients 
with chronic HCV after in vitro expansion.
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Figure  3.4:  Quantification  of  HCV  peptides  recognized  by  T  cells  after  in  vitro  expansion. 
Experimental plan:  PBMC were stimulated in vitro with the  106 different peptide pools. After  10 
days of in vitro expansion, cells were re-stimulated overnight with the initial stimulatory peptide 
pools in an IFN-gamma ELISPOT assay.  Lines were considered positive when SFC of stimulated 
wells  were at  least  double the  SFC  in  un-stimulated  wells.  Positive  lines  were  then  tested  with 
individual peptides present in the pools. A) The number of positive peptides found in the different 
patient groups using the experimental  plan outlined  is shown.  B)  Ex vivo and in vitro ELISPOT 
pattern  of response  against  HCV  mixtures  is  shown  for one  representative negative  control  and 
one chronic HCV patient.
1013.3.4  Identification of HCV-peptide reactive T cells cross-reacting with homologous 
sequences of common pathogens
Having established the presence HCV-peptide reactive T cells in the peripheral blood of 
HCV-negative subjects, we investigated whether T cells cross-reacting with homologous 
sequences of common pathogens can sustain these responses.
We  first  searched  the  National  Centre  for  Biotechnology  Information  Gene  Bank 
database  using the  “Blast program”  for peptides  displaying  a degree  of homology  with 
the eleven  HCV peptides  (Table  3.2)  able to activate directly  ex vivo  PBMC of normal 
subjects without risk factors.
Variable degrees of sequence homology with different pathogens or self human proteins 
were found by the in silico analysis for each HCV peptide analyzed. We thus focused our 
functional  analysis  on  the  following  3  sequences:  NS5B  28,,.25  (peptide  no.  563) 
PL  AR  A  A  WET  ARHTP  V, NS5B 2936.50 (peptide no. 588) GR  A  AICGK  YLFNW  A V and El 
36i  375  (peptide  no.  73)  YFSMVGNWAKVLVVL  which  were  selected  for the following 
criteria:
(1) the HCV peptides elicit high direct ex vivo frequency (NS5B  28ll_ 25 91  SFC/ subject 3, 
NS5B  2936_50 70  SFC/ subject  6 ,  El  361_375 48  SFC/ subject 4);  (2)  peptide reactivity  was 
confirmed  at  different  time  points  (not  shown),  (3)  high  sequence  homology  with 
common pathogens or antigens was noted (Table 3.3).
102Peptide Sequence Response Shared Homology
288 NS3  1436-50 
STDALMTGFTGDFDS
CD4 Measles*
73 El  361-375
YFSMVGNWAKVLVVL
CD4 Vaccinia virus
563 NS5B 2811-25 
PLARAAWETARHTPV
CD8 Human Herpes virus  1
15 Core 71-85
PEGRTWAQPGYPWPL
CD4 Human Papillomavirus* 
Human Herpes virus  1*
205 NS2/NS3  1021-35 
KG WRLLAPIT  AY AQQ
CD4 Human Enterovirus*
216 NS3  1076-90 
G V C  WTV YHG AGTRTI
CD4 Human Papillomavirus*
277 NS3  1381-95 
PLEVIKGGRHLIFCH
CD4 Rubella*
Human Herpes virus 7*
327 NS3  1631-45 
VQNEVTLTHPITKYI
CD4 Vaccinia virus
387 NS4B  1931-45 
PTHYVPESDAAARVT
CD8 Human Herpes virus 3
435 NS5A 2171-85 
LTSMLTDPSHITAEA
CD8 Measles
588 NS5B 2936-50 
GRAAICGKYLFNWAV
CD8 Hepatitis B virus
Table 3.2: HCV peptide responses detected in the negative control group 
indicates < 6 shared AA
103Peptides Sequence* Source GenBank
accession no.
HCV NS5B 28„ .25 PL  AR  A  A  WET  ARHTPV HCV genotype IB, NS5B P26624
HHV, UL 55 ATWQAETAMHT HHV1 P36296
HCV NS5B 2936.50 GRAAICGKYLFNWAV HCV genotype  IB, NS5B P26624
HBV Env 333^ 0 GKYLWEWA HBV-Major surface Ag Q05496
HCV El  361375 YFSMVGNWAKVLVVL HCV genotype IB, El P26624
W  275_284 LVGNWDKNDV Vaccinia Virus BAD97827
Table 3.3: HCV peptide sequence homology with common pathogens. 
Boldface indicates shared amino acids
The peptides HCV NS5B  2936and HCV El  36i_375 revealed clear homology respectively 
with  the  sequences  of  hepatitis  B  virus  (HBV)  envelope  (GKYLWEWAS)  and  with 
vaccinia  virus  (VV)  proteins  (LVGNWDKNDV)  respectively  (Table  3.3).  Peptides 
covering these homologous  sequences were synthesised and tested both directly ex vivo 
in  PBMC  and  then  on  HCV-peptide reactive T cell  lines but they  consistently failed  to 
activate PBMC and HCV peptide reactive T cells (not shown).
In contrast, evidence of cross-reactivity between the HCV-NS5B  2811-25  specific CD8+ T 
cells with a human herpes virus (HHV1) sequence was found. The 15-mer peptides NS5B 
281, 25 shared several amino acids with the UL55 protein of HHV1  (Table 3). However, the
104shared AA between the two sequences encompass an  11  AA stretch, a length that is not 
considered compatible with a classical CD8+ epitope. For this reason, we first determined 
the  HCV-  epitope  contained  within  the  15-mer  peptides.  Overlapping  10-  and  9-mers 
covering the  15-mer peptide NS5B  2811.25 region were tested directly ex vivo (Figure 3.5) 
to  determine  the minimal  sequence  able to  activate NS5B  2811_ 25  specific  CD8+  T cells. 
Figure 3.5 shows that the  10-mer NS5B  2816.25  AWETARHTPV peptide elicited a direct 
ex  vivo  IFN-y  ELISPOT  response  similar  to  the  NS5B  281l_25  PL  AR  A  AWETARHTPV 
peptide. In contrast, no response was activated by NS5B 281I 20 PLARAAWET and NS5B 
28I5.23AAWETARHT peptides. Having established that the NS5B  28n_25 peptide specific T 
cells  direct  their  recognition  on  the  10  mer  NS5B  2816.25  AWETARHTPV,  the 
corresponding homologous HHV1-peptide QAETAMHTSK was synthesized and tested. 
Figure 3.5b shows that the HHVl-peptide QAETAMHTSK can directly activate PBMC 
of the  subject  responding  to  HCV  NS5B  28,|_25  peptide.  In  addition,  HCV  NS5B  28n.25 
peptide specific T lines can be stimulated with both NS5B  2816_25  AWETARHTPV and 
HHV1  QAETAMHTSK peptides.
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Figure 3.5:  Recognition of NS5B 2si6 2 5 and HHV1  peptides by  HCV-NS5B CD8+ T cells, a) Ex- 
vivo  IFN-y  ELISPOT analysis.  PBMC of subject  3  were  stimulated overnight  with the  indicated 
peptides. The results are expressed  in spot forming cells (SFC)/ 2xl05 PBMC.  b)  Plots  represent 
IFN-y  producing  CD8+ cells  of the  NS5B  2 8 1 6 . 2 5  specific T cell  line  stimulated  with  no  peptide, 
NS5B  and  HHV1  UL55  2 9 . 3 9  peptides.  Numbers  in  the  right  upper  quadrant  indicate  the 
percentages of IFN-y producing CD8+ cells after 4 hours stimulation. Pep = peptide.
1063.4  DISCUSSION
This  study  was designed  to analyze  whether in vitro evaluation  of HCV-specific T cell 
responses in humans using large arrays of synthetic peptides is potentially altered by the 
presence of cross-reactive T cells specific  for different pathogens but with a degenerate 
recognition  of  HCV  peptides.  The  results  confirm  that  this  is  the  case,  since  mono- 
oligospecific  HCV-peptide reactive T cells can be found  in  the blood of HCV  negative 
adults  without  any  classical  risk  factors  of  HCV  infection  (including  past  blood 
transfusion, sexual contact with HCV  infected subjects and intravenous drug use).  In all 
of these HCV negative subjects, HCV peptide reactive CD4+ and/or CD8+ T cells were 
detected  when  a  large panel  of synthetic peptides covering the  whole HCV polyprotein 
(601  peptides)  was employed.  On the whole, T cell response against HCV peptides was 
clearly greater (both  in magnitude  and multispecificity)  in patients who recovered from 
HCV infection than in HCV negative adults. Nevertheless, for selected individual peptide 
mixtures,  the  reactive  T  cells  found  in  HCV  negative  adults  present  a  direct  ex  vivo 
frequency comparable with HCV-specific T cells present in subjects who recovered from 
HCV infection. In addition, these cells had the potential to expand and produce Thl-like 
cytokines  (IFN-y,  TNF-a)  but  not  IL-4  or  IL-5.  Thus,  at  least  functionally,  these 
responses  were  indistinguishable  from  classical  virus-specific  effector/memory  T  cells 
present in patients with resolved viral infection.
It is difficult to ascertain  whether the presence of these HCV-peptide reactive T cells in 
HCV-negative  patients  is  indicative  of previous  exposure  to  HCV  (thus,  suggesting  an
107under  estimation  of  HCV  infection  in  the  general  population)  or  whether  it  is  the 
consequence of a degenerate recognition of HCV-peptides by cross-reactive T cells.
We  favour  the  latter  interpretation  since  HCV-specific  T  cell  responses  present  in 
subjects who recovered from HCV infection are often multispecific with HCV-specific T 
cells  able  to  recognize  multiple  HCV  epitopes  located  in  the  different  HCV  proteins, 
while those found in HCV-negative subjects show T cells reactive to  1   or 2 peptides out 
of the 601  used. Furthermore, this mono-oligospecific HCV-reactive T cell response does 
not broaden into a multispecific response after in vitro expansion, a method that increases 
substantially the number of HCV peptides recognized by T cells of recovered and chronic 
patients. More importantly, we were able to demonstrate that NS5B 2 8i6-25 specific CD8+ 
T cells found in HCV negative subjects were reactive to a homologous HHV1   sequence. 
Thus,  in  addition  to  the  cross-reactivity  between  HCV  and  an  influenza  A  virus 
determinant  already  demonstrated  by  Wedemeyer  et al.  (Wedemeyer  et al.,  2001),  we 
found that a further human pathogen  might induce cross-reactive HCV-specific T cells, 
suggesting  that  T-cell  cross-reactivity  between  different  pathogens  is  a  common 
phenomenon in adults.
We cannot rule out occult hepatitis C in such subjects but in the absence of any indication 
of liver disease occult hepatitis C infection (Berasain et al., 2000; Castillo et al., 2004) is 
unlikely.
108Although we failed to demonstrate the direct evidence of cross-reactivity of all the HCV 
peptide-reactive T cells found in the HCV-negative subjects studied, we should not forget 
that T cell cross-reactivity does not necessarily depend on identity of amino acids on the 
linear sequence of the peptide. T cell receptors of a given T cell clone can be activated by 
quite  dissimilar peptides  (Hausmann  and  Wucherpfennig,  1997;  Hemmer et al.,  1999). 
Thus,  the  strategy  of identifying  cross-reactive  peptides  based  on  sequence  homology 
even though commonly used is bound to underestimate the extent of cross-reactivity. In 
addition, the search of homologous peptides is based on the search of known sequences, 
and thus unable to detect yet-unidentified homologous sequences.
What are the putative consequences  and potential  implications of the detection of HCV 
peptide-reactive  T  cells  in  HCV-negative  adults?  The  pathological  impact  of  cross­
reactivity on virus infection has been analyzed in animal models, where it was shown that 
previous  encounter  with  different  pathogens  can  influence  virus-related  immuno- 
pathology.  We  have  recently  shown  that  severe  cases  of  HCV  induced  hepatitis  are 
characterized by a large expansion of HCV-specific CD8+ T cells able to cross-react with 
an influenza neuraminidase sequence (Urbani et al., 2005a) suggesting that virus-related 
immuno-pathology can be influenced by the presence of potentially cross-reactive T cells 
in  humans  also.  The  demonstration  that  all  HCV-negative  adults  present  at  least  one 
HCV-peptide  reactive  T  cell  response  suggests  that  cross-reactivity  can  potentially 
influence the degree of immuno-pathology in HCV infection. Moreover, rapid expansion 
upon HCV exposure of memory responses originally primed by unrelated pathogens may
109favour protection against HCV if cross-reactivity leads to expansion of T cell specificities 
which are normally involved in HCV control.
The  identical  quantitative  detection  of HCV-peptide  reactive  T  cells  in  HCV-negative 
patients  with  or  without  risk  factors  suggests  that  HCV  peptide  reactive  T  cells  from 
sexual partners of HCV chronic patients are not necessarily primed by HCV.
Since  we  cannot  distinguish  between  HCV-primed  or  HCV  cross-reactive  T  cells,  the 
potential  protective  effect  of  isolated  HCV-peptide  reactive  T  cells  found  in  sexual 
partners  of patients  with  chronic  HCV  infection  is  questionable.  Cross-reactive T cells 
detected  in  vitro  may  be  primed  in  vivo by  unrelated pathogens  and  simply  recalled  in 
vitro by HCV epitopes irrelevant to virus control (since they are not generated by HCV 
antigen  processing during natural  infection).  However,  our data do not contest the idea 
that low level HCV inoculation can prime an HCV-specific cellular immune response. It 
is  noteworthy  that  when  HCV  contact  is  more  likely  to  occur  (i.e.  sexual  partners  of 
patients with acute HCV infection and high viremia) (Kamal et al., 2004) these subjects 
develop  a  multispecific  CD4+  and  CD8 +  response,  a  profile  different  from  the  oligo- 
reactivity found in our HCV-negative subjects.
A  further  interesting  observation  revealed  by  our  comprehensive  analysis  of  HCV- 
peptide  reactive  T  cell  response  in  different  groups  of HCV  infected  and  non-infected 
individuals  is  that  the  overall  quantity  and  the  individual  ex  vivo  frequency  of HCV- 
peptide reactive T cells is similar and frequently even lower in chronically HCV infected 
patients  than  in  HCV-negative  adults.  This  data  further  supports  the  evidence  that
110persistent  HCV  infection  qualitatively  alters  the  circulating  and  intrahepatic  pool  of 
HCV-specific T cells  (Accapezzato et al., 2004; Lauer et al., 2004;  Spangenberg et al., 
2005).  To  what extent HCV-peptide  reactive  T  cells  not found  in  chronically  infected 
patients are deleted, compartmentalized within the liver or suppressed in their functional 
capacity needs further investigation.
In  conclusion,  this  study  illustrates  that  HCV  peptide  reactive  T  cells  can  be 
demonstrated in adults irrespective of previous HCV exposure.  Therefore, the presence 
of such  isolated  HCV-peptide  reactive  T  cells  does  not  necessarily  equate  to  previous 
HCV  exposure since cross-reactivity between HCV  peptides  and  sequences of common 
pathogens, like HHV  1, was revealed. However, cross-reactivity instead of previous HCV 
priming does not exclude the potential for protection of cross-reactive T cells upon HCV 
exposure,  provided  the  homologous  HCV  epitopes  are  involved  in  the  induction  of 
protective  responses  in  natural  infection.  The  demonstration  that  the  comprehensive 
magnitude of HCV-peptide reactive T cells present in chronically HCV infected patients 
might even be lower than that of HCV-peptide reactive T cell response found in HCV- 
negative  adults,  adds  further  support to  the  argument for a profound  collapse  of virus- 
specific T cell response caused by HCV persistence.
IllCHAPTER 4
THE ROLE OF NKG2D MOLECULE ON HUMAN 
INTRAHEPATIC CD8+T CELLS IN CHRONIC
VIRAL HEPATITIS
1124.1.1  INTRODUCTION
Chronic viral hepatitis (HBV  & HCV)  is characterised by a lymphocyte infiltration into 
the infected liver and progressive liver injury that evolves from chronic inflammation to 
the development of fibrosis, cirrhosis and hepatocellular carcinoma (Beasley,  1988; Lok 
and McMahon, 2001;  McQuillan et al.,  1989; Seeff, 2002; Seeff et al., 2000).  It is now 
believed that the outcome of viral  hepatitis is determined by the host’s ability to mount 
efficient helper and cytotoxic T cell responses (Bertoletti and Maini, 2000). Many studies 
have investigated the population of intrahepatic lymphocytes (IHL) with greater emphasis 
on CD8+ T cells (Ferrari et al.,  1990; Grabowska et al., 2001; He et al.,  1999; Maini et 
al., 2000),  but despite the volume of experimental data, the modulation of this CD8+ T 
cell population remains poorly defined.
It is now clear that CD8+ T cells control virus replication through both cytolytic and non- 
cytopathic mechanisms, mediated by IFN-y and TNF-a (Guidotti and Chisari,  1996). The 
magnitude of the virus-specific CD8 + T cell response is considered to be the determining 
factor in virus control, while the quantity of HBV-specific CD8+ T cells has been shown 
to correlate with viral control and not liver damage (Maini et al., 2000). However, when 
the virus-specific CD8+ T cell response fails to control virus replication it may contribute 
to liver pathology through direct hepatocyte lysis and the recruitment of large numbers of 
non-virus  specific  CD8 +  T  cells  to  the  liver  (Ando  et al.,  1993;  Kusters  et  al.,  1996; 
Maini et al., 2000; Tiegs et al.,  1992). The virus-specific CD8+ T cell response is diluted 
as a result of the massive cellular infiltration and it is this non-virus specific lymphocytic
113infiltrate which is implicated in liver damage and inflammation in patients with persistent 
viral  replication.  The  large  non-virus  specific  component  of the  CD8+  T cell  infiltrate 
demonstrated  in  chronic  HBV  patients  with  active  liver  disease  is  consistent  with 
previous reports in animal studies. The recruitment of non-virus specific CD8+ T cells is 
mediated by  IFN-y  in  the  transgenic  mouse  model  of fulminant hepatitis  (Ando et al., 
1993)  and  similar  work  in  HBV  infected  chimpanzees  report  liver  damage  to  occur 
concomitantly with a massive infiltration of non-antigen specific CD8+ T cells (Guidotti 
etal.,  1999).
Experimental  work to date on IHL has focused primarily on the frequency and function 
of virus-specific  CD8+ T cells  (Ferrari  et al.,  1990;  Grabowska  et al.,  2001;  He et al., 
1999;  Maini  et al.,  2000).  It has now been established that virus-specific CD8+ T cells 
are  preferentially  recruited  to  the  infected  liver  (He  et  al.,  1999;  Maini  et  al.,  2000), 
however  these  intrahepatic  virus-specific  CD8+  T  cells  are  functionally  defective  in 
chronic hepatitis patients with  an  inability to produce antiviral cytokines (IFN-y) and in 
some  instances  produce  the  regulatory  cytokine  IL-10  (Accapezzato et al.,  2004).  It  is 
noteworthy  that  the  reduced  functional  ability  of effector CD8+  T  cells  in  chronically 
HCV infected livers also extends to non-virus specific CD8+ T cells (Nisii et al., 2006). 
While these  studies provide  greater insight into the function of CD8+ T cells and their 
contribution to liver injury and viral persistence, little is known regarding the activation 
requirements of IHL.
114This study sets out to dissect the possible mechanisms of liver injury mediated by non­
virus specific CD8+ T cells and the factors that govern it. We investigated the activation 
requirements  of  intrahepatic  CD8 +  T  cells  in  chronic  viral  hepatitis  with  particular 
emphasis  on  factors  that  modulate  the  classical  antigen  dependent  T  cell  response. 
Furthermore, we explored the possibility of TCR independent CD8+ T cell activation and 
how  this  might  function  in  chronic  viral  hepatitis.  We  investigated  the  role  of  the 
activating NK cell receptor, NKG2D, which is known to be present on CD8+ T cells, and 
analyse  its  impact  in  both  TCR  dependent  and  independent  processes  and  its  overall 
contribution to the immunopathology of viral hepatitis.
4.1.2  Classical TCR activation
CD8 + T cells are classically activated through their clonotypic T cell receptor (TCR) by 
MHC  class  I-peptide  molecules  (Figure  4.1).  Naive  CD8 +  T  cells  require  two 
independent signals to become fully activated. The first is an antigen specific signal, sent 
via  the  TCR.  The  second  signal,  termed  co-stimulation  is  independent  of the  antigen 
receptor  and  is  critical  to  allow  full  T  cell  activation,  sustain  cell  proliferation,  induce 
differentiation to effector and memory status and allow cell-cell cooperation (Frauwirth et 
al., 2002; Frauwirth and Thompson, 2002).
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Figure 4.1:  Activation  of  the  cytotoxic  T  lymphocyte  (CTL)  through  TCR  recognition  of  the 
HLA-class I viral peptide complex.
Naive lymphocytes stimulated through the TCR alone,
1)  fail to produce cytokines
2)  are unable to sustain proliferation
3)  often undergo apoptosis or become non-responsive to subsequent stimulation.
Co-stimulation  refers  to  a  critical  event  in  the  activation  process  whereby  interactions 
between  receptor/ligand  pairs on the responder lymphocyte and an “accessory cell”, an 
antigen presenting cell  (APC) in the case of T  cell  activation, serves to amplify antigen 
specific signaling through the TCR. CD28, the first cell  surface molecule shown to have
116co-stimulatory function (June et al.,  1990) and the related inducible co-stimulator (ICOS) 
molecules  appear  to  be  the  major  co-stimulatory  molecules  for  the  activation  of 
nai've/resting T cells or activated/effector T cells respectively  (Mueller,  2000).  CTLA-4 
and PD-1  share  structural  homology with CD28 and ICOS,  but are  inhibitory receptors 
and therefore are not described as co-stimulatory (Frauwirth et al., 2002; Frauwirth and 
Thompson, 2002).
More recently a new family of receptors previously thought to be restricted to NK cells, 
have been identified on effector and memory CD8+ T cells (Figure 4.2).  These receptors, 
the natural killer group 2 D (NKG2D) in particular, have been intensely studied and are 
reported to play a key role in immune mediated diseases  (Groh et al., 2003; Jabri et al., 
2000;  Ogasawara et al.,  2004).  NKG2D is  an activating receptor on NK cells,  CD8+ T 
cells and yb-TCR+ T cells (Bauer et al.,  1999; Jamieson et al., 2002; Wu et al.,  1999), 
and  experimental  data  supports  an  increasing  relevance  of  these  receptors  in  the 
activation of CD8+ T cell function. In addition, NKG2D has been shown to be important 
in T cell mediated, TCR independent epithelial damage in coeliac disease (C.D.), which 
resembles liver damage in chronic viral hepatitis.  Both conditions are associated with a 
massive CD8+ T cell infiltrate and the resulting pathology is believed to be mediated in 
an  antigen  non-specific  manner.  In  this  chapter  I  set  out  to  define  what  role  NKG2D 
plays in the immunopathogenesis of chronic HBV and HCV infection.
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Figure 4.2:  T  cell  activation;  the  classical  pathway  (TCR  mediated)  or  alternatively  activation 
through the NKG2D receptor.
4.1.3  The activating receptor, NKG2D
In  order to  understand  the  potential  involvement of NKG2D  in  the  activation  of virus 
specific  and  non-virus specific CD8+ T  cells in  chronic  viral  hepatitis (Figure 4.3),  we 
will first review the molecular biology of the NKG2D molecule.
In humans NK receptors are divided into 3 groups,
1)  killer immunoglobulin receptors (KIR)
2)  natural cytotoxicity receptors (NCR)
3)  c-type lectin Receptors.
118NKG2D is a  member of the c-type  lectin-activating receptor family.  It differs from the 
other  NKG2  members  (NKG2A,  NKG2C,  and  NKG2E)  which  are  highly  related  in 
sequence,  are  present as  heterodimers  with  CD94 and  recognize  a  non-classical  MHC- 
class  I  molecule  known  as  HLA-E  in  humans  (Braud  et  a l 1999).  NKG2D  is  a 
promiscuous receptor which  binds at least 6 different ligands including a family of cell 
surface  glycoproteins with  structural  homology to  MHC class I  proteins,  MHC class-I- 
related chain (MIC) A  and  MIC-B,  and  UL-16 binding proteins (ULBP) also known as 
RAET1  (Verneris et al., 2004).
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Figure 4.3:  NKG2D providing activating or co-stimulatory signals to the CD8+ T cell.
NKG2D  exists  as  a  transmembrane  glycoprotein  expressed  as  a  disulfide-bonded 
homodimer. It has no signaling motifs in the intracellular region, (Houchins et al.,  1991)
119but  instead  associates  non-covalently  with  the  adapter  protein  DAP  10  in  mouse  and 
human  NK  and  T cells  to  form  a  hexameric  complex  on  the  cell  surface.  Mouse  and 
human NKG2D differ,  in that signaling occurs exclusively through DAP  10  in humans 
but can also occur through DAP 12 in activated mouse NK cells (Rosen et al., 2004). The 
cytoplasmic domain of DAP  10 contains a YxxM motif. This is noteworthy as the YxxM 
motif is also found in the cytoplasmic domains of the CD28 and ICOS molecules where it 
is reported to impart a co-stimulatory  signal  (Chambers,  2001;  Chambers  et al.,  2001), 
supporting the role of NKG2D as a co-stimulatory molecule on CD8+ T cells, akin to that 
of CD28.
The  YxxM  motif  recruits  and  activates  the  p85  subunit  of  phosphoinositide-3  (PI3) 
kinase and Grb2.  This differs from DAP 12 which has an immunoreceptor tyrosine based 
activation motif (ITAM) in its cytoplasmic domain that recruits and activates the Syk and 
ZAP 70 protein  tyrosine  kinases  (Lanier et al.,  1998). Therefore it can be deduced that 
the  NKG2D  activity  may  well  differ  between  mice  and  humans  owing  to  this 
fundamental difference in individual activation pathways.
NKG2D activity may also differ between mice and humans owing to reported differences 
in  the  ligands,  with  the  high  affinity  ligands  retinoic  acid  early  inducible  1   (RAE  1) 
family  of  glycoproteins,  H60  and  murine  ULBP-like  transcript  1   (MULTI)  being 
identified in mice (Cerwenka et al.,  2000;  Diefenbach et al.,  2000). The MICA, MICB, 
ULBP, RAE-1  and H60 genes are polymorphic and so within the human population or in 
different  strains  of mice,  there  is  considerable  diversity.  NKG2D  ligands  in  mice  are
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mRNA which is reported to be widely detected (Ogasawara and Lanier, 2005).  MIC A/B 
ligands are stress inducible molecules (Groh et al.,  1996) and their expression on the cell 
surface  is  under the control of a heat shock promoter which can be induced by cellular 
stress, including heat shock, transformation or infection (both viral and bacterial) (Das et 
al.,  2001;  Groh  et  al.,  2001).  Expression  of  the  ligands  can  also  be  induced  by  the 
pathways  involved  in  cellular  responses  to  DNA  damage  and  in  human  and  mouse 
autoimmune diseases (Ogasawara and Lanier, 2005).
4.1.4  NKG2D and tumour immunity
NKG2D ligands are frequently expressed on  a substantial number of human and mouse 
tumours  and  could  potentially  act  as  danger  signals  to  alert  the  immune  system  to  the 
existence of these abnormal cells (Cerwenka et al., 2000; Diefenbach et al., 2000). This 
could provide a first line of defence against certain cancers, as tumours are known to be 
poorly immunogenic as they develop from self cells and  so are inefficiently recognized 
by the adaptive immune system. Human NK cells and y5-TCR+ T cells have been shown 
to efficiently kill tumours bearing NKG2D ligands (Bauer et al.,  1999; Groh et al.,  1999).
Furthermore the expression of NKG2D ligands on tumours has been reported to augment 
the generation  of tumour-specific T cells  (Diefenbach  et al., 2001). The possibility that 
immunotherapies could be used to influence the outcome of such tumours has also been
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of IL-12 with resulting prevention of carcinogen induced sarcoma formation in a mouse 
model (Smyth et al., 2005).
The  study  of  NKG2D  in  cancers  has  given  further  insight  into  its  role,  but  also  its 
limitations.  Cancer  patients  with  high  concentrations  of soluble  MIC  proteins  in  their 
serum were found to have reduced NKG2D expression on the CD8+ T cells (Groh et al., 
2002). The chronic exposure of NK cells or CD8+ T cells to soluble MIC proteins arising 
from  tumour  cells  or  cell  surface  NKG2D  ligands  leads  to  functional  impairment  of 
NKG2D  dependent  activation  (Groh  et  al.,  2002;  Ogasawara  and  Lanier,  2005; 
Oppenheim  et  al.,  2005).  Such  prolonged  exposure  to  the  NKG2D  ligands  may 
desensitize the NK cells and CD8+ T cells and in doing so lose the anti-tumour effect.
4.1.5  NKG2D and viral immunity
NK  cells  kill  targets  which  have  lost  or  express  insufficient  amounts  of MHC  class-I 
(Moretta  et al.,  2002).  This  is  a  frequent  event  in  tumour-  or  virus-infected  cells  and 
supports a role for NKG2D in the recognition of such cells.  However, there are reported 
differences  in  how  NKG2D  functions  in  different  cells  types.  Unlike  NK  cells,  cross- 
linking  NKG2D  on  antigen-specific  cytotoxic  T  lymphocyte  (CTL)  clones  does  not 
induce cytokine production, calcium flux or trigger cytotoxicity (Jamieson et al., 2002). 
However, NKG2D signaling is reported to augment cytotoxic and proliferative responses
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molecule (Groh et al., 2001).
Cytomegalovirus  (CMV)  is  of particular interest  in  this  scenario.  Spies  and  colleagues 
reported  that NKG2D can  serve  as  a  co-stimulatory  molecule on  CMV-specific  CD28- 
CD8+  T  cells  (Groh  et  al.,  2001).  Furthermore,  they  reported  the  expression  of MIC 
proteins  on  the  lung  tissue  sections  from  CMV-infected  patients,  thus  confirming  a 
central  role for the NKG2D-MIC  pathway during  viral  infections  and T cell  activation. 
Mouse and human studies have also demonstrated how CMV has evolved mechanisms to 
avoid  recognition  by  NKG2D  bearing  NK  and  T  cells  (Ogasawara  and  Lanier,  2005). 
These studies have shown that human CMV (HCMV) is capable of up-regulating MIC in 
human  lung  tissue  (Groh  et  al.,  2001),  but  HCMV  encodes  a  UL16  protein  that 
intracellularly retains three of the six human NKG2D ligands (ULBP1, ULBP2 and MIC 
B)  (Dunn  et al.,  2003;  Rolle  et al.,  2003;  Wu  et al.,  2003).  This escape  mechanism  is 
highlighted in fibroblasts infected with a UL 16-deletion HCMV, which were killed more 
efficiently than fibroblasts infected with wild type HCMV (Rolle et al., 2003).
MIC-B  has  been  detected  on  human  macrophages  infected  with  Influenza  A  or Sendai 
virus  and  this  is  reported  to  be  at  least  partially  dependent  on  virus  induced  IFNa 
production (Siren et al., 2004).  A further role for NKG2D has been described in mouse 
hepatitis virus (MHV)  (Dandekar et al.,  2005)  where central nervous system pathology, 
secondary  to  the  virus,  is  to  some  extent  a  consequence  of  the  NKG2D  dependent 
mechanism  mediated  by  y6-TCR+ T cells.  These  studies  indicate  a role for NKG2D  in
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prevent this surveillance.  The importance of this involvement cannot be underestimated 
when  we  consider  that  our  understanding  of  the  pathogenesis  of  viral  hepatitis  is 
continuously  evolving.  In  this  work  I  put  forward  an  argument  for  a  possible  role  for 
NKG2D in type B and C viral hepatitis.
4.1.6  NKG2D and TCR independent CD8+ T cell activation
The studies discussed  so far report the ability of NKG2D to function as a link between 
the  innate  and  adaptive  immune  system  and  demonstrate  how  NKG2D  can  modulate 
TCR signaling, effectively controlling antigen-specific killing (Groh et al., 2001; Groh et 
al., 2002; Jabri et al., 2000).
This  link  between  innate  and  adaptive  immunity  serves  to  focus  CTL  killing  on 
transformed targets, minimizing damage to unaltered cells expressing cross-reactive self 
antigen (Meresse et al., 2004).
Despite  convincing  data  to  support  this  co-stimulatory  role,  there  is  growing  evidence 
that  T  cells  could  be  activated  directly  through  the  NKG2D  signaling  pathway.  TCR 
independent cytolytic  activity  of CTL cultured with  IL-15  (or high doses of IL-2) have 
previously been reported (Gamero et al.,  1995). The intraepithelial intestinal CTL express 
high levels of NK cell associated receptors and expand on exposure to IL-15 (Jabri et al.,
1242000) and thus represent a mechanism of immunopathogenesis in Coeliac disease (C.D.). 
Infiltration by IL-15  (or high dose IL-2) activated CTL to the small intestinal epithelial 
compartment  is  associated  with  massive  cell  death,  supporting  a  role  for  TCR 
independent NK-like killing (Green and Jabri, 2003) in C.D.  Neither lower doses of IL-2 
(30u/ml)  nor  IL-7  were  capable  of arming  NKG2D  in  the  same  way  (Meresse  et al., 
2004).  Further  experiments  suggested  that  the  differential  effects  of  IL-15  were 
dependent on source and activation status of the CTL. Naive and resting memory CD8+ 
T  cells,  even  after  3  weeks  of  culture  in  IL-15,  were  incapable  of  arming  NKG2D 
mediated cytolysis.  However,  stimulation  with plate bound anti-CD3  mAb (24hrs) prior 
to incubation with IL-15 (or high dose IL-2) did arm NKG2D mediated lysis in naive and 
resting  memory  cells  (Meresse  et al.,  2004).  Thus  IL-15  primes the  NKG2D  signaling 
pathway, where its effects are most remarkable in the effector CD8+ T cell population.
1254.1.7  Why is coeliac disease important in understanding the immunopathogenesis of 
chronic viral hepatitis?
The intestinal epithelium in C.D. is the site of a massive TCRa|3+ CTL infiltration, which 
is thought to contribute to epithelial damage in an antigen-nonspecific manner (Green and 
Jabri, 2003).
It has been demonstrated that the presence of IL-15 in the tissue microenvironment of the 
gut  epithelium  increased  the  level  of CTL  NKG2D  expression  and  their  ability  to  kill 
MIC expressing targets independent of TCR activation.  This, in addition to reports that 
NKG2D  and  IL-15  reduced  the  TCR  activation  threshold  of  CTL,  suggests  that  the 
NKG2D  signaling  pathway  might  promote deleterious  autoimmune  responses  (Groh  et 
al., 2003; Meresse et al., 2004; Roberts et al., 2001). The presence of IL-15 in the liver 
(Golden-Mason  et  al.,  2004)  coupled  with  the  large  infiltration  of antigen-nonspecific 
CD8+  T  cells  in  viral  hepatitis  make  the  case  for the  NKG2D  signaling  pathway  as  a 
previously  unrecognized mechanism of liver damage. We will now examine the role of 
NKG2D in type B  and C chronic  viral hepatitis and define the mechanisms that control 
the cytolytic potential of intrahepatic lymphocytes.
1264.1.8  The expression and function of NKG2D molecule on intrahepatic CD8+ T cells 
in chronic viral hepatitis
Chronic viral hepatitis is an inflammatory disease of the liver mainly caused by persistent 
HBV and HCV infection. The mechanisms causing the destruction of hepatocytes and the 
associated chronic inflammation are still elusive, though CD8+ T cells are likely to play a 
leading role over the various cell populations (macrophages, granulocytes, platelets) that 
are  implicated  in  the  chronic  inflammatory  process.  Direct  recognition  of  infected 
hepatocytes  by  virus-specific  CD8+  T  cells  is  considered  to  represent  the  main  event 
responsible  for  initial  virus  clearance  and  hepatocyte  damage.  This  antigen-specific 
mediated  CD8+  T  cell  activation  triggers  the  liver  recruitment  of  inflammatory  cells, 
which can sustain and amplify the hepatic damage (Bertoletti and Maini, 2000).
However,  virus-specific  CD8+ T cells  are reported to represent,  at least during chronic 
infection, a minority of the intrahepatic CD8+ T cell infiltrate,  which is the hallmark of 
chronic active viral hepatitis (Colucci et al.,  1983; Dienes et al.,  1987; Yang et al.,  1988). 
Several  studies  have  shown  that,  both  in  HBV  and  HCV  related  chronic  hepatitis 
(Grabowska  et  al.,  2001;  He  et  al,  1999;  Maini  et  al,  2000),  less  than  10%  of the 
intrahepatic  CD8+  T cells  are  virus-specific.  In  addition  we  demonstrated that, during 
chronic  active hepatitis B,  virus-specific CD8+ T cells  are diluted  among  a majority of 
apparently non-antigen-specific CD8+ T cells,  a cell population where the pathogenetic 
impact has never been comprehensively evaluated (Maini et al., 2000).
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liver damage can be drawn from studies in coeliac disease (Green and Jabri, 2003; Jabri 
et al., 2000; Meresse et al., 2004), an intestinal inflammatory disorder induced by dietary 
gluten in genetically susceptible individuals. Here, gluten-specific T cells are considered 
the  culprits  in  initiating  the  inflammatory  process,  but  chronic  epithelial  damage  is 
maintained by gut infiltrating CD8+ T cells which undergo a genetic reprogramming of 
natural killer like cell function and can be activated independent of the TCR stimulation.
The TCR-independent activation of intraepithelial  CD8+ T cells  in coeliac disease  was 
reported to act through the crosslinking of NKG2D, with the ligands MIC-A and MIC-B, 
expressed by epithelial  cells under conditions of stress.  This has been reported to be an 
IL-15 dependent process, and it is noteworthy that IL-15 is produced in the infected liver 
(Golden-Mason et al., 2004). We thus hypothesized that the bulk of intrahepatic CD8+ T 
cells charateristic of the cellular hepatic infiltrate during chronic viral hepatitis might be 
involved  in  chronic  liver  damage  through  a  process  of  CD8+  T  cell  activation 
independent of antigen-specific recognition.  To investigate this possibility we analysed 
the  expression  of NKG2D  on  freshly  isolated  CD8+  T  cells  from  chronically  infected 
human  livers  (HBV  &  HCV).  We  also  studied  the  expression  of the  natural  ligands  of 
NKG2D  molecules,  including  MIC-A  and  MIC-B,  on  human  hepatocytes.  We  then 
measured  the  functional  impact  of  NKG2D  and  IL-15  on  TCR-dependent  and 
independent activation of intrahepatic CD8+ T cells.
1284.2  MATERIALS AND METHODS
4.2.1  Intrahepatic and peripheral blood mononuclear cells
Patients undergoing liver biopsy as part of their work-up in the viral hepatitis clinic were 
invited to partake in the study. After informed consent was obtained, a liver biopsy was 
performed under ultra-sound guidance.  Only biopsies in excess of 1.5cm in length were 
used for the purpose of the study.  1.5cm of liver tissue was fixed in  10% zinc formalin for 
histological examination and remaining tissue was analyzed directly ex vivo.
Further specimens were obtained at the time of liver transplantation for end-stage chronic 
viral  hepatitis  (HCV,  n=12;  HBV,  n=7).  Intrahepatic lymphocytes  were  harvested from 
fresh  tissue  using  two  different  methods.  Mechanical  disruption  of liver tissue  and  the 
yield of lymphocytes was performed as described previously (Curry et al., 2000). Briefly, 
liver  tissue  was  dissected  and  homogenized  through  a  70pm  nylon  cell  strainer  (BD 
Falcon,  USA)  to  remove  tissue  clumps.  The  filtrate  was  then  washed  with  PBS  at 
1800rpm  x  lOmins  and  one  further  wash  at  1500rpm  x  8mins.  The  final  pellet  was 
resuspended in complete RPMI supplemented with  10% fetal calf serum (FCS), 2mM L- 
glutamine,  100  U/ml  penicillin,  100  pg/ml  streptomycin,  and  50  pg/ml  2- 
mercaptoethanol (2-ME).
Alternatively,  excess  liver  tissue  not  required  for  diagnostic  purposes  was  extensively 
washed in RPMI and then digested with collagenase (Sigma, St. Louis, Mo;  1   mg/ml) and 
DNAse (Sigma,  25  ng/ml) for  1   h  at 37  °C.  The cell  suspension was  washed twice and
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gradient.
Patient peripheral blood lymphocytes (PBL) were prepared in parallel by standard density 
gradient centrifugation as previously described.  Briefly, PBMC were isolated from fresh 
heparinized  blood  by  Ficoll-Hypaque  density  gradient  centrifugation  and  suspended  in 
RPMI  1640 supplemented with 25 mM Hepes, 2 mM L-glutamine, 50 /ig/ml gentamycin 
and  8%  human  serum  (complete medium) and  used immediately in phenotypic analysis 
or functional studies.
4.2.2  Phenotypic analysis
For phenotypic staining, mononuclear cells (PBL & IHL) were incubated with CD8 PE- 
Cy5  (BD Pharmingen,  San Diego,CA)  +/- CD3 FITC (BD Pharmingen,  San Diego,CA) 
and the following antibodies for 30min on ice; NKG2D-PE, CD28-PE, CD56-PE, IgGl- 
PE (BD Pharmingen, San Diego,CA). Following incubation cells were washed with PBS 
three  times,  resuspended  in  2%  paraformaldehyde  and  acquired  using  FACScan  flow 
cytometer (BD Biosciences, San Diego, CA).
To assess the effect of cytokines on NKG2D expression, mononuclear cells (PBL & IHL) 
were cultured  in;  IL-2  (20-300U/ml),  IL-7  (20-100ng/ml),  IL-15  (20-100ng/ml), MIP-a 
(lOpg/ml),  MIP-|3 (lOpg/ml)  and  IFN-y  (1,000 U/ml)  for 24-72  hours.  The  use of high 
doses of cytokines in this manner, ie 300U/ml of IL-2, was aimed at generating NK like 
lines.
1304.2.3  Generation of ex vivo expanded and activated T cells (NKG2D+ T cells)
PBMC were isolated from healthy donors by density gradient centrifugation. T cells were 
activated  and expanded  as described  (Vemeris et al.,  2004).  Briefly,  mononuclear cells 
were resuspended at 2xl06 cells/ml in complete RPMI supplemented with  10% fetal calf 
serum  (FCS),  2mM  L-glutamine,  100  U/ml  penicillin,  100  pg/ml  streptomycin,  and  50 
pg/ml 2-mercaptoethanol (2-ME) at 37°C, 5% CO2.
On day 0, cells were incubated with IFN-y (1,000 U/ml; AL-Immunotools) for 24 hours. 
Cells were then stimulated with anti-CD3 (25ng/ml; Serotec) and recombinant IL-2 (rlL- 
2; 300U/ml; R+D Systems). Thereafter, cells were stimulated with rIL-2 (300U/ml) every 
3-5 days and fresh medium  was added to maintain a cell density of approx.  2xl06 for a 
total of 14-28 days.
4.2.4  Functional assay
CD107a-PE  antibody  (BD  Pharmingen,  San  Diego)  was  used  for degranulation  assays. 
Functional  assays  were  set  up  with  plate  bound  antibody  as  follows;  Isotype  control, 
NKG2D only,  CD3  only,  CD3+NKG2D or CD3+CD28.  Plates  were blocked overnight 
@ 4°C with CD3 (1 pg/ml), NKG2D (lOpg/ml) or combination either of CD3/NKG2D or 
CD3/CD28 (CD28  lOpg/ml) in  100 pi of 0.05 M carbonate buffer (pH 9.6). Plates were 
washed  three  times  with  RPMI  to  remove  unbound  antibody.  Mononuclear cells  were 
then transferred to the plate in  lOOpl complete RPMI plus CD 107a PE and incubated for 
6-16  hours  (Betts  and  Koup,  2004)  in  the  presence  or  absence  of  20ng/ml  IL-15.
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(incubation 30min on ice) and analyzed by flow cytometry.
4.2.5  Generation of NK clones
NK  clones  were  generated  in  Dan  Davis’s  laboratory  at  Imperial  College  and  kindly 
provided to us for use in this project.
4.2.6  Purification of primary human hepatocytes
Normal human liver tissue was obtained from healthy tissue surrounding liver metastases 
following informed consent according to ethical and moral guidelines of the institution.
Tissue  sections  were  collected  in  William’s  E  medium  and  maintained  at  4°C  for  a 
maximum  of  2  hours  before  cell  isolation.  Hepatocytes  were  isolated  by  enzyme 
perfusion  described  for  use  with  human  liver by  Strain  et al  with  some  modifications 
(Strain et al.,  1991). A section of liver of about  100-200g was cut and exposed vessels on 
a single surface were cannulated with 3 mm internal diameter tubing.
The  tissue  was  perfused  sequentially  at  50  ml/min  with  500  ml  PBS-HEPES  wash 
solution to remove William’s E medium, 500 ml  PBS-Hepes-0.5 mM EGTA and again 
with  500  ml  PBS-HEPES  wash  solution.  Finally,  300  ml  enzyme  solution  [0.05% 
collagenase  (Roche,  Indianapolis,  IN),  0.012%  hyaluronidase  (Sigma,  Dorset,  UK), 
0.025%  dispase  II  (Roche),  0.005%  DNAse  (Roche)  containing  5  mM  CaCl2], 
maintained  at 41°C,  was perfused  with recirculation and enzymatic digestion continued
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mechanically  dissociated  in  200  ml  HBSS  (Invitrogen)  containing  10%  FBS,  5mM 
CaCl2. The cell suspension was filtered through a 60 pM cell strainer and pelleted at 37xg 
for  10 min  at 4°C.  Cells  were washed  3x  in  HBSS  containing  10%  FBS,  5mM  CaCl2  
after  which  viability  and  yield  were  assessed.  Purified  hepatocytes  were  used 
immediately  after  isolation  or  from  frozen  stocks  thawed  from  70%  University  of 
Washington solution, 20% FBS and  10% DMSO freezing medium.  Isolated hepatocytes 
did  not  contain  lymphocytes/monocytes  as  assessed  by  flow  cytometry  and  appeared 
greater  than  90%  pure  by  microscopic  analysis  and  forward  vs.  side  scatter  by  flow 
cytometry.  Contamination  with some endothelial  cells could not be ruled out however, 
endothelial  cell  surface  markers  (VCAM-1,  HLA-DR)  were  undetectable  in  FACs 
staining.
4.2.7  Cell Lines and medium
The  hepatocyte-like cells,  HepG2, used  as targets to assess the role of NKG2D as a co­
stimulator, were grown and maintained in RPMI  1640 (Autogen Bioclear, Wiltshire, UK) 
supplemented with  10% heat inactivated FBS, 20 mM Hepes, 0.5 mM sodium pyruvate, 
100  U/ml  penicillin,  100  ug/ml  streptomycin,  MeM  amino  acids  +  L-glutamine,  MeM 
non-essential  amino  acids  (Invitrogen  Ltd,  Paisley,  UK)  and  5  pg/ml  Plasmocin 
(InvivoGen, San Diego, CA) to prevent mycoplasma contamination.
HBci8 27  specific  CD8+  T  cell  clones  were  generated  from  resolved  HLA-A2+  HBV 
patients.  PBMC  were  isolated from fresh heparinized blood by Ficoll-Hypaque density
133gradient centrifugation.  Short term lines were made by stimulating PBMC in Aim-V 2% 
hABs with  lpM of either HBcI8 2 7 or HBpolymerase455.6 3  peptides + 20 U/ml IL-2 (R&D 
systems, Abingdon, UK) for 10 days.
HBc)8_ 27  specific  CD8+  T  cells  were  labelled  with  PE-conjugated  HLA-A2  class  I 
pentamers (Proimmune, Oxford, UK) bearing the HBc1 8 .27 epitope for 30 min at 37°C and 
purified  via  magnetic  cell  sorting  using  anti-PE microbeads  (Miltenyi  Biotech,  Surrey, 
UK).  CD8+ T cells were then cloned by limiting dilution assay and clonal populations 
were expanded  in  Aim-V,  2% hAB  serum, 20 U/ml  IL-2,  10 ng/ml IL-7,  and  10  ng/ml 
IL-15 (R&D systems, Abingdon, UK) with  1.5 ug/ml PHA (Sigma-Aldrich, Dorset, UK) 
using allogenic irradiated PBMC as feeder cells.
1344.3  RESULTS
CD8+ T cells infiltrating HBV and HCV chronically infected livers express high levels of 
NKG2D.  Freshly  isolated  intrahepatic  and  circulating  T  cells  were  stained  with 
fluorescent conjugated  antibodies  and  analyzed  immediately  with  flow  cytometer.  The 
majority of intrahepatic CD8+ T cells (anti-CD3+ and anti-CD8+) were CD28 negative in 
both normal and chronically infected livers. All intrahepatic and circulating CD8+ T cells 
expressed  NKG2D  molecules,  but  NKG2D  expression  was  consistently  higher  in  the 
liver-infiltrating  CD8+  T  cells  than  in  their circulating  counterpart,  in  all  patients  with 
chronic  HBV  (n=5  subjects)  and  HCV  (n=  8  subjects)  infected  livers  (Figure  4.4a,b). 
However,  no  correlation  was  found  between  levels  of  NKG2D  expression  and  ALT 
values or inflammatory score (Table 4.1).
NKG2D  up-regulation  in  intrahepatic  CD8+  T  cells  was  detected  in  both  collagenase 
treated and mechanically disrupted biopsies, ruling out the purification process employed 
to  harvest  IHL,  as  an  explanation  for  the  increased  NKG2D  expression.  NKG2D 
expression  was  higher  in  the  CD28-  than  in  the  CD28+  population  of CD8+  T  cells. 
These  data  show  that  intrahepatic  CD8+  T  cells  express  higher  levels  of  NKG2D 
molecules both in HBV and HCV related chronic hepatitis.
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Figure 4.4.  (a)  Histograms  representing  NKG2D expression  on  PBL and  IHL for normal  liver, 
HBV and  HCV infected  livers, (b) NKG2D expression CD8+T cells A immune fluoresence (I.F.) 
(liver-blood).  NKG2D  is  preferentially  expressed  by  intrahepatic  CD8+ T  cells  in  chronic  viral 
hepatitis.
136PATIENT  VIRUS
HBV
ALT
115
PBL
NKG2D
expression
23
Liver
NKG2D
expression
37
Liver Histology
Moderate to severe hepatitis
HBV
HBV
HBV
HBV
HBV
HCV
HCV
HCV
HCV
HCV
HCV
HCV
HCV
HCV
80
45
24
66
62
60
64
42
95
49
66
57
68
74
25
25
13
22
19
18
38
21
27
14 
21 
24 
17
22
29
55
39
30 
42
30 
47
32 
35
33 
46 
37
31
40
Moderate chronic hepatitis, developing 
cirrhosis
Cirrhosis, moderate inflammatory activity 
Marked fibrosis, mild inflammatory 
activity
Cirrhosis, moderate inflammatory activity 
Mild hepatitis, developing cirrhosis 
Mild chronic hepatitis, mild fibrosis 
Mild chronic hepatitis, mild fibrosis 
Cirrhotic liver, moderate chronic hepatitis 
Moderate lymphocytic infiltrate, mild 
fibrosis
Cirrhosis, moderate inflammatory activity 
Cirrhosis, mild inflammatory activity 
Cirrhosis, moderate inflammatory activity 
Mild fibrosis, non specific chronic 
inflammation
Chronic hepatitis, mild fibrosis
Table  4.1.  Patient  characteristics.  NKG2D  expression  (I.F.)  correlated  with  ALT  values  and 
histopathology.
1374.3.1  The exclusive modulation of NKG2D expression by IL-15
IL-15  has  been  shown  to  enhance  the  surface  expression  of NKG2D  molecules  while 
other cytokines like TNF-a, IL-7, IL-10 and IL-12 have no detectable effect (Roberts et 
al., 2001).
We analyzed whether, in addition to IL-15 (Kakumu et al.,  1997), other cytokines (IFN-y, 
IP-10,  MIP-a,  MIP-p)  known  to  be  present  in  chronic  viral  hepatitis  might  influence 
NKG2D expression.
As shown in figure 4.5, only exposure to IL-15 rapidly increases the NKG2D expression 
in peripheral and intrahepatic CD8+ T cells. IP-10, MIP-a and MIP-P have no effect and 
only modest effects were detectable with IFN- y.
These  results  suggest  that  the  selected  up-regulation  of  NKG2D  molecules  found  in 
intrahepatic  CD8+  T  cells  of  HBV  and  HCV  infected  livers  might  be  preferentially 
mediated by IL-15.
1383 5
30
6  2 5  
S   20
|   “
*   "
5
0
--0-~Med 
IFN-y 
IL-15 
IP-10 
MIP-a 
MIP-p
24h
time
48h
Figure 4.5. IL-15 enhances NKG2D expression on CD8+T cells over time. The maximum effect 
was at 48 hours in vitro culture.
4.3.2  NKG2D-mediated activation of intrahepatic CD8+ T cells
Cross-linking of NKG2D  molecules  on  CD8+ T  cells does  not  normally  induce T  cell 
activation.  However, recent reports have shown that CD8+ T cells maintained in culture 
in particular conditions or present in tissue with aberrant IL-15 production can be directly 
activated by NKG2D signalling alone.  Because of the high NKG2D expression detected 
on liver-infiltrating CD8+ T cells present in  chronic viral hepatitis (both type B and C), 
we investigated whether these cells can be directly activated by NKG2D cross-linking.
139Activation of CD8+ T cells  was tested by measuring CD 107 expression,  a marker of T 
cell  degranulation  in  CD8+  T  cells  stimulated  by  plate-bound  antibody.  NKG2D  is 
capable of directly stimulating NK-cells, but failed to directly stimulate peripheral T cells 
expressing high levels of NKG2D molecules after IL-15 incubation. (Fig 4,6a, b).
More importantly, we could not detect any direct in vitro NKG2D-mediated activation of 
intrahepatic  CD3+CD8+  T  cells  purified  from  HBV  (n=8)  and  HCV  (n=12)  infected 
livers. Experiments were performed both in the presence and absence of IL-15 (20ng/ml). 
Intrahepatic  T  cells  had  the  ability  to efficiently  increase  CD 107  expression  after anti- 
CD3  antibody  mediated  stimulation,  on  the  contrary  cross-linking  with  anti-NKG2D 
antibody  alone  was  insufficient  to  activate  the  degranulation  pathway  in  intrahepatic T 
cells purified from HBV and HCV infected livers. (Figure 4.6c, d).
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Figure  4.6.  CD 107  degranulation  assay  was  used  to  measure  the  direct  activation  through  the 
NKG2D receptor of NK cells, NKG2D+ T cells, intrahepatic T cells (HBV & HCV).
4.3.3  NKG2D molecule: a co-stimulatory effect
Several  studies  have  demonstrated  that  NKG2D  molecules  can  act  as  co-stimulatory 
molecules for  both  mouse  and  human  CD8+ T  cells.  To characterize  whether  NKG2D 
can  act  as  a  potential  costimulatory  molecule  in  the  CD8+  T  cell  response  against 
infected hepatocytes,  we first studied its effects on activation of HBV-specific CD8+ T 
cells  clones  selected  from  patients  with  resolved  hepatitis  B  infection.  The  core  18-27
141specific  CD8+ T  cell  clone,  used  for the  functional  experiments,  presents  a  phenotype 
compatible  with fully  differentiated  effector CD8+ cells (CCR7  negative,  CD62L-) and 
express  NGK2D  molecules to  values similar to the  bulk of intrahepatic T  cells  (Figure 
4.7a).
Core 18-27 Expression of NKG2D  Polymerase Expression of NKG2D
Figure  4.7a.  NKG2D  expression  on  the  T  cell  clones  (core  18-27  &  Polymerase).  Filled 
histogram represents NKG2D expression, shown in the presence of an isotype control.
To test the  effect of NKG2D  ligation on  the  activation  of core  18-27  specific CD8+ T 
cells,  HLA-A2+  HepG2  cells  were  pulsed  with  different  concentrations  of core  18-27 
peptide.  After  removal  of unbound  peptide  with  extensive  washing,  the  peptide  pulsed 
hepatocyte-Iike cells were mixed with CTL clones at an effector to target ratio of 1:1  in 
the  presence  of  1   or 5  pg/ml  of anti-NKG2D  antibodies  or  isotype  control  antibodies. 
Figure 4.7b shows that the addition of NKG2D antibodies inhibits substantially CD8+ T 
cell degranulation, particularly in the presence of limiting amount of peptide.
These results suggest that NKG2D molecules can act as a costimulatory molecule during 
the recognition of virus-infected hepatocytes by virus-specific effector CD8+ T cells.
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Figure 4.7b. NKG2D co-stimulates HBV-specific CD8+ T cells in vitro. HepG2 cells known to 
express MIC-A/B are pulsed with core  18-27 peptide, co-cultured with core  18-27 CD8+ T cell 
clones in the presence of the NKG2D blocking antibody.
We then tested whether NKG2D molecules were able to co-stimulate the TCR-dependent 
activation of intrahepatic CD8+ T cells.  Intrahepatic T cells were incubated overnight in 
wells  coated  with  anti-CD3  alone,  anti-CD3  and  anti-NKG2D,  or  isotype  control 
antibodies  in  the  presence  of  IL-2  or  IL-15.  Anti-CD3  dependent  activation  of 
intrahepatic T  cells was co-stimulated by  NKG2D cross-linking only in the presence of 
IL-15 (Figure 4.8).
These  results  support the  possibility  that  NKG2D  molecules  can  act  as  co-stimulatory 
molecules  on  intrahepatic T  cells,  depending  on the  cytokine  milieu  present within the 
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Figure  4.8(A),  (B).  NKG2D  co-stimulates  intrahepatic  CD8+  T cells  in  the  presence  of  IL-15. 
CD107  expression  is  measured  as  mean  fluoresence  (M.F.)  intensity.  X  axis  represents  the 
various antibodies used.
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Figure 4.8c. IHL (HBV) exhibiting NKG2D co-stimulation in the presence of IL-15.
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Figure 4.8d. IHL (HCV) exhibiting NKG2D co-stimulation in the presence of IL-15.
1454.4  DISCUSSION
In an attempt to further investigate the potential contribution of intrahepatic CD8+ T cells 
in liver damage we set out to analyse in this study whether liver infiltrating CD8+ T cells 
present  phenotypic  and  functional  characteristics  of  NK-like  cells.  The  phenotypic 
comparison  of  NKG2D  expression  on  intrahepatic  and  circulating  CD8+  T  cells 
demonstrates that intrahepatic cells in both HBV and HCV chronically infected patients 
display a consistently higher NKG2D expression.
It  is  likely  that  such  up-regulation  is  mediated  by  the  presence  of intrahepatic  IL-15. 
Among the different cytokines that are present in the liver during chronic inflammation 
(IFN-y,  MIP-a,  MIP-(3,  IP-10  and  IL-15)  we  demonstrated  that  only  IL-15  has  the 
capacity to up-regulate NKG2D expression in peripheral blood.  IL-15 does not only up- 
regulate  NKG2D  expression,  in  addition  its  production  in  the  intestinal  epithelium  of 
patients  with  coeliac  disease  is  instrumental  in  T-cell  receptor  independent  T  cell 
activation of NKG2D expressing T cells.
However,  despite  the  enhanced  phenotypic  expression  and  the  production  of IL-15  in 
infected  human  livers,  we  could  not  demonstrate  T-cell  receptor  independent  T  cell 
activation of intrahepatic NKG2D expressing T cells. Freshly purified intrahepatic T cells 
failed  to be  directly  activated  by  cross-linking  with  anti-NKG2D  antibodies,  while this 
assay  was  robust  enough  to  activate  classical  NK-cells.  Furthermore,  we  found  no 
correlation  between  NKG2D  expression  and  ALT  values,  an  indirect  marker  of  the
146possible involvement of NKG2D-expressing CD8+ T cells in liver damage. However, the 
potential  limitations  of  our  methods  need  to  be  underlined  before  excluding  the 
possibility that intrahepatic T cells are not endowed with NK-like features.
The purification of intrahepatic T cells through enzymatic means might have altered the 
responsiveness  of the  cells  mediated  by  NKG2D  alone.  Harvested  intrahepatic  T  cells 
were viable and could be activated by anti-CD3  cross-linking, however NKG2D signals 
through  a  different  pathway,  involving  DAP-10  adaptor protein,  which  might  be  more 
sensitive to the robust T cell handling involved in intrahepatic T cell purification. More 
importantly,  our NKG2D  mediated  activation  assay,  involves exclusive NKG2D cross- 
linking, since anti-NKG2D antibodies were directly bound to the plates.
In contrast, previous reports demonstrate an NKG2D-mediated activation of T cells using 
redirected cytolytic assays, in which NKG2D antibodies were bound to the Fc receptor of 
P815 cells. It is possible that adhesion molecules present on the target cells are necessary 
to  stabilize  the  NKG2D  interaction  and  thus  improve  the  sensitivity  of  the  assays. 
Consistent  with  this  possibility  is  the  fact  that  the  anti-NKG2D  plate-bound  activation 
assay used in our work, activated only 16% of true NK cells.
In contrast to the inability to stimulate CD8 + T cell degranulation alone, engagement of 
NKG2D  increases  the  CD8+  T  cell  degranulation  of  TCR-stimulated  cells.  This  co­
stimulatory  activity  was  detected  both  in  the  in  vitro  expanded  HBV-specific  CD8+  T 
cells activated by  recognition  of MHC class  I  viral  peptide complex  and  in the ex vivo
147purified  intrahepatic  CD8+  T  cells  activated  by  anti-CD3  antibody  engagement  in  the 
presence of IL-15. It is thus likely that NKG2D expression on intrahepatic virus-specific 
CD8+  cells  and  the  presence  of the  IL-15  in  the  intrahepatic  microenvironment  might 
play  a  role  in  the  recognition  of  virus  infected  hepatocytes.  Hepatocytes  express  low 
levels of HLA-class I molecules. NKG2D expression on virus-specific CD8+ T cells and 
IL-15 might act in concert to lower the activation threshold of effector CD8+ T cells, and 
permit efficient recognition of hepatocytes expressing lower levels of viral antigens.
The  demonstration  of increased  expression  of the  NKG2D  ligands  on  virally  infected 
hepatocytes will be a critical  step to the progression and development of this work. This 
is work in progress and  although we have detected increased expression of ULBP-3 on 
HCV infected hepatocytes, this ligand or any of the other NKG2D ligands for that matter 
were not consistently detected on virally infected human hepatocytes.  However, it must 
be pointed  out that  our data  are  too few  at  this  time  to  draw  any  concrete  conclusions 
regarding the expression of NKG2D ligands in chronic viral hepatitis.  The  whole  series 
of  NKG2D  ligands  will  require  detailed  analysis  in  future  studies  with  particular 
emphasis on their expression in different pathological conditions (and at various stages of 
such conditions) in order to fully elucidate the impact of NKG2D expression on CD8+ T 
cell activation.
In conclusion, in this work we analysed the phenotypic expression and functional role of 
the NKG2D molecule during chronic viral hepatitis in humans. We report a consistently 
higher  expression  of  NKG2D  molecule  on  intrahepatic  CD8+T  cells.  However,  the
148functional  significance of this phenotypic finding remains  uncertain.  Increased NKG2D 
expression does not seem to allow  a T-cell receptor independent, NK-like, CD8+ T cell 
activation,  but  does  provide  a  co-stimulatory  effect  in  TCR-mediated  CD8+  T  cell 
activation.  A greater understanding of the potential pathogenetic role of the intrahepatic 
CD8+ T cell  infiltration present in chronic viral hepatitis is likely to necessitate a more 
detailed  analysis  of  the  NKG2D-mediated  CD8+  T  cell  activation,  coupled  with  a 
comprehensive  study  of  the  expression  of  NKG2D  ligands  on  purified  hepatocytes 
present in different pathological conditions.
149CHAPTER 5 
DISCUSSION AND FUTURE WORKIn this Chapter, I address the broader implications of the data presented in this thesis and 
outline where I envisage this work will go in the future.
Chronic  type  B  and  C  hepatitis  is  a  major  cause  of  morbidity  worldwide.  The 
mechanisms  responsible  for  the  development  of  chronic  disease  as  opposed  to  viral 
clearance  and  lifelong  immunity  are  ill-defined,  but  it  is  established  that  the  different 
components  of  innate  and  adaptive  immune  response  contribute  to  these  variable 
outcomes.
In this Thesis we have primarily focused on the role of T cells in chronic viral hepatitis, 
which represent a component of adaptive immunity necessary for both viral clearance and 
disease pathogenesis.
The main  body  of work presented  in Chapter 3  examines the influence  of T cell cross­
reactivity  on  HCV-specific T cell  responses.  We  start with the premise,  “that no one is 
naive”, but instead each individual has a lifelong exposure to numerous pathogens which 
shapes  and  moulds  their  own  exclusive  T  cell  repertoire.  Such  variation  in  the 
immunological  make-up  is  likely  to contribute  to different  interpretations  of the T cell 
response but may  also  influence disease outcome.  In keeping  with this, the presence of 
cross-reactive  T  cell  response  between  common  human  pathogens  and  HCV-peptides 
alter the  analysis  and  the  consequent  interpretation  of the  role  of HCV-specific  T  cell 
response.  Studies  to  date  have  pursued  a  line  of  investigation  to  detect  potential 
protective HCV  epitopes by  testing HCV-negative  subjects  with known risk factors for
151HCV infection.  The presence of HCV-specific T cells in this HCV-negative population 
has been  assumed to represent a  “protective T cell  response”.  We  argue that this is not 
necessarily accurate, as our data demonstrates that HCV-peptide specific reactive T cells 
can be the result of cross-reactivity with other pathogens and not exclusively the result of 
direct HCV priming.  However,  our data does distinguish  between  the broad repertoire 
seen  after  recovery  from  acute  hepatitis  C,  and  the  narrow  cross  reactive  focus  we 
observed.
Importantly,  our  data  support  the  possibility  that  cross-reactive  T  cells  can  potentially 
alter the clinical profile of HCV infections. Urbani et al have reported that the presence of 
a robust and vigorous single CD8+ T cell response directed against a single HCV epitope 
cross- reacting  with  an  influenza epitope was associated with a severe hepatitis and did 
not result  in  viral  clearance  (Urbani  et al.,  2005a).  This work demonstrates how  cross­
reactivity might in some selected cases influence the clinical and pathological profile of 
HCV-disease. In this Thesis the demonstration of cross-reactivity between HCV peptides 
and  sequences  of common  pathogens,  such  as  human  herpes  virus  suggest  that  cross­
reactivity is not an unusual event. Furthermore, we can deduce that if cross-reactivity is a 
frequent occurrence,  it is  almost  certainly  another variable  contributing  to  the  different 
clinical outcomes of HCV infection.
Lastly, our analysis of the whole HCV-specific T cell repertoire in such diverse groups 
from  non-HCV  infected  newborns  and  adults to  chronic  carriers of HCV  has provided 
further evidence  of the  ability  of the  virus  to qualitatively  alter the  circulating  pool  of
152HCV-specific T cells. It was important to demonstrate that the comprehensive magnitude 
of HCV-peptide reactive T cells present in chronically  HCV infected patients is similar 
and in some cases even lower than that of HCV-peptide reactive T cell response found in 
HCV-negative adults.
The  conspicuous  deficit  of HCV-peptide  specific  T  cells  in  chronically  HCV-infected 
patients  found  in  our  work  confirms  the  profound  collapse  of  virus-specific  T  cell 
responses  caused  by  HCV  persistence  previously  reported  by  Spangenberg  and  others 
(Spangenberg et al., 2005, Accapezzato et al., 2004, Lauer et al., 2004).
It is noteworthy that  such  responses  are  not necessarily restored  with combination anti­
viral therapy, or in some cases only transiently improved, stressing the limitations of the 
current drug regimens for the treatment of HCV.
The work presented in Chapter 4 deals with the impact of the activating receptor NKG2D 
on the modulation of CD8+T cells in chronic viral hepatitis. We asked whether this novel 
receptor is a player in the mediation of liver damage in hepatitis B and C viral infection. 
If so, can the role of this receptor be more clearly defined to enable us to manipulate such 
factors for the treatment of chronic viral hepatitis in the future?
In this Thesis, I have focused on the destruction of hepatocytes and the development of 
chronic inflammation  leading to progressive liver damage.  I used the work of Bertoletti 
and Maini  as a benchmark to develop one of the central hypotheses of this study.  Liver 
damage  is  largely  mediated  by  CD8+  T  cells  and  direct  recognition  by  virus-specific
153CD8+ T cells is considered to be the main event for initial viral clearance and hepatocyte 
damage.  The  dilution  of  this  virus-specific  component  in  the  massive  CD8+  T  cell 
infiltrate  is  a  hallmark  of chronic  viral  hepatitis.  It  is  this  non-virus  specific  infiltrate 
which  appears  to  be  the  variable  in  chronic  disease,  with  almost  equivalent  absolute 
numbers  of  virus-specific  CD8+  T  cells  in  both  self  limited  infection  and  in  chronic 
hepatitis.  The  role  of this  population  of  non-antigen  specific  CD8+  T  cells  is  poorly 
understood.  More  precisely,  what  modulates  this  population  of  cells  and  what  their 
pathogenetic impact is,  remains unclear.  These are the questions we  set out to tackle in 
this work.
Studies in coeliac disease, discussed in detail  in this Thesis, provide  an exciting line of 
investigation  as  to  how  this  population  of  cells  may  be  implicated  in  chronic  viral 
hepatitis.  It has been reported  in Coeliac  disease  that the  intestinal  epithelial  damage is 
mediated by the large infiltrate of non-antigen specific CD8+ T cells and that these cells 
are activated in a TCR-independent manner (Meresse et al., 2004). The requisite for such 
activation  appears  to  be  the  right  inflammatory environment  and  more  specifically  this 
refers to the presence of IL-15. If we take these conditions and apply them to the virally 
infected liver, we find the optimum tissue microenvironment to support the activation of 
a  large  population  of non-antigen  specific  CD8+  T  cells  to  mediate  liver damage  in  a 
similar way.
More importantly, the TCR independent activation of CD8+ T cells in Coeliac disease is 
through  the  activating  receptor,  NKG2D.  We  were  able  to  demonstrate  the  increased
154expression  of this  activating  receptor  on  the  IHL  of chronically  infected  human  livers 
(HBV & HCV) for the first time.  Having established this, we then set out to investigate 
whether  these  liver  infiltrating  CD8+  T  cells  present  both  phenotypic  and  functional 
characteristics of NK  cells.  Increased expression  of NKG2D was found consistently  on 
intrahepatic CD8+ T cells in chronic viral hepatitis.  In keeping with previous reports in 
coeliac disease, we show that it is likely that IL-15 is responsible for this upregulation of 
NKG2D (Green  and  Jabri,  2003,  Moresse  et al.,  2004).  However,  unlike the reports in 
coeliac disease we could not demonstrate that these conditions in the virally infected liver 
could  support T cell  activation  of intrahepatic  NKG2D expressing  CD8+ T cells.  This 
study reports that freshly purified CD8+ T cells could not be directly activated by cross- 
linking with anti-NKG2D antibodies. Consistent with these findings, NKG2D expression 
could not be directly correlated with ALT values, a crude marker of NKG2D-expressing 
CD8+ T cell mediated liver damage.
However, as I have stressed in Chapter 4, this does not preclude a role for NKG2D in the 
mediation  of  liver  damage  in  chronic  viral  hepatitis.  We  accept  that  our  assay,  the 
CD 107a degranulation assay, may not be sufficiently robust and so our methodology has 
inherent weaknesses,  namely the reliance on exclusive NKG2D cross-linking with plate 
bound anti-NKG2D  antibodies.  Moreover,  it  is noteworthy that other work on NKG2D 
has used the P815 tumour cell line and this is something that we will look at in the future. 
We will also use this work as a springboard to comprehensively analyse the expression of 
the  NKG2D  ligands  on  virally  infected  human  hepatocytes.  This  is  something  we 
previously  investigated,  but  our  data  are  too  limited  at  this  time  to  draw  any  firm
155conclusions.  Future work will focus on the presence or absence of the NKG2D ligands, 
MIC-A,  MIC-B,  ULBP-1,  2,  &  3  on virally infected hepatocytes, but more importantly 
we  will  have  to  consider  the  timeframe  of  such  an  evaluation.  HBV  and  HCV  are 
dynamic diseases, in a constant state of evolution from liver inflammation to fibrosis and 
cirrhosis.  The  detection  of such  ligands  will  almost  certainly  vary  with  disease  state, 
namely  the  level  of inflammation,  the degree of fibrosis and  so on.  In this respect,  our 
work  provides  a  mere  snapshot  of  ligand  expression  and  indeed  the  involvement  of 
NKG2D which we will certainly refine in future work.
Furthermore, the data we present in this work does provide evidence that NKG2D has a 
costimulatory role in chronic viral hepatitis. We could demonstrate the ability of NKG2D 
to increase CD8+ T cell degranulation of TCR stimulated T cells. This Thesis reports on 
how  NKG2D  and  IL-15  act  in  concert  to  mediate  this  costimulatory  effect  and  so 
undoubtedly contribute to liver damage in chronic viral hepatitis. I think this represents a 
significant line of investigation for the future as we know that therapeutic starategies may 
be able to focus on the blockage of the NKG2D receptor or even the IL-15 effect and so 
limit liver damage.
Finally,  I  conclude that NKG2D has  a role  in the liver damage  associated  with chronic 
viral hepatitis, but its precise level of involvement will need further evaluation. This work 
has laid the foundation for the further investigation of this important activating receptor, 
present  on  IHL  of  virally  infected  patients.  I  would  like  to  take  this  work  further  to 
qualify the role of NKG2D in chronic viral hepatitis and its modulation of CD8+T cells.
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191APPENDIX 1 
HCV Protein
1. Core
2. Core
3. Core
4. Core
5. Core
6. Core
7. Core
8. Core
9. Core
10. Core
II. Core
12. Core
13. Core
14. Core
15. Core
16. Core
17. Core
18 Core
19 Core
20. Core
21. Core
22 Core
23. Core
24. Core
25. Core
26. Core
27. Core
28. Core
29. Core
30. Core
31. Core
32. Core
33. Core
34. Core
35. Core
36. Core
37. Core/El
Peptide Sequence  AA#
M STN PKPQRKTKRNT  1-15
KPQRKTKRNTNRRPQ  6-20
TKRN TN RRPQ D V KFP  11-25
NRRPQDVK.FPGGGQI  16-30
DVKFPGGGQIVGGVY  21-35
GGGQ1VGGVYLLPRR  26-40
V GGVYLLPRRGPRLG  31-45
LLPRRGPRLGVRATR  36-50
GPLRGVRATRKTSER  41-55
VRATRKTSERSQPRG  46-60
K TSERSQPRGRRQPI  51 -65
SQPRGRRQPIPKARR  56-70
RRQ PIPKARRPEGRT  61-75
PKARRPEGRTW AQPG  66-80
PEGRTW AQPGYPW PL  71-85
W AQPGYPW PLYGNEG  76-90
YPW PLYGNEGCGW AG  81-95
Y G NEGCGW AGW LLSP  86-100
CG W AGW LLSPRGSRP  91-105
W LLSPRGSRPS W GPT  96-110
RG SRPSW GPTDPRRR  101-115
SW GPTDPRRRSRNLG  106-120
D PRRRSRNLGKVIDT  111-125
SRNLGKV1DTLTCGF  116-130
KVIDTLTCGFADLM G  121-135
LTCGFADLM GY1PLV  126-140
ADLM GY1PLVGAPLG  131-145
YIPLVGAPLGGAARA  136-150
GAPLGGAARALAHGV  141-155
GAARALAHGVRVLED  146-160
LAHGVRVLEDGVNYA  151-165
RVLEDGVNYATGNLP  156-170
GVNYATGNLPGCSFS  161-175
TGNLPGCSFSIFLLA  166-180
GCSFS1FLLALLSCL  171-185
1FLLALLSCLTVPAS  176-190
LLSCLTVPASAYQVR  181-195
19238. Core/El TVPASA Y QV RN SSG L 186-200
39. Core/El AYQVRNSSGLYHVTN 191-205
40. El N SSGLYHVTNDCPNS 196-210
41. El YHVTNDCPNSSIVYE 201-215
42. El DCPNSS1VYEAADA1 206-220
43. El S1VYEAADA1LHTPG 211-225
44. El AADA1LHTPGCVPCV 216-230
45. El LHTPGCVPCVREGNA 221-235
46. El CVPCVREGNASRCW V 226-240
47. El REGNASRCW VAVTPT 231-245
48. El SRCW VAVTPTVATRD 236-250
49. El AVTPTV A TRD G KLPT 241-255
50. El VATRDGKLPTTQLRR 246-260
51. El G KLPTTQLRRHIDLL 251-265
52. El TQ LRRHIDLLVGSAT 256-270
53. El HIDLLVGSATLCSAL 261-275
54. El VGSATLCSALYVGDL 266-280
55. El LCSALYVGDLCGSVF 271-285
56. El YVGDLCGSVFLVGQL 276-290
57 El CG SV FLVGQLFTFSP 281-295
58. El LVGQLFTFSPRRHW T 286-300
59. El FTFSPRRHW TTQDCN 291-305
60. El RRH W TTQDCNCSIYP 296-310
61. El TQDCNCS1YPGHITG 301-315
62 El CS1YPGHITGHRM AW 306-320
63. El GH1TGHRM AW DM M M N 311-325
64 El HRM AW DM M M NW SPTA 316-330
65 El DM M M NW SPTAALVVA 321-335
(/' El W SPTAALVVAQLLRI 326-340
67 El ALVVAQLLR1PQAIM 331-345
68 El QLLR1PQA1MDM1AG 336-350
69 El PQA1M DM1AGAHW GV 341-355
70. El DM1AGAHW GVLAG1A 346-360
71. El AHW GVLAG1AYFSM V 351-365
72. El LAG1AYFSM VGNW AK 356-370
73. El YFSM VGNW AKVLVVL 361-375
74. El GNW AKVLVVLLLFAG 366-380
75. E1/E2 V LVVLLLFAGVDAET 371-385
76. E1/E2 LLFAGVDAETHVTGG 376-390
77. E1/E2 V DAETHVTGGSAGRT 381-395
78. E1/E2 HVTGGSAGRTTAGLV 386-400
79. E2 SAGRTTAGLVGLLTP 391-405
80. E2 TAGLVGLLTPGAKQN 396-410
81. E2 GLLTPGAKQNIQL1N 401-415
82. E2 GAKQN1QL1NTNGSW 406-420
83. E2 IQL1NTNGSW HINST 411-425
84 E2 TNGSW H1NSTALNCN 416-430
19385. E2 H1NSTALNCNESLNT 421-435
86. E2 ALNCNESLNTGW LAG 426-440
87. E2 ESLNTGW LAGLFYQH 431-445
88. E2 GW LAGLFYQHKFNSS 436-450
89. E2 LFYQHKFNSSGCPER 441-455
90. E2 K FNSSGCPERLASCR 446-460
91. E2 GCPERLASCRRLTDF 451-465
92. E2 LASCRRLTDFAQGW G 456-470
93. E2 RLTDFAQGW GPISYA 461-475
94. E2 AQGW GPISYANGSGL 466-480
95. E2 P1SYANGSGLDERPY 471-485
96. E2 NGSGLDERPYCW HYP 476-490
97. E2 DERPYCW HYPPRPCG 481-495
98. E2 CW HYPPRPCG1VPAK 486-500
99. E2 PRPCG1VPAKSVCGP 491-505
100. E2 1VPAKSVCGPVYCFT 496-510
101. E2 SVCGPVYCFTPSPVV 501-515
102. E2 VYCFTPSPVVVGTTD 506-520
103. E2 PSPVVVGTTDRSGAP 511-525
104. E2 VGTTDRSGAPTYSW G 516-530
105. E2 RSGAPTYSW GANDTD 521-535
106. E2 TYSW GANDTDVFVLN 526-540
107. E2 ANDTDVFVLNNTRPP 531-545
108. E2 VFVLNNTRPPLGN WF 536-550
109. E2 NTRPPLGNW FGCTW M 541-555
110 E2 LGNW FGCTW M NSTGF 546-560
111 E2 GCTW M NSTGFTKVCG 551-565
112 E2 N STG FTKVCGAPPCV 556-570
1   1   ■ E2 TKVCGAPPCV1GGVG 561-575
114 E2 APPCVIGGVGNNTLL 566-580
1  15 E2 1GGVGNNTLLCPTDC 571-585
116 E2 NNTLLCPTDCFRKHP 576-590
117. E2 CPTDCFRKHPEATYS 581-595
118. E2 FRKHPEATYSRCGSG 586-600
119. E2 EATYSRCGSGPW 1TP 591-605
120. E2 RCGSGPW ITPRCM VD 596-610
121. E2 PW 1TPRCM VDYPYRL 601-615
122. E2 RCM VDYPYRLW HYPC 606-620
123. E2 YPYRLW HYPCTINYT 611-625
124. E2 W HYPCT1NYT1FKVR 616-630
125. E2 T1NYT1FKVRMYVGG 621-635
126. E2 IFKVRM YVGGVEHRL 626-640
127. E2 M Y VGG VEH RLE AACN 631-645
128. E2 VEHRLEAACNW TRGE 636-650
129. E2 EAACNW TRGERCDLE 641-655
130. E2 W TRGERCDLEDRDRS 646-660
131. E2 RCDLEDRDRSELSPL 651-665
194132. E2 D RDRSELSPLLLSTT 656-670
133. E2 ELSPLLLSTTQW QVL 661-675
134. E2 LLSTTQW QVLPCSFT 666-680
135. E2 Q W QVLPCSFTTLPAL 671-685
136. E2 PCSFTTLPALSTGLI 676-690
137. E2 TLPALSTGLIHLHQN 681-695
138. E2 STGL1HLHQN1VDVQ 686-700
139. E2 HLHQNIVDVQYLYGV 691-705
140. E2 IVDVQYLYGVGSS1A 696-710
141. E2 YLYGVGSS1ASW A1K 701-715
142. E2 GSS1ASW A1KW EYVV 706-720
143. E2 SW AIKW EYVVLLFLL 711-725
144. E2 W EYVVLLFLLLADAR 716-730
145. E2 LLFLLLADARVCSCL 721-735
146. E2 LADARVCSCLW M M LL 726-740
147. E2 VCSCLW M M LL1SQAE 731-745
148. E2/p7 W M M LL1SQAEAALEN 736-750
149. E2/p7 1SQAEAALENLV1LN 741-755
150. E2/p7 AALENLVILNAASLA 746-760
151. p7 LVILNAASLAGTHGL 751-765
152. P7 AASLAGTHGLVSFLV 756-770
153. P? GTHGLVSFLVFFCFA 761-775
154. p7 VSFLVFFCFAW YLKG 766-780
155. p7 FFCFAW YLKGRW VPG 771-785
156 p7 WYLK.GR W VPGAVYAF 776-790
157. P? RW VPGAVYAFYGM W P 781-795
158. p7 AVYAFYGM W PLLLLL 786-800
1  59 p7 Y G M W PLLLLLLALPQ 791-805
160 p7/NS2 LLLLLLALPQRAYAL 796-810
161 p7/NS2 LALPQRAYALDTEVA 801-815
162 p7/NS2 RAYALDTEVAASCGG 806-820
163. NS2 DTEVAASCGGVVLVG 811-825
164. NS2 A SCGGVVLVGLM ALT 816-830
165. NS2 VVLVGLM ALTLSPYY 821-835
166. NS2 LM ALTLSPYYKRY1S 826-840
167. NS2 LSPY YKRY1SW CM W W 831-845
168. NS2 KJRYISW CMW W LQYFL 836-850
169. NS2 W CM W W LQYFLTRVEA 841-855
170. NS2 LQYFLTRVEAQLHVW 846-860
171. NS2 TRVEAQLHVW VPPLN 851-865
172. NS2 QLHVW VPPLNVRGGR 856-870
173. NS2 VPPLNVRGGRDAVIL 861-875
174. NS2 VRGGRDAVILLM CVV 866-880
175. NS2 DAV1LLM CVVHPTLV 871-885
176. NS2 LM C V VH PTLVFD1TK 876-890
177. NS2 HPTLVFDITKLLLA1 881-895
178. NS2 FD1TKLLLA1FGPLW 886-900
195179. NS2 LLLAIFGPLW ILQAS 891-905
180. NS2 FG PLW ILQASLLKVP 896-910
181. NS2 ILQASLLKVPYFVRV 901-915
182. NS2 LLKVPYFVRVQGLLR 906-920
183. NS2 YFVRVQGLLRICALA 911-925
184. NS2 QGLLR1CALARKIAG 916-930
185. NS2 ICALARKIAGGHYVQ 921-935
186. NS2 RKIAGGHYVQMA11K 926-940
187. NS2 GHYVQM A11KLGALT 931-945
188. NS2 M AI1KLGALTGTYVY 936-950
189. NS2 LG A LTGTYVYNHLTP 941-955
190. NS2 GTYVYNHLTPLRDW A 946-960
191. NS2 N HLTPLRDW AHNGLR 951-965
192. NS2 LRDW AHNGLRDLAVA 956-970
193. NS2 HNGLRDLAVAVEPVV 961-975
194. NS2 DLAVAVEPVVFSRM E 966-980
195. NS2 VEPVVFSRM ETKLIT 971-985
196. NS2 FSRM ETKL1TW GADT 976-990
197. NS2 TKL1TW GADTAACGD 981-995
198. NS2 W GADTAACGDI1NGL 986-1000
199 NS2 A A CGDIINGLPVSAR 991-1005
200. NS2 1INGLPVSARRGQE1 996-1010
201. NS2 PVSARRGQE1LLGPA 1001-1015
202. NS2 RGQE1LLGPADGM VS 1006-1020
203 NS2 LLGPADGM VSKGW RL 1011-1025
204 NS2/NS3 DG M V SKG W RLLAPIT 1016-1030
205 NS2/NS3 KGW RLLAP1TAYAQQ 1021-1035
206 NS2/NS3 LAPITAYAQQTRGLL 1026-1040
207 NS3 AYAQQTRGLLGC1IT 1031-1045
208 NS3 TRGLLGCI1TSLTGR 1036-1050
209 NS3 GC11TSLTGRDKNQV 1041-1055
210. NS3 SLTGRDKNQVEGEVQ 1046-1060
211 NS3 DKNQVEGEVQ1VSTA 1051-1065
212. NS3 EGEVQ1VSTATQTFL 1056-1070
213 NS3 1V ST  AT QTFL ATCIN 1061-1075
214 NS3 TQTFLA TCIN GV CW T 1066-1080
215. NS3 ATCINGVCW TVYHGA 1071-1085
216. NS3 GVCW TVYHGAGTRTI 1076-1090
217. NS3 VYHGAGTRTIASPKG 1081-1095
218. NS3 GTRTIASPKGPVIQM 1086-1100
219. NS3 ASPKGPVIQM YTNVD 1091-1105
220. NS3 PVIQM YTNVDQDLVG 1096-1110
221. NS3 YTNVDQDLVGW PAPQ 1101-1115
222. NS3 QDLVGW PAPQGSRSL 1106-1120
223. NS3 W PAPQGSRSLTPCTC 1111-1125
224. NS3 GSRSLTPCTCGSSDL 1116-1130
225. NS3 TPCTCGSSDLYLVTR 1121-1135
196226. NS3 GSSDLYLVTRHADV1 1126-1140
227. NS3 Y LVTRHADVIPVRRR 1131-1145
228. NS3 HADV1PVRRRGDSRG 1136-1150
229. NS3 PVRRRGDSRGSLLSP 1141-1155
230. NS3 GDSRGSLLSPRP1SY 1146-1160
231. NS3 SLLSPRPISYLKGSS 1151-1165
232. NS3 RPISYLKGSSGGPLL 1156-1170
233. NS3 LKGSSGGPLLCPAGH 1161-1175
234. NS3 GGPLLCPAGHAVGLF 1166-1180
235. NS3 CPAGHAVGLFRAAVC 1171-1185
236. NS3 AVGLFRAAVCTRGVA 1176-1190
237. NS3 RAAVCTRGVAKAVDF 1181-1195
238. NS3 TRGVAKAVDF1PVEN 1186-1200
239. NS3 K.AVDFIPVENLETTM 1191-1205
240. NS3 1PVENLETTM RSPVF 1196-1210
241. NS3 LETTM RSPVFTDNSS 1201-1215
242. NS3 RSPVFTDNSSPPAVP 1206-1220
243. NS3 TDNSSPPAVPQSFQV 1211-1225
244. NS3 PPAV PQS FQ V AH LH A 1216-1230
245. NS3 QSFQVAHLHAPTGSG 1221-1235
246. NS3 AHLHAPTGSGKSTKV 1226-1240
247. NS3 PTGSGKSTKVPAAYA 1231-1245
248. NS3 KSTKVPAAYAAQGYK 1236-1250
249. NS3 PAAYAAQGYK.VLVLN 1241-1255
250. NS3 AQGYK.VLVLNPSVAA 1246-1260
251 NS3 VLVLNPSVAATLGFG 1251-1265
25? NS3 PSVAATLGFGAYM SK 1256-1270
75"' NS3 TLGFGAYM SK.AHGVD 1261-1275
254 NS3 AYM SKAHGVDPN1RT 1266-1280
255. NS3 AHGVDPNIRTGVRT1 1271-1285
256. NS3 PN1RTGVRTITTGSP 1276-1290
257. NS3 GVRT1TTGSPITYST 1281-1295
258. NS3 TTGSP1TYSTYGK.FL 1286-1300
259. NS3 1TYSTYGKFLADGGC 1291-1305
260. NS3 YGK.FLADGGCSGGAY 1296-1310
261. NS3 ADGGCSGGAYDI11C 1301-1315
262. NS3 SGGAYD111CDECHS 1306-1320
263. NS3 D111CDECHSTDATS 1311-1325
264. NS3 DECHSTDATSILGIG 1316-1330
265. NS3 TDATS1LG1GTVLDQ 1321-1335
266. NS3 ILG1GTVLDQAETAG 1326-1340
267. NS3 TVLDQAETAGARLVV 1331-1345
268. NS3 AETAGARLVVLATAT 1336-1350
269. NS3 ARLVVLATATPPGSV 1341-1355
270. NS3 LATATPPGSVTVSHP 1346-1360
271. NS3 PPGSVTVSHPN1EEV 1351-1365
272. NS3 TVSHPN1EEVALSTT 1356-1370
197273. NS3 N1EEVALSTTGEIPF 1361-1375
274. NS3 ALSTTGE1PFYGKAI 1366-1380
275. NS3 GE1PFYGKA1PLEVI 1371-1385
276. NS3 YGKA1PLEV1KGGRH 1376-1390
277. NS3 PLEVIKGGRHL1FCH 1381-1395
278. NS3 KGGRHLIFCHSKKKC 1386-1400
279. NS3 L1FCHSK.KJKCDELAA 1391-1405
280. NS3 SKKKCDELAAKLVAL 1396-1410
281. NS3 DELAAKLVALG1NAV 1401-1415
282. NS3 K.LVALGINAVAYYRG 1406-1420
283. NS3 GINAVAYYRGLDVSV 1411-1425
284. NS3 AYYRGLDVSV1PTSG 1416-1430
285. NS3 LDVSVIPTSGDVVVV 1421-1435
286. NS3 1PTSGDVVVVSTDAL 1426-1440
287. NS3 DVVVVSTDALM TGFT 1431-1445
288. NS3 STDALM TGFTGDFDS 1436-1450
289. NS3 M TGFTGDFDSVIDCN 1441-1455
290. NS3 GDFDSV1DCNTCVTQ 1446-1460
291. NS3 VIDCNTC VTQTVDFS 1451-1465
292. NS3 TCV TQTVDFSLDPTF 1456-1470
293. NS3 TVDFSLDPTFTIETT 1461-1475
294. NS3 LDPTFTIETTTLPQD 1466-1480
295. NS3 T1ETTTLPQDAVSRT 1471-1485
296. NS3 TLPQDAVSRTQRRGR 1476-1490
297. NS3 AVSRTQRRGRTGRGK 1481-1495
298. NS3 QRRGRTGRGKPG1YR 1486-1500
299. NS3 TGRGK.PGIYRFVAPG 1491-1505
300 NS3 PG1YRFVAPGERPSG 1496-1510
’ .01 NS3 FVAPGERPSGM FDSS 1501-1515
302 NS3 ERPSGM FDSSVLCEC 1506-1520
303. NS3 M FDSSVLCECYDAGC 1511-1525
304. NS3 VLCECYDAGCAW YEL 1516-1530
305. NS3 Y DAGCAW YELTPAET 1521-1535
306. NS3 AW YELTPAETTVRLR 1526-1540
307. NS3 TPAETTVRLRA Y M NT 1531-1545
308. NS3 TVRLRAYM NTPGLPV 1536-1550
309. NS3 AYM NTPGLPVCQDHL 1541-1555
310. NS3 PGLPVCQDHLEFW EG 1546-1560
311. NS3 CQDHLEFW EGVFTGL 1551-1565
312. NS3 EFW EGVFTGLTH1DA 1556-1570
313. NS3 VFTGLTH1DAHFLSQ 1561-1575
314. NS3 TH1DAHFLSQTKQSG 1566-1580
315. NS3 HFLSQTKQSGEN FPY 1571-1585
316. NS3 TKQSGENFPYLVAYQ 1576-1590
317. NS3 ENFPYLVAYQATVCA 1581-1595
318. NS3 LVAYQATVCARAQAP 1586-1600
319. NS3 ATVCARAQAPPPSW D 1591-1605
198320. NS3 RA QAPPPSW DQM W KC 1596-1610
321. NS3 PPSW DQM W KCL1RLK 1601-1615
322. NS3 QM W KCLIRLKPTLHG 1606-1620
323. NS3 L1RLKPTLHGPTPLL 1611-1625
324. NS3 PTLHGPTPLLYRLGA 1616-1630
325. NS3 PTPLLYRLGAVQNEV 1621-1635
326. NS3 Y RLGAVQNEVTLTHP 1626-1640
327. NS3 VQNEVTLTHPITKY1 1631-1645
328. NS3 TLTHP1TKYIM TCM S 1636-1650
329. NS3 ITKYIM TCM SADLEV 1641-1655
330. NS3/NS4A M TCM SADLEVVTSTW 1646-1660
331. NS3/NS4A ADLEVVTSTW VLVGG 1651-1665
332. NS3/NS4A V TSTW VLVGGVLAAL 1656-1670
333. NS4A VLVGGVLAALAAYCL 1661-1675
334. NS4A VLAALAAYCLSTGCV 1666-1680
335. NS4A A A YCLSTGCVVIVGR 1671-1685
336. NS4A STGCVVIVGRIVLSG 1676-1690
337. NS4A V1VGR1VLSGKPAI1 1681-1695
338. NS4A 1VLSGKPA11PDREV 1686-1700
339 NS4A KPA1IPDREVLYQEF 1691-1705
340. NS4A PDREVLYQEFDEM EE 1696-1710
341. NS4A/NS4B LYQEFDEM EECSQHL 1701-1715
342. NS4A/NS4B DEM EECSQHLPY1EQ 1706-1720
343. NS4A/NS4B CSQHLPY1EQGM M LA 1711-1725
344 NS4B PY IEQGM M LAEQFKQ 1716-1730
345 NS4B G M M LAEQFKQKALGL 1721-1735
346 NS4B EQFKQKALGLLQTAS 1726-1740
Al NS4B KALGLLQTASRQAEV 1731-1745
V'lX NS4B LQTASRQAEV1TPAV 1736-1750
349 NS4B RQAE VITPA VQTN W Q 1741-1755
350 NS4B 1TPAVQTNW QKLEVF 1746-1760
351 NS4B QTNW QK.LEVFW AKHM 1751-1765
352 NS4B KLEVFW AKHM W NF1S 1756-1770
353. NS4B W AKHM W NF1SG1QYL 1761-1775
354 NS4B W NFISG1QYLAGLST 1766-1780
355. NS4B G1QYLAGLSTLPGNP 1771-1785
356. NS4B AGLSTLPGNPA1ASL 1776-1790
357. NS4B LPGNPA1ASLM AFTA 1781-1795
358. NS4B AIASLM AFTAAVTSP 1786-1800
359. NS4B M AFTAAVTSPLTTGQ 1791-1805
360. NS4B A VTSPLTTGQTLLFN 1796-1810
361. NS4B LTTGQTLLFN1LGGW 1801-1815
362. NS4B TLLFN1LGGW VAAQL 1806-1820
363. NS4B ILGGW VAAQLAAPGA 1811-1825
364. NS4B VAAQLAAPGAATAFV 1816-1830
365. NS4B AAPGAATAFVGAGLA 1821-1835
366. NS4B ATAFVGAGLAGAA1G 1826-1840
199367. NS4B GAGLAGAAIGSVGLG 1831-1845
368. NS4B GAA1GSVGLGKVLVD 1836-1850
369. NS4B SVGLGKVLVDILAGY 1841-1855
370. NS4B KVLVD1LAGYGAGVA 1846-1860
371. NS4B ILAGYGAGVAGALVA 1851-1865
372. NS4B GAGVAGALVAFKIM S 1856-1870
373. NS4B GALVAFKIM SGEVPS 1861-1875
374. NS4B FKIM SGEVPSTEDLV 1866-1880
375. NS4B GEVPSTEDLVNLLPA 1871-1885
376. NS4B TEDLVN LLPA1LSPG 1876-1890
377. NS4B NLLPAILSPGALVVG 1881-1895
378. NS4B 1LSPGALVVGVVCAA 1886-1900
379. NS4B ALVVGVVCAA1LRRH 1891-1905
380. NS4B VVCAA1LRRHVGPGE 1896-1910
381. NS4B ILRRHVGPGEGAVQW 1901-1915
382. NS4B VGPGEGAVQW M NRLI 1906-1920
383. NS4B GAVQW M NRL1AFASR 1911-1925
384. NS4B M NRL1AFASRGNHVS 1916-1930
385. NS4B AFASRGNHVSPTHYV 1921-1935
386. NS4B GNHVSPTHYVPESDA 1926-1940
387. NS4B PTHYVPESDAAARVT 1931-1945
388. NS4B PESDAAARVTA1LSS 1936-1950
389. NS4B AARVTA1LSSLTVTQ 1941-1955
390. NS4B A1LSSLTVTQLLRRL 1946-1960
391 NS4B LTVTQLLRRLHQW 1S 1951-1965
392 NS4B LLRRLHQW ISSECTT 1956-1970
393 NS4B/NS5A HQW 1SSECTTPCSGS 1961-1975
394. NS4B/NS5A SECTTPCSGSW LRDI 1966-1980
*95 NS4B/NS5A PCSGSW LRD1W DW IC 1971-1985
396. NS5A W LRDIW DW ICEVLSD 1976-1990
397. NS5A W DW 1CEVLSDFKTW L 1981-1995
398 NS5A EVLSDFK.TW LKAKLM 1986-2000
399. NS5A FKTW  LKAKLM  PQLPG 1991-2005
400. NS5A KAKLM PQLPGIPFVS 1996-2010
401. NS5A PQLPGIPFVSCQRGY 2001-2015
402. NS5A 1PFVSCQRGYRGVW R 2006-2020
403. NS5A CQRGYRGVW RGDGIM 2011-2025
404. NS5A RGVW RGDG1M HTRCH 2016-2030
405. NS5A GDG1MHTRCHCGAE1 2021-2035
406. NS5A HTRCHCGAEITGHVK 2026-2040
407. NS5A CGAE1TGHVKNGTM R 2031-2045
408. NS5A TGHVKNGTM R1VGPR 2036-2050
409. NS5A NGTM RIVGPRTCRNM 2041-2055
410. NS5A IVGPRTCRNM W SGTF 2046-2060
411. NS5A TCRNM W SGTFP1NAY 2051-2065
412. NS5A W SGTFPINAYTTGPC 2056-2070
413. NS5A P1NAYTTGPCTPLPA 2061-2075
200414. NS5A TTG PCTPLPAPNYKF 2066-2080
415. NS5A TPLPAPNYKFALW RV 2071-2085
416. NS5A PNYKFALW RVSAEEY 2076-2090
417. NS5A A LW RVSAEEYVEIRR 2081-2095
418. NS5A SAEEYVEIRRVGDFH 2086-2100
419. NS5A VE1RRVGDFHYVSGM 2091-2105
420. NS5A VGDFHYVSGM TTDNL 2096-2110
421. NS5A YVSGM TTDNLKCPCQ 2101-2115
422. NS5A TTDN LKCPCQIPSPE 2106-2120
423. NS5A KCPCQIPSPEFFTEL 2111-2125
424. NS5A 1PSPEFFTELDGVRL 2116-2130
425. NS5A FFTELDGVRLHRFAP 2121-2135
426. NS5A d g v r l h r f a p p c k .p l 2126-2140
427. NS5A H RFAPPCKPLLREEV 2131-2145
428. NS5A PCKPLLREEVSFRVG 2136-2150
429. NS5A LREEVSFRVGLHEYP 2141-2155
430. NS5A SFRVGLHEYPVGSQL 2146-2160
431. NS5A LHEYPVGSQLPCEPE 2151-2165
432. NS5A V GSQLPCEPEPDVAV 2156-2170
433. NS5A PCEPEPDVAVLTSM L 2161-2175
434. NS5A PDVAVLTSM LTDPSH 2166-2180
435. NS5A LTSM LTDPSH1TAEA 2171-2185
436. NS5A TDPSH1TAEAAGRRL 2176-2190
437. NS5A ITAEAAGRRLARGSP 2181-2195
438 NS5A AGRRLARGSPPSM AS 2186-2200
439 NS5A ARGSPPSM ASSSASQ 2191-2205
440. NS5A PSM ASSSASQLSAPS 2196-2210
441 NS5A SSASQLSAPSLKATC 2201-2215
442 NS5A LSAPSLKATCTANHD 2206-2220
443 NS5A LKATCTANHDSPDAE 2211 -2225
444 NS5A TANHDSPDAEL1EAN 2216-2230
445. NS5A SPDAELIEANLLW RQ 2221-2235
446. NS5A LIEANLLW RQEM GGN 2226-2240
447. NS5A LLW RQEM GGN1TRVE 2231-2245
448. NS5A EM GGN1TRVESENKV 2236-2250
449. NS5A 1TRVESENKVVILDS 2241-2255
450. NS5A SENKVV1LDSFDPLV 2246-2260
451. NS5A V1LDSFDPLVAEEDE 2251-2265
452. NS5A FDPLVAEEDEREVSV 2256-2270
453. NS5A AEEDEREVSVPAE1L 2261-2275
454. NS5A REVSVPAE1LRKSRR 2266-2280
455. NS5A PAEILRKSRRFARAL 2271-2285
456. NS5A RKSRRFARALPVW AR 2276-2290
457. NS5A FARALPVW ARPDYN P 2281-2295
458. NS5A PV W ARPDYN PPL VET 2286-2300
459. NS5A PDYNPPLVETW KKPD 2291-2305
460. NS5A PLVETW KKPDYEPPV 2296-2310
201461. N S5A W K K PD Y E P PV V H G C P 2301-2315
462. N S5A Y E P PV V H G C P L P P PR 2306-2320
463. N S5A V H G C P L P P PR S P P V P 2311-2325
464. N S5A LP P P R SP P V P P P R K K 2316-2330
465. N S5A SPP V P PP R K K R T V V L 2321-2335
466. N S5A PPR K K R T V V L T E S T L 2326-2340
467. N S5A R T V V L T E ST L S T A L A 2331-2345
468. N S5A T E ST L S T A L A E L A T K 2336-2350
469. N S5A S T A L A E L A T K S FG S S 2341-2355
470. N S5A ELA T K SFG SSSTSG 1 2346-2360
471. N S5A SFG S S ST SG IT G D N T 2351-2365
472. NS5A STSG 1T G D N T T T SSE 2356-2370
473. N S5A T G D N T T T S S E P A P S G 2361-2375
474. N S5A T T SS E P A P SG C P PD S 2366-2380
475. N S5A PA P S G C PP D SD V E S Y 2371-2385
476. N S5A C P P D S D V E SY  SSM PP 2376-2390
477. N S5A D V E SY S SM P P L E G E P 2381-2395
478. N S5A S S M P P L E G E P G D P D L 2386-2400
479. N S5A L E G E PG D PD L S D G S W 2391-2405
480. N S5A G D P D L S D G S W S T V S S 2396-2410
481 N S5A S D G S W S T V SS G A D T E 2401-2415
482. N S5A S T V SS G A D T E D V V C C 2406-2420
483. N S5A /N S5B G A D T E D V V C C SM S Y S 2411-2425
484. N S5A /N S5B D V V C C S M S Y S W T G A L 2416-2430
485 N S5B S M S Y S W T G A L V T PC A 2421-2435
486 N S5B W T G A L V T P C A A E E Q K 2426-2440
487 N S5B V TPC A A EE Q K LP1N A 2431-2445
4 tu ‘ N S5B A E E Q K L P1N A L SN SL 2436-2450
48<» N S5B LP1N A L SN SLLR H H N 2441-2455
490 N S5B L S N SL L R H H N L V Y ST 2446-2460
491 N S5B LR H H N L V Y  STTSR SA 2451-2465
492. N S5B L V Y ST TSR SA C Q R Q K . 2456-2470
493 N S5B T S R S A C Q R Q K K V T F D 2461-2475
494. N S5B C Q R Q K X V T FD R L Q V L 2466-2480
495. N S5B K V T FD R L Q V L D SH Y Q 2471-2485
496. N S5B R L Q V L D SH Y Q D V L K E 2476-2490
497. N S5B D SH Y Q D V L K E V K A A A 2481-2495
498. N S5B D V L K E V K A A A S K V K A 2486-2500
499. N S5B V K A A A SK V K A N  LLSV 2491-2505
500. N S5B S K V K A N L L SV E E A C S 2496-2510
501. N S5B N L L SV E E A C S L T P P H 2501-2515
502. N S5B E E A C S L T PP H S A K S K 2506-2520
503. N S5B L T PP H SA K S K F G Y G A 2511-2525
504. N S5B S A K S K F G Y G A K D V R C 2516-2530
505. N S5B FG Y G A K D V R C H A R K .A 2521-2535
506. N S5B K D V R C H A R R A V A H 1N 2526-2540
507. N S5B H A R K A V A H IN S V W K D 2531-2545
202508. NS5B VAHINSVW KDLLEDS 2536-2550
509. NS5B SVW KDLLEDSVTP1D 2541-2555
510. NS5B LLEDSVTP1DTTIM A 2546-2560
511. NS5B VTP1DTTIM AKNEVF 2551-2565
512. NS5B TTIM AKNEVFCVQPE 2556-2570
513. NS5B KNEVFCVQPEKGGRK 2561-2575
514. NS5B CVQPEKGGRKPARLI 2566-2580
515. NS5B KGGRKPARL1VFPDL 2571-2585
516. NS5B PARLIVFPDLGVRVC 2576-2590
517. NS5B VFPDLGVRVCEKM AL 2581-2595
518. NS5B GVRVCEKM ALYDVVS 2586-2600
519. NS5B EKM ALYDVVSKLPLA 2591-2605
520. NS5B YDVVSK.LPLAVMGSS 2596-2610
521. NS5B K.LPLAVMGSSYGFQY 2601-2615
522. NS5B VM GSSYGFQYSPGQR 2606-2620
523. NS5B YGFQYSPGQRVEFLV 2611-2625
524. NS5B SPGQRVEFLVQAW KS 2616-2630
525. NS5B VEFLVQAW KSKKTPM 2621-2635
526. NS5B QAW KSKKTPM GFSYD 2626-2640
527. NS5B KKTPM GFSYDTRCFD 2631-2645
528. NS5B GFSYDTRCFDSTVTE 2636-2650
529. NS5B TRCFDSTVTESD1RT 2641-2655
530. NS5B STVTESD1RTEEAIY 2646-2660
531. NS5B SDIRTEEAIYQCCDL 2651-2665
532. NS5B EEA1YQCCDLDPQAR 2656-2670
533 NS5B QCCDLDPQARVA1K.S 2661-2675
534 NS5B DPQARVAIK.SLTERL 2666-2680
535 NS5B VA1KSLTERLYVGGP 2671-2685
536 NS5B LTERLYVGGPLTN SR 2676-2690
537. NS5B YVGGPLTNSRGENCG 2681-2695
538. NS5B LTNSRGENCGYRRCR 2686-2700
539. NS5B GENCGYRRCRASGVL 2691-2705
540. NS5B YRRCRASGVLTTSCG 2696-2710
541. NS5B ASGVLTTSCGNTLTC 2701-2715
542. NS5B TTSCGNTLTCY1KAR 2706-2720
543. NS5B NTLT CY 1  KARA AC RA 2711-2725
544. NS5B Y1KARAACRAAGLQD 2716-2730
545. NS5B AACRAAGLQDCTM LV 2721-2735
546. NS5B AGLQDCTM LVCGDDL 2726-2740
547. NS5B CTM LVCGDDLVV1CE 2731-2745
548. NS5B CGDDLVV1CESAGVQ 2736-2750
549. NS5B VV1CESAGVQEDAAS 2741-2755
550. NS5B SAGVQEDAASLRAFT 2746-2760
551. NS5B EDAASLRAFTEAM TR 2751-2765
552. NS5B LRAFTEAM TRYSAPP 2756-2770
553. NS5B EAM TRYSAPPGDPPQ 2761-2775
554. NS5B YSAPPGDPPQPEYDL 2766-2780
203555. NS5B GDPPQPEYDLELITS 2771-2785
556. NS5B PEYDLEL1TSCSSNV 2776-2790
557. NS5B ELITSCSSNVSVAHD 2781-2795
558. NS5B CSSNVSVAHDGAGKR 2786-2800
559. NS5B SVAHDGAGKRVYYLT 2791-2805
560. NS5B GAGKRVYYLTRDPTT 2796-2810
561. NS5B VYYLTRDPTTPLARA 2801-2815
562. NS5B RDPTTPLARAAW ETA 2806-2820
563. NS5B PLARAAW ETARHTPV 2811-2825
564. NS5B AW ETARHTPVNSW LG 2816-2830
565. NS5B RHTPVNSW LGN1IM F 2821-2835
566. NS5B NSW LGNI1M FAPTLW 2826-2840
567. NS5B NIIM FAPTLW ARM 1L 2831-2845
568. NS5B APTLW ARM 1LM THFF 2836-2850
569. NS5B ARM1LM THFFSVLIA 2841-2855
570. NS5B M THFFSVLIARDQLE 2846-2860
571. NS5B SVL1ARDQLEQALNC 2851-2865
572. NS5B RDQLEQALNCE1YGA 2856-2870
573. NS5B QALNCEIYGACYSIE 2861-2875
574. NS5B EIYGACYSIEPLDLP 2866-2880
575. NS5B CYS1EPLDLPPIIQR 2871-2885
576. NS5B PLDLPPIIQRLHGLS 2876-2890
577. NS5B P1IQRLHGLSAFSLH 2881-2895
578. NS5B LHGLSAFSLHSYSPG 2886-2900
579. NS5B AFSLHSYSPGEINRV 2891-2905
580. NS5B SYSPGE1NRVAACLR 2896-2910
581. NS5B E1NRVAACLRKLGVP 2901-2915
582 NS5B AACLRKLGVPPLRAW 2906-2920
58* NS5B KLGVPPLRAW RHRAR 2911-2925
584. NS5B PLRAW RHRARSVRAR 2916-2930
585 NS5B RHRARSVRARLLSRG 2921-2935
586. NS5B SVRARLLSRGGRAAI 2926-2940
587 NS5B LLSRGGRAA1CGKYL 2931-2945
588. NS5B GRAAICGKYLFNW AV 2936-2950
589. NS5B CGKYLFN W A VRTKLK 2941-2955
590. NS5B FNW AVRTKLKLTP1A 2946-2960
591. NS5B RTK.LKLTPIAAAGRL 2951-2965
592. NS5B LTP1AAAGRLDLSGW 2956-2970
593. NS5B AAGRLDLSGW FTAGY 2961-2975
594. NS5B DLSGW FTAGYSGGDI 2966-2980
595. NS5B FTAGYSGGD1YHSVS 2971-2985
596. NS5B SGGD1YHSVSHARPR 2976-2990
597. NS5B YHSVSHARPRW FW FC 2981-2995
598. NS5B HARPRW FW FCLLLLA 2986-3000
599. NS5B W FW FCLLLLAAGVGI 2991-3005
600. NS5B LLLLAAGVG1YLLPN 2996-3010
601. NS5B LLLAAGVGIYLLPNR 2997-3011
204